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Age-related macular degeneration: a global health care burden
Age-related macular degeneration (AMD) is a widespread problem and a considerable 
health care burden. It is the most important cause of irreversible severe vision loss in 
the elderly Western population.1 The global prevalence of AMD is estimated to be 9% 
and reaches up to 11% in those of European ancestry.2 Prevalence increases with age, 
rising up to 20% in populations of over 80 years (figure 1).3  The number of people 
affected is expected to rise and by the year 2020 there will be a staggering 200 million 
people with AMD worldwide. Approximately 12 million of these people will develop 
the debilitating neovascular advanced stage of disease, in many cases necessitating 
intravitreal anti-VEGF treatment.
Figure 1. Total prevalence of poor vision as a function of age, specified by cause. AMD= age-related 
macular degeneration; POAG= primary open-angle glaucoma.3
The etiology is multifactorial, meaning there is not one specific cause, but there are 
multiple risk factors contributing to its development. Well-known environmental risk 
factors include smoking, family history of AMD, cataract surgery, obesity and dietary 
factors such as low antioxidant intake.4-7 Genetic factors are an important component of 
the etiology as the proportion of disease variance due to genetic factors, or heritability, 
of AMD is estimated to be approximately 70%.8 These genetic factors are usually so-
called single nucleotide polymorphisms (SNPs). SNPs are small alterations in a person’s 
DNA, or genetic variants, which may be commonly seen in the normal, unaffected 
population. However, some SNPs predispose the carrier to AMD. Genetic studies point 
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towards the involvement of the complement system in disease development, as several 
variants in complement genes (CFH, C2/CFB, C3, CFHR1, CFHR3, CFI) are strongly 
associated with AMD.9-13 The role of the complement system was corroborated by 
presence of complement components in drusen, which are retinal deposits known as the 
hallmark lesions of AMD.14 In addition, physiological measurements in blood serum 
of activated complement, demonstrated an increased level of complement activation in 
AMD patients versus controls.15-17 The extensive application of genome-wide association 
studies (GWAS) in large AMD cohorts has led to the identification of several other 
genetic associations, indicating contributions to disease etiology of pathways involved 
in lipid metabolism, extracellular matrix remodeling and angiogenesis.18
The hallmark lesions of AMD are drusen: small deposits under the level of the retinal 
pigment epithelium (RPE) (figure 2). Drusen appear as yellowish spots in the retina 
and can vary in aspect and size from ≤63µm (hard drusen) to >63µm (soft drusen). The 
composition of drusen has been studied extensively. At least 40% of the druse consists 
of lipids that are potentially accounted for by the secretion of lipoproteins by RPE.19 In 
addition, a number of druse proteins have been described, notably inflammatory factors 
including complement components as mentioned previously. Less than 10 small hard 
drusen may be physiological in healthy elderly people and are thought to reflect normal 
aging of the retina.20 
Figure 2. Fundus photograph of patient with intermediate age-related macular degeneration showing 
many small and large drusen.
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The early and intermediate phases of disease typically show only drusen and pigmentary 
changes in the retina, vision loss is generally mild at this stage.21, 22 However, approximately 
25% of these people will progress to the advanced stage of AMD within 15 years and 
will experience severe vision loss.23  Advanced AMD comprises two distinct phenotypic 
entities. Approximately half of patients that progress to advanced AMD will develop 
geographic atrophy, whereas the other half develops neovascular AMD.2 In geographic 
atrophy the profound thinning of the outer retinal layers results in a complete loss of 
function, when the atrophy affects the center of the macula irreversible blindness is 
the result.24 At the moment there is no proven therapy for geographic atrophy. The 
classification of AMD according to the Cologne Image Reading Center and Laboratory 
(CIRCL) protocol25, 26 is summarized in table 1.
Table 1. CIRCL protocol for AMD classification on fundus photography
Early AMD ≥10 small drusen (<63 μm) and pigmentary changes or the presence of 1–14 
intermediate (63–124 μm) drusen within 6 mm of the fovea
  
Intermediate AMD ≥15 intermediate drusen or any large drusen (≥125 μm in diameter) within 6 
mm of the fovea
  
Advanced: 
Geographic atrophy
Subfoveal atrophy of the RPE of at least 175μm in diameter within 1 mm of 
the fovea
  
Advanced: 
Neovascular AMD
Choroidal neovascularization secondary to AMD
Neovascular AMD and vascular endothelial growth factor
Neovascular AMD is the second form of advanced AMD and the most common cause 
for visual impairment. Vision loss from neovascular AMD is usually rapid and common 
complaints are blurred central vision, distortion of straight lines (metamorphopsia), and/
or central visual field defects (scotoma).27 In most patients vision loss starts unilateral 
and, initially, may go unnoticed by the patient due to the compensatory effect of the 
fellow eye. Often, however, the second eye will also develop neovascular complications, 
at a risk of 10% per year.28, 29 Neovascular AMD is driven by increased levels of vascular 
endothelial growth factor (VEGF) that are typically released in hypoxic circumstances. 
The VEGF family consists of several members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, 
VEGF-E and placental growth factor (PlGF). VEGF-A is the predominantly involved 
factor in neovascular AMD pathogenesis. It is the primary regulator of angiogenesis and 
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exerts its action through activation of the VEGF receptor 2 (VEGFR2).30, 31 Upregulation 
of the VEGF pathway in AMD causes newly formed, brittle vessels to grow from the 
choroid, through Bruch’s membrane and into the retina (figure 3)32. This choroidal 
neovascularization (CNV) leaks fluid and plasma constituents into the retina leading to 
rapid and severe visual loss.33 
Figure 3. Invasion of choroidal neovascularization into the sub- and intraretinal space. Image from 
scienceofamd.org.32
Different CNV lesion types are recognized, each with their own phenotypic features. 
The CNV complex of the classic subtype lies between the RPE and the neurosensory 
retina34. Its appearance on fluorescein angiography is of a well-demarcated area of leakage, 
typically with a hypofluorescent rim surrounding the lesion (figure 4A).35 The classic 
subtype is commonly referred to as “type 2 neovascularization”. The most common 
is the occult lesion type (~50% of cases),36 also known as “type 1 neovascularization”, 
where the neovascular complex is located just beneath the retinal pigment epithelium 
(RPE). On fluorescein angiography, occult lesions are characterized as lesions with 
speckled hyperfluorescence with poorly demarcated borders (figure 4B).35 The classic 
and the occult CNV subtypes regularly coincide in the same lesion, where the lesion is 
referred to as predominantly classic in case more than 50% of the lesion consists of classic 
CNV or as minimally classic when it is less. Less common is the retinal angiomatous 
proliferation (RAP) subtype, or “type 3 neovascularization”, occurring in approximately 
10-30% of cases.36, 37 In RAP an anastomosis forms between a choroidal and a retinal 
vessel. It usually presents as small intraretinal hemorrhages on fundus photography, 
combined with a hyperfluorescent hotspot on fluorescein angiography (figure 4C). A 
pigment epithelium detachment develops in almost all patients during the later stages.38, 
39 The final CNV subtype is polypoidal choroidal vasculopathy (PCV), however there 
is ongoing discussion whether PCV should be treated as a subtype of AMD or an 
entirely different disease entity.40 The characteristic lesion in PCV is an inner choroidal 
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network of dilated vessels which may be seen as red-orange polyp-like protrusions in the 
retina (figure 4E).40 PCV is uncommon in Caucasians, but primarily affects pigmented 
individuals, especially Asians and African-Americans.40 RAP and PCV may be easily 
missed with conventional techniques and usually require further diagnostic imaging, 
such as indocyanine green angiography (figure 4D,F).41 
Figure 4. A. Fluorescein angiography (FA) of a classic neovascularization with a well-demarcated 
hyperfluorescent area of leakage. B. FA of occult neovascularization with speckled appearance. C. Retinal 
angiomatous proliferation (RAP) on FA, the lesion is indicated by the arrow. D. Indocyanine green 
angiography showing a hotspot at the site of the RAP lesion. E. Polypoidal choroidal vasculopathy (PCV) 
on FA with a clear network of polyp-like structures. F. Indocyanine green angiography confirming the 
presence of a polypoidal lesion in PCV. Images from Duane’s Ophthalmology.41
General introduction
15
Anti-VEGF treatment in AMD: a therapeutic revolution 
Before the anti-VEGF era, photodynamic therapy (PDT) was the first-line AMD 
treatment. PDT was introduced in 1999 and was an important development in AMD 
treatment, being able to prevent severe vision loss in 61% of patients.42 However, 
because of the availability of other highly effective drugs it is now seldom considered as a 
treatment option in AMD with the exception of PCV, where PDT may be administered 
in combination with anti-VEGF.43 
Recognition of the pivotal role of VEGFs in the pathogenesis of neovascular AMD 
prompted the development of intraocular anti-VEGF drugs to suppress the neovascular 
lesions. This class of drugs represented a huge leap in the treatment for macular 
degeneration. The first anti-VEGF drug was pegaptanib sodium (Macugen), an aptamer 
(oligonucleotide strand) binding specifically to isoform VEGF 165.44 In 2004 the first 
randomized controlled trial (RCT) of pegaptanib sodium versus sham injection was 
published showing how pegaptanib could prevent much of the visual loss associated 
with neovascular AMD. Despite this anti-VEGF treatment, patients were still losing 
approximately 6-10 letters on average 
Neovascular AMD treatment was truly revolutionized when in 2006 the VEGF 
antibodies were discovered as a potential therapy. The first to be tried in clinical practice 
was bevacizumab (Avastin). Bevacizumab is a VEGF-A antibody originally developed 
as a systemically administered cancer drug for colon carcinoma, but in case reports45, 46 
it was shown that it could also successfully inhibit CNV in AMD through intravitreal 
injection. This finding gave rise to the development of an anti-VEGF drug made 
specifically for ocular administration. Thus ranibizumab (Lucentis) entered the playing 
field. Ranibizumab was developed with similar properties as bevacizumab (VEGF-A 
blocking), but consists only of the fragment antigen-binding (Fab) region without the 
fragment crystallizable (Fc) domain. The much smaller molecular size was thought to 
facilitate distribution across all retinal layers to the choroidal neovascular structure. In 
the two large RCTs MARINA and ANCHOR the superiority of ranbizumab over sham 
treatment was unmistakably proven.47, 48 In contrast to pegaptanib, ranibizumab was 
able to improve vision, with patients gaining 8 to 10 letters on average over the course 
of 1 year. This led to the registration of ranibizumab as treatment for neovascular AMD. 
Although ranibizumab was registered for AMD and bevacizumab never entered the 
registration process, large price differences between the two (approximately a factor 20) 
meant ophthalmologists still used bevacizumab in clinical practice. A RCT was therefore 
designed to evaluate the difference in effectiveness. Published in 2011, the CATT study 
showed no discernible difference between the two drugs with respect to visual acuity 
change.49 Subsequent studies confirmed this.50-52 These comparative RCTs also did not 
find differences in adverse events. Both ranibizumab and bevacizumab can enter the 
systemic circulation, but the half-life of bevacizumab is much longer,53 which had some 
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ophthalmologists worried that bevacizumab may increase the risk of stroke or myocardial 
infarction. A subsequent Cochrane review confirmed there were no differences in serious 
adverse events and specifically in arteriothrombotic events.54 Hereafter, the favorable 
cost-effectiveness profile of bevacizumab prompted some national ophthalmological 
societies, such as the Dutch Ophthalmology Society, to adopt this drug as first choice 
therapy for neovascular AMD in their guidelines.55 However, since it is not officially 
registered for AMD, other national guidelines still recommend not to use bevacizumab 
as a first choice treatment.56 
The huge success of ranibizumab in neovascular AMD led to the development of new 
anti-VEGF drugs and aflibercept (“VEGF Trap”) is the latest. It functions as a decoy 
for VEGF-A, VEGF-B and PIGF, containing the binding portions of VEGF receptor 
1 and 2. The alternative design was thought to have a greater binding affinity to VEGF 
and showed more potency in vitro than ranibizumab or bevacizumab.57 However, the 
pivotal RCT consisting of two cohorts from North-America and Europe, dubbed VIEW 
1 and VIEW 2, was published in 2012 and showed that there was no difference in effect 
on visual acuity or retinal thickness between aflibercept and ranibizumab.58 Aflibercept 
however did have the advantage that it could be administered less frequently, once every 
two months instead of monthly. 
Since the effectiveness in large cohorts appears to be similar, it can be challenging for 
ophthalmologists to decide which should be the primary treatment in the individual 
patient; bevacizumab, ranibizumab, or aflibercept. At the moment, the world is divided 
as to which anti-VEGF drug to use. We do not know whether all three drugs can be 
expected to have the same effect in each individual and what factors would influence 
the differential response. Furthermore, the contribution of the drugs on benefits for 
society in terms of quality of life gain and cost reduction may influence this decision. 
In addition, once we have established the first choice drug after careful review of all the 
evidence, the next step is to determine a secondary drug for further treatment of non-
responders, which will preferably be a drug with a different therapeutic action.
Anti-VEGF treatment: clinical practice
The first RCTs administered ranibizumab by intravitreal injection every month.47, 48 In 
clinical practice monthly injections proved to be a logistic and financial challenge and 
many clinics could not keep up with the large flow of treatments in this big patient 
population. One of the first adaptations to the original monthly regimen was an attempt 
to reduce injection frequency by an as-needed strategy (pro re nata; PRN). The Pronto 
study showed that good visual acuity gains could also be achieved by treating only when 
patients had lost 5 letters of visual acuity in combination with new or persistent fluid on 
optical coherence tomography (OCT).59 The Pronto study was able to achieve a 9 letter 
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gain in vision with a mean only of 5.6 injections over 1 year. In subsequent comparative 
studies it was shown that the PRN treatment strategy yielded similar visual gains as 
the monthly regimen.49, 50 Thus, many clinics adopted this new PRN regimen. Other 
popular treatment regimens include the treat-and-extend regimen in which patients 
receive an injection every visit, but the time between visits is extended when there is no 
fluid on OCT or shortened when fluid has recurred.51  
The visual outcomes in the pivotal RCTs were very encouraging. However, RCTs are 
highly controlled environments where only specific patients with mostly beneficial 
characteristics are allowed to participate. In clinical practice many patients will present 
themselves with AMD, who would not fit the criteria for inclusion in RCTs. Also, 
in clinical practice, we cannot maintain the highly controlled setting as in RCTs. The 
pivotal RCTs that we now base our treatment guidelines on, including those advocating 
PRN regimens, required patients to be monitored monthly. In clinical practice, due to 
practical and logistical issues, treatment may be delayed, follow-up may be inconsistent 
and there may be more divergence from protocol, such as terminating treatment 
at a patient’s request while it would still be indicated. These issues are sometimes 
unavoidable, however, they may affect the value of the treatment in real life. We know 
from observational studies conducted in other European countries that effects in RCTs 
are often not reached in clinical practice.60-65 Observational studies are needed to evaluate 
the actual effect of anti-VEGF drugs in clinical practices. This may have consequences 
for the general prognosis of a patient group and the amount of non-responders we may 
expect to encounter. Furthermore, evaluating our treatment effects can help us identify 
areas for improvement. With these questions in mind, we wondered what the effect of 
anti-VEGF therapy for AMD was in our own clinics in the Netherlands.
Non-response to anti-VEGF therapy
The visual prognosis of the average patient with neovascular AMD has considerably 
improved after the implementation of anti-VEGF therapy. Nevertheless, vison does 
not improve in all AMD patients treated with anti-VEGFs and in approximately 10% 
of patients the vision declines by 15 letters even in the pivotal RCTs.47-50 Although 
this gives us a good indication of the effectiveness of the treatment and the amount 
of non-response, these numbers do not necessarily represent all people that should be 
considered non-responder. The amount and subset of non-responders varies according 
to the definition used. It may depend on what cut-off for visual acuity loss is considered 
relevant, or even using a different method to define non-response such as fluid resolution 
on OCT may yield a completely different subset of non-responders. There is currently 
no generally accepted definition of non-response, but roughly, non-response can be 
subdivided in two major subtypes: functional or anatomical. The functional type 
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refers to response in terms of visual acuity. Anatomical response is defined by retinal 
thickness on optical coherence tomography (OCT). Many studies have tried to find 
predictive factors for functional response, but anatomical response gains interest. The 
advantage of non-response as a functional measure is that it is directly related to quality 
of life and thus the most relevant outcome for the patient.66 On the other hand, the 
anatomy on OCT is usually what determines the ophthalmologist’s decision to retreat 
and it is considered a more objective measure of response with less confounding factors. 
Unfortunately, response on OCT and visual acuity are not very well correlated,67 so 
although a convenient measure, OCT changes may not be very meaningful to an 
individual patient.    
Although we do not know beforehand who will respond to therapy and who will not, 
there are certain characteristics that can help us predict who the non-responders are. 
These characteristics may be clinical, phenotypic, and genetic factors.68, 69 Clinical and 
phenotypic factors consistently associated with poor functional treatment results are: 
increasing age and poor baseline visual acuity.70, 71 Good baseline visual acuity has been 
associated with more risk of vision loss. This is most likely a results of the floor-ceiling 
effect where patients with bad baseline visual acuity are not able to lose any more vision, 
as opposed to patients with good baseline visual acuity. Type of CNV may also be 
predictive of non-response. In some studies patients with classic CNV were less likely to 
gain vision as opposed to those with occult CNV,70 however this finding could not be 
replicated in other studies.72, 73 
Given the importance of genetic predisposition in AMD, genetic markers have been 
of major interest in non-response prediction as well. To date many SNPs have been 
found to be associated with the development of AMD, notably risk variants in the 
ARMS2 and complement factor H (CFH) genes. Several studies have tried to identify 
underlying genetic factors predictive of treatment response, but so far results have been 
inconsistent.69 The CFH Y402H and the ARMS2 A69S risk variants are both strongly 
involved in AMD etiology and were therefore the most likely candidates for response 
prediction. Some studies have reported that both risk variants are associated with poorer 
response to anti-VEGF therapy.74-78 Conversely, several studies have not found any 
association of these risk factors with response or have even seen opposite effects.79-81 To 
get a better view of the current evidence, recent meta-analyses have been performed for 
the CFH Y402H risk variant.82-84 Although the included studies were heterogeneous 
in population and treatment outcome, they were able to show that the CFH Y402H 
risk variant was associated with worse response to anti-VEGF therapy, increasing the 
odds for poor response by approximately 1.6 when carrying two risk alleles compared 
to none. 
The VEGF pathway is also highly interesting for non-response prediction as this 
pathway is of course the target of anti-VEGF therapy. Some SNPs in the VEGF-A 
gene have been tested, but only few studies have been able to show an association with 
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treatment response.68, 69 Lack of association could be because relevant functional variants 
in the VEGF pathway are not present or have not yet been identified, or because studies 
were underpowered. In a large study by Smailhodzic et al. it was shown that although 
effect sizes of individual SNPs are small, an accumulation of risk alleles in CFH Y402H, 
ARMS2 A69S and VEGF-A rs699947 can make a difference of as much as 10 letters 
between patients that carry few risk alleles and those that carry all risk alleles.85 This 
indicates that for response prediction it may be more valuable to compose a risk score of 
multiple SNPs to strengthen the power of the analysis. 
A number of genetic and non-genetic factors are thought to be associated with non-
response, but it remains unclear what the relevance of these factors are in the prediction 
of non-response, considering that effect sizes, especially of genetic factors, are generally 
small. It is unknown how well a combined model of the known clinical and genetic factors 
may predict non-response and how much of variation in response is still unexplained. 
So far, non-responders have been identified through trial and error. Patients are treated 
with the first line therapy, and in case of non-response two options remain: discontinue 
treatment or switch to a different anti-VEGF drug. Because withholding treatment 
ultimately means losing vision,86 the patient and ophthalmologist will often opt for 
an alternative drug. The pharmacological mechanism of the three available anti-VEGF 
drugs is very similar and thus it is unclear what the value would be of switching to a 
different drug. Furthermore, although the mean effectiveness is comparable between 
agents, but we do not know whether individuals will respond differently to different 
drugs. In The Netherlands the first choice treatment is bevacizumab, because of its 
superior cost-effectiveness profile. The VEGF-blocking action of bevacizumab and 
ranibizumab is virtually the same, but the active portion of aflibercept is not a VEGF 
antibody but rather a VEGF decoy-receptor.57 Also, switching from bevacizumab to 
ranibizumab has so far yielded little and contradicting results.87-90 Therefore, when a 
patient does not respond to bevacizumab, switching to aflibercept would make the most 
sense. Considering the expense of aflibercept and the burden of intraocular treatment, 
it is however important to find out what the value is for the patient when switching to 
this drug. 
Anti-VEGF treatment and non-response in diabetic macular edema
Following the success of anti-VEGF in AMD, the same strategy was applied in other 
retinal disorders that were characterized by fluid in the macula. Diabetic macular edema 
(DME) is such a retinal disorder with overlapping pathophysiological mechanisms.91, 92 
Loss of vision in diabetic retinopathy is most often caused by DME, both in type 1 and 
2 diabetes. Approximately 7% of all diabetics are affected, making it the number one 
cause for vision loss in the working age population.93, 94
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As in AMD, the VEGF pathway plays a crucial role in DME. In DME, fluid accumulation 
in the retina originates from the retinal capillaries which have become damaged by 
the hyperglycemic conditions. The increased permeability of the retinal capillaries is 
mediated through increased VEGF levels as well as inflammatory factors.95 Although 
the pathophysiology is similar to AMD, the inflammatory pathways plays a much more 
prominent role in DME. Furthermore, in DME, the retinal capillaries are the origin of 
the fluid as opposed to the choroidal vessels in AMD.
Prior to 2012 when ranibizumab received approval for use in DME, laser photocoagulation 
was the primary treatment for center-involving DME. Laser photocoagulation mostly 
led to stabilization of vision and carried a substantial risk of scotoma formation.96 
RCTs comparing anti-VEGF therapy to laser photocoagulation in patients with central 
macular edema found that not only was anti-VEGF far superior, it also resulted in an 
average gain of ~10 letters of vision. Considering that these studies also could not find 
an added effect of anti-VEGF combined with laser, anti-VEGF quickly replaced laser 
as the primary choice of treatment.97-102 The functional success was accompanied by 
anatomical improvement and the CRT of patients decreased by ~180 µm on average in 
the ranibizumab and aflibercept RCTs. For bevacizumab, the effect on retinal thickness 
was less pronounced with a mean decrease of approximately 110 µm. As in AMD, the 
question remained which drug should be the preferred primary treatment. In the protocol 
T study, a  large head-to-head-to-head trial of the Diabetic Retinopathy Clinical Research 
Network (DRCRN) comparing all three anti-VEGF agents, aflibercept was shown to be 
superior to ranibizumab and bevacizumab in DME-patients with baseline Snellen visual 
acuity below 20/40 after 1 year.103 After 2 years, aflibercept still had significantly better 
vision gains than bevacizumab, but not ranibizumab.104 In patients with baseline visual 
acuity of 20/40 or more, there was no significant difference in functional effect. With 
regard to anatomical effect there was no obvious difference between aflibercept and 
ranibizumab, however as expected from previous RCTs, bevacizumab resulted in 50-70 
µm less CRT reduction. Despite the difference in anatomical effect but with regard to 
the much lower costs of bevacizumab, the current advice is to administer aflibercept in 
patients with poor baseline vision (<20/40 Snellen) and bevacizumab in patients with 
moderate tot good baseline vision.105 
Considering the involvement of an inflammatory component to DME pathophysiology, 
corticosteroids are also applied as a treatment option in DME. The most commonly 
used and studied steroid treatment is intravitreal triamcinolone acetonide (TAC), 
which may be administered up to every 16 weeks.106 In the protocol I study comparing 
ranibizumab, laser and TAC, TAC was initially effective in reducing CRT but this 
effect seemed to wane over time.97 Also improvement of visual acuity was limited to 
the pseudophakic eyes. Therefore, steroids are usually not a first choice treatment, since 
they have not been proven to be more effective than anti-VEGF and more importantly, 
steroids are associated with adverse events such as cataract formation and increased 
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intraocular pressure.97, 107 However, steroids can be an appropriate second line treatment 
when anti-VEGF therapy fails, especially in pseudophakic eyes.108-110 Possibly, the 
inflammatory component is more active in anti-VEGF non-responders, warranting an 
anti-inflammatory approach as opposed to an anti-VEGF approach. 
Due to different pathophysiological mechanisms involved in DME, treatment effects of 
anti-VEGF may differ from AMD and study results can likely not be readily extrapolated 
from AMD to DME. Anti-VEGF therapy in clinical practice for DME needs to be 
evaluated separately from AMD to give us a good idea of whether our DME treatment 
is effective and how many patient do not respond to treatment. Management of non-
responders may vary from AMD as well, as the specific involvement of the inflammatory 
pathway in DME may mean different optimal strategies for individual non-responders. 
Other treatments: prevention of advanced AMD
In the previous sections we have seen that anti-VEGF therapy requires intensive 
treatment and monitoring, and importantly, often does not completely restore all vision. 
Prevention of disease progression to advanced AMD could be a potential strategy to 
reduce patient, physician, and societal burden. In the absence of a definite cure for AMD, 
much could be gained by slowing progression to the advanced stages by addressing 
modifiable AMD risk factors. 
Currently, the only intervention proven to reduce the progression to advanced AMD is 
oral intake of high doses of antioxidants (vitamin C, vitamin E and lutein/zeaxanthin) 
combined with zinc supplements for intermediate or unilateral advanced AMD. The 
Age-Related Eye Disease Study (AREDS), a randomized controlled trial showed that 
these supplements were able to reduce AMD progression by 25% by 5 years.111 The 
exact mechanism of the protective effects of antioxidants and zinc has not yet been 
elucidated. Improving our understanding of this mechanism could help us optimize 
preventive treatments, either by more optimal targeting of the involved pathways by 
other treatments or by targeting a specific subgroup of patients that benefit most of the 
preventive measure. 
Aim of this thesis
In general, the aim of this thesis was to identify areas in the treatment of AMD that 
require optimization and to assess optimization strategies. Areas for optimization 
were sought on an individual level to support personalized healthcare decisions and 
on a general population level  to support the development of high-quality treatment 
guidelines. Three sub-objectives were  distinguished: 1) to predict non-response to 
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anti-VEGF treatment in patients with neovascular AMD, 2) to evaluate and identify 
new areas for improvement of both the injection procedure and anti-VEGF treatment 
in clinical practice, and 3) to evaluate the cost- effectiveness of anti-VEGF treatment 
for  neovascular AMD. More specifically, chapter 2 and 4b this thesis aimed to 
evaluate effectiveness of anti-VEGF treatment in clinical practice for AMD and DME 
respectively. In chapter 3a-c, in support of personalized healthcare, we aimed to improve 
the prediction of non-response by modelling non-response and identifying new genetic 
predictors. In chapter 4a and b we assessed the effectiveness of second-line treatments 
for AMD and DME after first-line bevacizumab. In chapter 5 we compare and address 
the cost-effectiveness of the three anti-VEGF treatments for AMD. In chapter 6 we 
evaluate and identify new areas for improvement of the anti-VEGF injection procedure. 
Finally, in chapter 7 we aim to elucidate mechanisms behind AMD prevention with zinc 
supplements. 
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Purpose: The HELIOS (Health Economics with Lucentis in Observational Settings) 
study was designed on request of the Dutch Health Authority for an observational study 
to assess the effectiveness and safety of ranibizumab for neovascular age-related macular 
degeneration (wet AMD) in daily practice. 
Methods: The HELIOS study was a two-year prospective, observational, open-label, 
multicenter study involving 14 sites. Patients with wet AMD were enrolled and observed 
for a period of 24 months. The data were collected at baseline and at the visits closest 
around the time points 3, 6, 12, 18 and 24 months after inclusion.  
Results: Treatment with ranibizumab resulted in prevention of vision loss. The mean 
ETDRS score increased from 45.1 letters at baseline to 48.5 letters at 24 months. This 
was achieved with a mean of 7.8 injections over 24 months. Stabilization in visual acuity 
was also reflected by the scores on the quality of life EQ-5D questionnaire, which did not 
significantly change over the study period. The more subjective EQ-VAS questionnaire 
showed an overall improvement. The VFQ-25 questionnaire was also mostly stable over 
time. After 24 months, 32.2% of the patients gained ≥ 1 letter and 17.1% gained > 15 
letters. Patients completing the loading phase were better responders, as demonstrated 
by increased long-term visual acuity. In addition, ranibizumab was well tolerated and 
had a safety profile commonly seen in routine clinical practice. 
Conclusion: This study demonstrates that also in daily practice ranibizumab was 
effective in preventing vision loss over a period of 24 months. No new safety findings 
were identified.
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Introduction
Neovascular age-related macular degeneration (AMD) is the primary cause of severe 
and irreversible vision loss in the Netherlands and frequently results in legal blindness 
with resulting considerable economic burden 1-3. Its prevalence worldwide is increasing 
concomitantly with life expectancy, and epidemiological forecasts estimate that the 
number of affected patients over 65 years of age will rise up to two-fold by 2030. Well 
known risk factors for AMD include age, smoking and genetic predisposition 4, 5. 
Several treatments are currently available for wet AMD patients. Ranibizumab (Lucentis®) 
is a monoclonal antibody Fab fragment, that inhibits neovascularisation and leakage 
from vessels by binding to vascular endothelial growth factor A (VEGF-A) 6, 7. The 
efficacy of ranibizumab has been demonstrated in pivotal Phase III trials (MARINA, 
ANCHOR and PIER) in which patients with choroidal neovascularisation (CNV) 
associated with AMD receiving intravitreal injections of ranibizumab experienced a 
sustained improvement in mean visual acuity over time 7-9. In addition, ranibizumab 
was well tolerated and considered safe 10, 11. 
Although the efficacy data from the above mentioned phase III trials is convincing, we 
should be aware that the results observed in clinical trials do not always translate well 
to clinical practice. Observational studies located in several European countries have 
been conducted to evaluate the efficacy of ranibizumab for neovascular AMD in clinical 
practice in their respective countries 12-22. Following marketing approval of ranibizumab 
for neovascular AMD, the Dutch Health Authority had requested an observational 
study to assess the effectiveness and safety of ranibizumab in daily clinical practice in the 
Netherlands. The HELIOS (Health Economics with Lucentis in Observational Setting) 
study was designed to fulfil this request. The objectives of this study were to describe 
effectiveness, safety, treatment patterns and patient reported quality of life (QoL) 
outcomes in patients with neovascular AMD being treated with ranibizumab in real life 
practice settings over 24 months.  
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Materials and methods
Study design
A two-year prospective, observational, open-label, multicenter study was conducted 
to assess the effectiveness, safety and associated practice patterns in patients with 
neovascular AMD being treated with ranibizumab. The HELIOS study involved 14 
sites in the Netherlands and enrolled 243 patients. Approval from an Independent 
Ethics Committee for this study was not required, since no intervention was required 
in the treatment and/or behaviour of the patients, and patients were only observed. All 
included patients provided an oral informed consent, and treatment had to be compliant 
with the prescribing information 23. This study adhered to the Tenets of the Declaration 
of Helsinki and the Medical Research Involving Human Subjects Act (WMO). Patients 
were eligible for this study if they were diagnosed with wet AMD and had a recent 
disease progression with or without prior therapy. Diagnosis of wet AMD was based 
on presence of macular drusen and retinal pigment epithelial changes and signs of 
subretinal neovascularisation involving the centre of the macula on fluorescein and/or 
indocyanin green angiography and/or optical coherence angiography (OCT). Disease 
progression was defined as recent vision loss of more than 5 ETDRS letters, macular 
haemorrhage or signs of increased subretinal or intraretinal leakage on OCT. Patients 
were excluded if they participated in a clinical trial, (i.e. used investigational drugs at the 
time of enrolment or within 30 days or 5 investigational half-lives, whichever is longer) 
or when they did not provide informed consent.
Treatment and data collection
Treatment. All patients were treated with 0.5 mg ranibizumab (10 mg/ml) at the baseline 
visit. All patients should have been treated according to the prescribing information 23, 
which means starting with a loading phase of monthly injections for three consecutive 
months. The loading phase was followed by the maintenance phase, which includes 
that patients were monitored every month for disease progression. According to the 
prescribing information, reinjections are required when patients experience a loss of 
visual acuity of 5 letters or more, however, most physicians also retreated when there 
were clear signs of disease progression. All patients treated with ranibizumab at the 
baseline visit were followed in the study, even if the treatment had been interrupted. 
Data collection. Patient data were collected at baseline and during routine visits 
approximately at 3, 6, 12, 18 and 24 months after enrolment, based on normal patient 
management procedures and upon discretion of the physician (there were no scheduled 
visits as per protocol and any visit could be recorded). At baseline, patient characteristics 
such as socio-demographic data, medical history, history of current disease, history 
of co-morbidities and ophthalmologic examinations were recorded, if performed. In 
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addition, information on concomitant AMD medication and prior AMD treatment 
was collected. At each visit, the treating physician recorded the patient’s disease status, 
therapeutic decisions (including retreatment criteria for each additional ranibizumab 
injection) and assessed any adverse events.
Efficacy and safety assessments
Visual acuity outcomes. The primary objective of this study was to describe visual acuity 
outcomes in the real life setting in patients with wet AMD that were treated with 
ranibizumab for 24 months. These outcomes were described for the whole population, 
but also for the different lesion subtype groups (predominantly classic, occult, minimally 
classic), as well as for treatment-naive versus non-treatment naive patients. 
Visual acuity was either measured as Early Treatment of Diabetic Retinopathy Study 
(ETDRS) scores starting at 2 m and converted to 1 m, or as Snellen fractions. All 
Snellen fractions were converted to approximate ETDRS scores, for analysis purpose, 
using the formula: approx ETDRS= 85+50xlog(Snellen fraction) 24. The approximate 
ETDRS scores were rounded to the nearest letter.
Drug exposure and treatment patterns. To determine drug exposure and treatment 
patterns the number of injections per eye and the treatment intervals over the 24 month 
assessment period were analysed, separately for treatment-naive and previously treated 
patients, and for those who did or did not complete the 3 month loading phase.
Health related Quality of Life. The health related quality of life was assessed using the 
generic health assessment utility tool EuroQol (EQ-5D) as well as the visual-specific 
National Eye Institute Visual Function Questionnaire (NEI VFQ-25). The EQ-5D 
questionnaire comprises five levels: mobility, self-care, usual activities, pain/discomfort 
and anxiety/depression. These five states were combined to produce a single index 
measure for quality of life. The EQ-VAS was used to record patient’s self-rated health on 
a visual analogue scale, with 0 was labelled as “worst imaginable health state” and 100 as 
“best imaginable health state”. The VFQ-25 consisted of 25 vision-targeted questions, 
representing 11 vision related constructs, plus one additional single-item general health 
rating question. The questionnaires were scored at baseline, and at visits around month 
6, 12, and 24, as scheduled by the physician.
Safety Assessments. To evaluate safety and tolerability of treatment with ranibizumab all 
adverse and serious adverse ocular and non-ocular events (AE/SAE) were recorded. 
Statistical Analysis
There was a moderate amount of missing data, which was due to the observational 
nature of the study, since physicians were not obliged to provide all data. All evaluations 
were considered explorative in nature. Descriptive statistics were used to report results. 
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Differences in absolute values of visual acuity measurements between visits were 
evaluated using repeated measures analysis of variance (ANOVA). Change from baseline 
in visual acuity or quality of life values were assessed with repeated measures analysis of 
covariance (ANCOVA) with baseline and lesion subtype as covariate. A Chi-squared 
test was used to assess differences in improvement categories between lesion subtypes. 
In case of significant results, post hoc tests were performed for further exploration. All 
statistical tests used were two-sided, with α=0.05 as level of significance. 
Results
Patient disposition and demographics
In total, 243 patients with wet AMD were included into the study and started with 
ranibizumab treatment (the safety population, consisting of patients who received at least 
one ranibizumab injection). Of these 243 patients, 231 patients had a baseline and at 
least one post-baseline visual acuity measurement. This patient population was defined as 
the study population and used for all analyses except for the safety analysis. 153 patients 
of the study population completed the study. The reason for study discontinuation was 
loss to follow up (n=43), patient death (n=18), withdrawal of informed consent (n=5) 
or of unknown cause/other (n=12).
The patient characteristics were as expected for a wet AMD population and are described 
in table 1. Concomitant ocular conditions were observed in 20% of patients (table 1). Of 
these, 3.5% were treated by vitrectomy surgery of the primary involved eye. The other 
16.5% consisted of other concomitant ocular conditions, such as glaucoma, cataract, 
pseudo-xanthoma elasticum, diabetic retinopathy, retinal vein occlusion, myopia, 
amblyopia, branch retinal vein occlusion, phaco emulsification and pseudophakia. 
Furthermore, patients in the study population reported on concomitant vascular 
conditions. Other relevant (but not specified) non-ocular conditions were reported for 
19.5% of the patients in the study population (table 1). 
The majority of the patients (61.9%) had an occult lesion subtype, 17.7% had a 
predominantly classic lesion, 16.9% of the patients had a minimally classic lesion 
and 3.5% had a lesion type which was characterized as other. The CNV location was 
subfoveal for most of the patients (80.5%), while 13.9% had the CNV lesion juxtafoveal 
and 5.6% extrafoveal. 
A total of 192 patients (83.1%) included in the study were treatment-naive, while 
39 patients (16.9%) were treated before with one or more therapies (11.7% with 
bevacizumab, 1.7% with ranibizumab, 2.2% with PDT, 2.2% with laser and 0.9% 
with other). Evaluation of concomitant therapies administered before and during the 
study revealed that only 26 patients received other treatment during the study, of which 
bevacizumab and ‘other’ were most frequently reported. 
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The baseline data for the different subgroups of lesion subtypes, and naive versus non-
naive patients were comparable and only some small differences could be observed, but 
none were considered relevant for the outcome of the study.
Table 1. Key baseline demographics and disease characteristics of the study population
Baseline Characteristics Value
   
Total population n = 231
   
Mean age ± SD (years) 77.9 ± 8.2
Gender, n (%)  
male 95 (41.1%)
female 136 (58.9%)
Ethnicity, n (%)  
Caucasian 231 (100%)
   
AMD risk factors, n (%)  
current smoker 47 (20.3%)
former smoker 76 (32.9%)
family history of AMD 44 (19.0%)
   
Concomitant ocular conditions, n (%)  
history of vitrectomy surgery 8 (3.5%)
other 38 (16.5%)
Concomitant vascular conditions, n (%)  
coronary artery disease 44 (19.0%)
cerebrovascular artery disease 16 (6.9%)
peripheral vascular disease 50 (21.6%)
Other relevant non-ocular conditions, n (%) 45 (19.5%)
 
Mean visual acuity at baseline ± SD (letters) 45.1 ± 21.5 
CNV lesion, n (%)  
occult 143 (61.9%)
predominantly classic 41 (17.7%)
minimally classic 39 (16.9%)
other 8 (3.5%)
CNV location, n (%)  
subfoveal 186 (80.5%)
juxtafoveal 32 (13.9%)
extrafoveal 13 (5.6%)
Treatment, n (%)  
no previous treatment 192 (83.1%)
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Efficacy
Visual acuity
The mean ETDRS letter score for the study population at baseline was 45.1 ± 21.5 
letters (n=231) which slightly increased during the study to a mean ETDRS score of 
48.5 ± 25.1 letters (n=152) at 24 months, though not significantly (p=0.222) (table 2a). 
The treatment effects of ranibizumab, defined as change from baseline, were significantly 
different in the different lesion subtype groups (p=0.006). Also absolute visual acuity 
scores were significantly different between the lesion subtype groups (p<0.001) (table 
2b). Patients in the occult subtype group had consistently higher visual acuity scores 
throughout the study period compared to the minimally classic and predominantly 
classic groups (figure 1). 
Figure 1. Course of mean visual acuity (EDTRS letters) over time for the different lesion subtype groups
Visual acuity was also compared in treatment-naive versus non treatment-naive patients. 
There seemed to be a slightly better response to ranibizumab in the treatment-naive 
patients (from 44.3 ± 21.6 letters at baseline to 49.3 ± 24.7 at 24 months) versus non-
treatment naive patients (from 49.2 ± 20.8 letters at baseline to 45.0 ± 26.7 at 24 
months), although not statistically significant (p=0.532) (figure 2). The injection pattern 
was similar for both patient groups, 7.8 ± 4.1 injections in the treatment naive group 
versus 8.1 ± 4.3 injections in the non-naive group after 24 months, demonstrating that 
the difference in visual acuity was not due to a larger amount of ranibizumab injections.
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Figure 2. Course of mean visual acuity (ETDRS letters) over time for treatment naive vs. non-treatment 
naive patients
The visual acuity scores after 24 months were categorized in 4 BCVA outcome groups: 
significant improvement (gain of > 15 letters), improvement (gain of 15 - 0 letters), 
stabilization (loss of 0 - 15 letters) or deterioration (loss of > 15 letters). Of all patients, 
79.6% demonstrated an improvement or a loss of less than 15 letters. As shown in table 
3, 26 patients (17.1%) receiving ranibizumab showed a significant improvement in 
visual acuity, 49 patients (32.2%) showed an improvement, 46 patients (30.3%) showed 
a stabilization of visual acuity, and in  31 patients (20.4%) deterioration of visual acuity 
occurred. 
A similar pattern was observed for the different lesion subtype groups. No statistical 
differences were observed when comparing the lesion subtype groups (p=0.914).
Table 2a. Mean visual acuity as ETDRS letter score, mean visual acuity change from baseline and mean 
number of injections over time for the study population
 
Mean visual acuity EDTRS 
letter score ± SD
Mean visual acuity change 
from baseline EDTRS 
letters ± SD
Mean number of 
injections ± SD
Baseline 45.1 ± 21.5 (n=231) 1.0 ± 0.0
3 months 49.4 ± 22.7 (n=216) 4.6 ± 14.9 3.0 ± 0.7
6 months 48.4 ± 23.2 (n=203) 3.0 ± 18.1 4.1 ± 1.4
12 months 50.7 ± 24.0 (n=183) 4.4 ± 19.6 5.5 ± 2.3
18 months 49.7 ± 23.9 (n=168) 3.2 ± 22.1 6.7 ± 3.2
24 months 48.5 ± 25.1 (n=152) 1.0 ± 20.4 7.8 ± 4.2
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Table 3. Visual acuity scores after 24 months of ranibizumab treatment categorized in BCVA outcome 
scores
ETDRS category   Study population, n (%)
Significant improvement: > 15 letters improvement 26 (17.1%)
Improvement: 1-15 letters improvement 49 (32.2%)
Stabilization: 0-15 letters loss 46 (30.3%)
Deterioration: > 15 letters loss 31 (20.4%)
Drug exposure
Amount of ranibizumab injections
The total study population received a mean of 5.5 ± 2.3 injections during the first year 
(table 2a). The amount of injections in the second year were less than in the first year, 
since over the total 24 month period a mean of 7.8 ± 4.2 injections were administered. 
There were no differences observed in injection patterns for patients in the different 
lesion subtype groups.
Treatment patterns
In total, 184 patients (79.7%) completed the loading phase of one injection per month 
for 3 consecutive months, while 47 patients (20.3%) did not. Of the patients that did 
not complete the loading phase 28 (71.2%) were treatment naive, compared to 156 
(81.2%) of the patients that completed the loading phase. This was not a statistically 
significant difference (p=0.194). The average treatment interval between the first and 
second injection was 31.9 ± 9.1 days and between the second and third injection was 
34.3 ± 8.8 days for the patients that completed the loading phase. The average treatment 
interval between the first and third injection was 66.1 ± 12.6 days, which is in agreement 
with the three months duration of the loading phase. 
The visual acuity in the patients completing the loading phase increased from 44.2 ± 
21.6 at baseline to 51.0 ± 24.0 at 24 months follow-up. This increase in visual acuity 
was accompanied with an average of 7.4 ± 4.1 ranibizumab injections. This in contrast 
to patients who did not complete the loading phase, who had a decrease in mean visual 
acuity from 48.6 ± 20.9 letters at baseline to 37.6 ± 27.2 letters at 24 months follow-up, 
with an average of 5.6 ± 3.5 injections (p<0.001) (figure 3). Comparing the number of 
treatments between the two groups revealed a significant difference (p=0.005), suggesting 
that the total number of treatments is dependent on completion of the loading phase. 
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Figure 3. Course of mean visual acuity (ETDRS letters) over time for patients who completed the loading 
phase vs. patients who did not complete the loading phase
Health-Related Quality of Life and Visual Function Outcome
The EQ-5D questionnaire was used to assess quality of life and the EQ-VAS recorded 
the patient’s self-rated health. Over the course of 24 months of ranibizumab treatment, 
there were no significant changes from baseline in the EQ-5D index scores, indicating 
stabilization of the disease (p=0.936) (table 4a). However, for the EQ-VAS score an 
increase was observed after 24 months of ranibizumab treatment (from 53.7 ± 32.6 at 
baseline to 70.9 ± 16.7 at 24 months; p<0.001), demonstrating an improvement in self-
rated health as judged by the individual patient (table 4a). There were no differences in 
changes in quality of life between the lesion subtype groups (p=0.892).
wThe VFQ-25 questionnaire was used to assess the visual function outcome of patients 
being treated with ranibizumab. As demonstrated in table 4b, five of the eleven vision 
related subscale scores demonstrated a significant difference between visits for change 
from baseline between visits in visual function outcome during ranibizumab treatment: 
general vision (p = 0.023), ocular pain (p = 0.013), near activities (p = 0.043), distance 
activities (p = 0.014) and social functioning (p = 0.021).  Results for the lesion subtype 
groups were similar, except for distance activities and peripheral vision, where the 
minimally classic lesion subtype showed slightly worse results over time (data not 
shown). 
Table 4a. Health-related Quality of Life score of the EQ-5D and EQ-VAS questionnaires at baseline, 6, 
12 and 24 months (study population)
  EQ-5d score, mean ± SD EQ-VAS score, mean ± SD
Baseline 0.7880 ± 0.2193 (n=217) 53.7 ± 32.6
6 months 0.7800 ± 0.2532 (n=172) 60.6 ± 29.8
12 months 0.7804 ± 0.2319 (n=155) 59.6 ± 29.1
24 months 0.7864 ± 0.2127 (n=118) 70.9 ± 16.7
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Safety
In total, 64 adverse events occurred in 45 patients (18.5%) of the safety population, 
of which 29 were serious adverse events (SAE) occurring in 27 patients (11.1%). The 
majority of adverse events had a mild to moderate intensity and were considered not 
related to the ranibizumab treatment. Furthermore, most observed events were ocular: 
31 patients (12.8%) reported 40 ocular events.
The most commonly reported adverse events were detachment of retinal pigment 
epithelium (2.1%), eye pain (1.2%), conjunctival haemorrhage (0.8%), retinal pigment 
epithelial tear (0.8%), vitreous floaters (0.8%), visual impairment (1.2%) and cataract 
(0.8%). 
The reported SAE’s consisted of death (16), cardiac death (2), cardiac disorders of 
which one myocardial infarction (2), choroidal haemorrhage (1), iris bombé (1), retinal 
detachment (1), intraocular pressure increased (1), cardiac operation (1), cerebrovascular 
accident (1), gastric cancer (1), metastatic lung cancer (1) and lower limb fracture (1). 
The majority of the SAEs were considered by the physician as not suspected to have a 
relation with the study drug. Observations that were considered to be progression of 
the disease (e.g. pigment epithelial detachment) were not regarded as adverse events. 
The adverse events reported in this study were consistent with safety data from previous 
studies. 
Discussion
Although the efficacy and safety of ranibizumab in licensed indications has been clearly 
demonstrated in the clinical trial program of ranibizumab 7-11, the efficacy and safety in 
routine clinical practice may differ. The present observational study was conducted to 
investigate this in more detail over a period of 24 months in 243 wet AMD patients, in 
clinical practice in the Netherlands. 
Most patients (79.6%) demonstrated a stabilization or improvement of visual acuity in 
the primary involved eye after 24 months of treatment. This result was observed in the 
total study population as well as for the different lesion subtype groups. In comparison, 
in the MARINA and ANCHOR studies 94.5% and 96.4% of the patients showed 
stabilization or improvement.
The effect of ranibizumab was also investigated in treatment-naive and non treatment-
naive patients. Non treatment-naive patients seemed to show stabilization of vision, 
while in treatment-naive patients an improvement in visual acuity score was observed 
after 24 months, suggesting that treatment-naive patients respond better to ranibizumab 
treatment, though this was not significant. 
A mean of 5.5 ± 2.3 injections were administered in the total study population during 
the first year and 7.8 ± 4.2 injections over two years. The mean number of injections 
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per patient after one year were similar to that observed in the SUSTAIN study (5.6 
injections) 25 and slightly higher than in the SAILOR study, which demonstrated a 
mean number of 4.9 injections (in cohort 1) 26. There are not many data on an ‘as-
needed’ (PRN) regimen for two years. The mean number of injections after two years 
was lower than in the ranibizumab as-needed arm of the 2-year CATT study (mean 
number of injections 12.6) and in the as-needed arm of the 2-year IVAN study (median 
of 13 injections) 27, 28. The effectiveness of an as-needed regimen after two years has 
been shown by the CATT and IVAN studies. However, the mean gain in visual acuity 
after two years in this observational study was somewhat lower than seen in these large 
trials. After two years, patients in the CATT and IVAN study gained an average of 4-5 
letters. This higher gain in letters could be explained by the larger number of injections 
in the 2-year CATT and IVAN studies combined with the monitoring which was much 
stricter that what is usual in daily practice. In addition, patients included in our study 
had relatively low baseline visual acuity. This could reflect a patient group with more 
advanced neovascular AMD and with lower capacity to improve due to more progressive 
photoreceptor damage. 
The relatively low injection numbers together with the suboptimal functional outcomes 
at 24 months compared to the clinical trials, suggest that patient management could be 
improved. 
Though substantial differences in efficacy could be seen compared to the clinical trials, the 
results from other observational studies on ranibizumab efficacy were in general similar to 
the current study 12-22. Considering the treatment patterns, an apparent increase in long-
term visual acuity was found in patients who completed the loading phase compared to 
a decrease in visual acuity in those who did not. The importance of the loading phase 
on final visual acuity in observational studies has been shown previously 21 and we could 
corroborate that finding. However, patients that completed the loading phase received a 
larger total amount of ranibizumab injections, which might also explain the better visual 
acuity outcome in the study of Gupta et al. as well as in ours. The Belgium HELIOS 
study 22, an observational study performed alongside but independent of the Dutch 
HELIOS study, had markedly less favourable visual acuity results of 1.6 letter gain after 
1 year and a loss of 2.4 letters after 2 years, despite having a similar set-up and similar 
injection frequencies. A marked difference was that in the Belgium HELIOS study only 
about half of patients had a complete loading phase, compared to 80% in the Dutch 
HELIOS study, again showing the importance of completing the loading phase. Visual 
acuity gains in previous observational studies after 1 year ranged between 1 and 8 letters 
on ETDRS chart depending on which treatment regime was applied. Studies including 
monthly monitoring showed the better visual acuity results of 7 to 8 letter gains after 
1 year 15, 17, 18. In our study, monthly monitoring visits were not mandated and though 
part of the prescribing information this was left to the treating physician’s discretion. 
Possibly, strictness of monitoring could explain the variation in outcomes between the 
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observational studies. Injection frequencies between observational studies were quite 
similar, ranging from 4 to 7 injection in 1 year. 
The overall stabilization of visual acuity in our study was confirmed by the patient-
reported stabilization of the disease as measured by the Quality of Life EQ-5D scores 
and by the NEI VFQ-25 scores. There was no clear effect of ranibizumab treatment 
on EQ-5D and VFQ-25 scores. Interestingly, the EQ-VAS indicated that ranibizumab 
treatment results in an increase in quality of life appreciation according to the patient. 
The difference observed between the EQ-5D index and EQ-VAS outcome might be 
explained by the fact that the EQ-5D index can be regarded as a deterministic, societal 
based measure, whereas the EQ-VAS is a single direct ‘holistic’ assessment from the 
patient’s perspective. Therefore, the EQ-VAS leaves patients free to merge all relevant 
health state domains, and thus might be broader than the five EQ-5D domains. These 
data indicate that patients may benefit from ranibizumab treatment with regard to 
overall quality of life improvement (measured by the EQ-5D VAS score). Part of the 
effect might come from improvement in other (not-measured) health state domains.
Evaluation of the safety and tolerability demonstrated that the ranibizumab treatment 
during 24 months was associated with relatively few AEs in 45 (18.5%) patients and 
SAEs in 27 (11.1%) patients. The majority of SAEs were considered not to be related 
to the ranibizumab treatment. No new safety issues were identified in this study and 
the results are in line with safety data from previous studies 7-11, 25, 26. The LUMINOUS 
study 29, a retrospective observational study of four European registries including 
HELIOS, showed that the safety profile was comparable between registries for most 
AEs. However, we cannot exclude that there is a possible underreporting of AEs due to 
the observational setting of the study. 
In conclusion, this study demonstrates that ranibizumab treatment is effective in 
preventing vision loss over a period of 24 months. Completing the loading phase has 
a possible impact on long-term visual acuity outcome, thereby demonstrating the 
importance of monthly injections of ranibizumab for three consecutive months. This 
study was performed under the “old” label with a loading phase of three consecutive 
injections and then a PRN regimen. Ranibizumab now has a new label where treatment 
is given monthly and continued until maximum visual acuity is achieved. This might 
result in better treatment outcomes. Lastly, ranibizumab treatment was well tolerated 
and no new safety findings were identified. The suboptimal functional outcomes at 24 
months, suggest that patient management could be improved. 
A prospective, observational, open-label, multicenter study to investigate the daily treatment 
practice of ranibizumab in patients with neovascular age-related macular degeneration
49
References
1. Pascolini D, Mariotti SP, Pokharel GP, et al. 2002 global update of available data on visual impairment: 
a compilation of population-based prevalence studies. Ophthalmic epidemiology 2004; 11(2): 67-115.
2. Congdon N, O’Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among 
adults in the United States. Archives of ophthalmology 2004; 122(4): 477-85.
3. Brown MM, Brown GC, Stein JD, Roth Z, Campanella J, Beauchamp GR. Age-related macular 
degeneration: economic burden and value-based medicine analysis. Canadian journal of ophthalmology 
Journal canadien d’ophtalmologie 2005; 40(3): 277-87.
4. Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the 
United States. Archives of ophthalmology 2004; 122(4): 564-72.
5. Schmidt-Erfurth UM, Richard G, Augustin A, et al. Guidance for the treatment of neovascular age-
related macular degeneration. Acta ophthalmologica Scandinavica 2007; 85(5): 486-94.
6. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: 
crystal structure of an affinity-matured Fab in complex with antigen. Journal of molecular biology 
1999; 293(4): 865-81.
7. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular 
degeneration. The New England journal of medicine 2006; 355(14): 1419-31.
8. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy 
for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. 
Ophthalmology 2009; 116(1): 57-65 e5.
9. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for 
neovascular age-related macular degeneration: PIER study year 2. American journal of ophthalmology 
2010; 150(3): 315-24 e1.
10. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmology 
clinics of North America 2006; 19(3): 361-72.
11. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related 
macular degeneration: evidence from clinical trials. The British journal of ophthalmology 2010; 94(1): 
2-13.
12. Cohen SY, Mimoun G, Oubraham H, et al. Changes in visual acuity in patients with wet age-related 
macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE 
study. Retina 2013; 33(3): 474-81.
13. Finger RP, Wiedemann P, Blumhagen F, Pohl K, Holz FG. Treatment patterns, visual acuity and 
quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment 
for neovascular age-related macular degeneration in Germany. Acta ophthalmologica 2013; 91(6): 
540-6.
14. Wolf A, Kampik A. Efficacy of treatment with ranibizumab in patients with wet age-related macular 
degeneration in routine clinical care: data from the COMPASS health services research. Graefe’s 
archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und 
experimentelle Ophthalmologie 2014; 252(4): 647-55.
Chapter 2
50
15. Lala C, Framme C, Wolf-Schnurrbusch UE, Wolf S. Three-year results of visual outcome with 
disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular 
degeneration. Acta ophthalmologica 2013; 91(6): 526-30.
16. Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK. Evaluation of injection frequency and 
visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. 
Ophthalmology 2009; 116(9): 1740-7.
17. Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE. Effects of 
ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related 
macular degeneration. American journal of ophthalmology 2009; 147(5): 831-7.
18. Querques G, Azrya S, Martinelli D, et al. Ranibizumab for exudative age-related macular 
degeneration: 24-month outcomes from a single-centre institutional setting. The British journal of 
ophthalmology 2010; 94(3): 292-6.
19. Rotsos T, Patel PJ, Chen FK, Tufail A. Initial clinical experience of ranibizumab therapy for 
neovascular age-related macular degeneration. Clinical ophthalmology 2010; 4: 1271-5.
20. Gerding H, Loukopoulos V, Riese J, Hefner L, Timmermann M. Results of flexible ranibizumab 
treatment in age-related macular degeneration and search for parameters with impact on outcome. 
Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische 
und experimentelle Ophthalmologie 2011; 249(5): 653-62.
21. Gupta B, Adewoyin T, Patel SK, Sivaprasad S. Comparison of two intravitreal ranibizumab treatment 
schedules for neovascular age-related macular degeneration. The British journal of ophthalmology 
2011; 95(3): 386-90.
22. Rakic JM, Leys A, Brie H, et al. Real-world variability in ranibizumab treatment and associated 
clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related 
macular degeneration: the HELIOS study. Clinical ophthalmology 2013; 7: 1849-58.
23. Summary of Product Characteristics Lucentis. 2008.
24. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. 
Retina 2010; 30(7): 1046-50.
25. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab 
in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011; 118(4): 
663-71.
26. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb study to 
evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. 
Ophthalmology 2009; 116(9): 1731-9.
27. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular 
age-related macular degeneration: two-year results. Ophthalmology 2012; 119(7): 1388-98.
28. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related 
choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013; 
382(9900): 1258-67.
A prospective, observational, open-label, multicenter study to investigate the daily treatment 
practice of ranibizumab in patients with neovascular age-related macular degeneration
51
29. Holz FG, Bandello F, Gillies M, et al. Safety of ranibizumab in routine clinical practice: 1-year 
retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS 
programme. The British journal of ophthalmology 2013; 97(9): 1161-7.

Prediction of treatment response

Chapter 3a
Predicting non-response to ranibizumab in patients 
with neovascular age-related macular degeneration.
Freekje van Asten
Maroeska M. Rovers 
Yara T.E. Lechanteur 
Dzenita Smailhodzic 
Philipp S. Muether 
John Chen
Anneke I. den Hollander 
Sascha Fauser 
Carel B. Hoyng
Gert Jan van der Wilt
B. Jeroen Klevering
Ophthalmic Epidemiol. 2014 Dec;21(6):347-55.
Chapter 3a
56
Purpose: To validate known and to determine new predictors of non-response to 
ranibizumab in patients with neovascular age-related macular degeneration (AMD) and 
to incorporate these factors into a prediction rule.
Methods: This multicenter, observational cohort study included 391 patients treated 
with ranibizumab for neovascular AMD. We performed genetic analysis for single 
nucleotide polymorphisms in AMD-associated genes and collected questionnaires 
regarding environmental factors and disease history. The primary outcome was non-
response to treatment, which we defined as a loss of visual acuity of 30% of letters or 
more.  
Results: Of the 391 patients, 47 were classified as non-responder. Independent predictors 
for non-response were: age, baseline visual acuity, diabetes mellitus and accumulation 
of risk alleles in the CFH, ARMS2 and VEGF-A genes. The area under the receiver 
operating characteristic (ROC) curve was 0.77 (95% confidence interval: 0.70 - 0.84). 
We derived a clinical prediction rule, with possible total risk scores ranging from 0 to 
19 points. The absolute risk of non-response varied from 3% to 52% between risk score 
groups.    
Conclusion:. This is an important step towards a clinical prediction rule that can aid 
clinicians in identifying AMD patients with increased likelihood of non-response and 
consequently contribute to making shared treatment decisions. 
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Introduction
Age-related macular degeneration (AMD) remains the leading cause of severe visual 
impairment in the Western world 1. Neovascular AMD accounts for approximately 10% 
of all patients with AMD, but is responsible for the majority of AMD-related severe 
vision loss 2, 3. In this type of AMD, choroidal blood vessels invade the central retina 
and subretinal space, leaking serous fluid, lipids and blood leading to fibrous scarring. 
Untreated, choroidal neovascularizations (CNV) will result in a loss of 1-3 Early 
Treatment Diabetic Retinopathy Study (ETDRS) lines (5-15 letters) at 3 months and 
3-4 lines at 1 year 4. In recent years, intraocular administered drugs (ranibizumab and 
bevacizumab) aimed at blocking vascular endothelial growth factor A (VEGF-A) have 
become the mainstay of treatment for neovascular AMD. Although these agents have 
improved visual prognosis considerably 5, 6, about 10% of the patients do not respond to 
this therapy and still experience substantial visual loss, namely a loss of 15 letters or more, 
which is comparable to the natural course of the disease 6, 7. Treatment can become quite 
burdensome particularly for the elderly patients, as patients have to visit the clinic at 
monthly intervals. By reliably identifying non-responders early in the treatment process, 
the burden from otherwise ineffective and costly intraocular injections may be reduced. 
Several studies have suggested that genetic factors influence the response to anti-VEGF 
therapy in AMD. To date no single nucleotide polymorphism (SNP) has been consistently 
associated with treatment response. Both the Y402H risk allele in the CFH gene and 
the ARMS2 A69S have been linked to a reduced treatment effect, subsequent reports, 
however, could not corroborate this effect 8-16. Recently, Smailhodzic and co-workers 
demonstrated that accumulation of high-risk alleles in the CFH, ARMS2 and VEGF-A 
(rs699947) genes were associated with poor response rates to ranibizumab treatment 
and a younger age of onset of neovascular disease 17. Besides underlying genetic factors, 
several reports have shown that non-responders tend to be older, demonstrate larger 
neovascular lesions and present with a higher visual acuity at baseline 18-21. 
In this study, we assessed the combined effect of known and newly determined response-
related factors in neovascular AMD. The objective of this study was to develop a clinical 
prediction model to help identify non-responders for ranibizumab in patients with 
neovascular AMD. 
Materials and Methods
Population
We evaluated 391 eyes of 391 unrelated Caucasian patients aged 50 years or older with 
active CNV secondary to AMD. All study participants were enrolled between June 
2008 and June 2010 in the European Genetic Database (EUGENDA), a multicenter 
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database for the clinical and molecular analysis of AMD. All patients were treated at the 
Departments of Ophthalmology of the Radboud University Nijmegen Medical Center, 
the Netherlands; the University of Cologne, Germany; or the McGill University Health 
Center, Montreal, Canada. This observational cohort study was performed in accordance 
with the tenets of the Declaration of Helsinki (1983 revision) and the Medical Research 
Involving Human Subjects Act (WMO). The approval of the local ethics committee 
was obtained for all three centers and written informed consent was acquired from all 
participants.
The diagnosis active neovascular AMD was established by retinal specialists based on 
signs of leakage on fluorescein angiography (FA)8 (Spectralis HRA+OCT, Heidelberg 
Engineering, Heidelberg, Germany; or Imagenet, Topcon Corporation, Tokyo, Japan), 
combined with presence of fluid or blood during ophthalmic examination or on spectral-
domain optical coherence tomography (OCT) (Spectralis HRA+OCT, Heidelberg 
Engineering, Heidelberg, Germany). The lesion type of the CNV was determined by 
FA, and was classified into 4 categories: occult with no classic component, minimally 
classic, predominantly classic and retinal angiomatous proliferation (RAP) 6. Prior 
to retinal imaging, pupillary dilatation was achieved with topical 1.0% tropicamide 
and 2.5% phenylephrine. Patients with retinal disorders other than AMD, including 
manifest diabetic retinopathy, were excluded. 
Each participant underwent best-corrected visual acuity (BCVA) assessments prior 
to and after treatment with three monthly 0.5 mg ranibizumab injections. For 314 
(80.3 %) patients the Snellen visual acuity was collected retrospectively at a later time 
point after treatment, whereas 77 (19.7%) patients were followed prospectively during 
treatment using ETDRS visual acuity. We did not adopt any exclusion criteria based 
on visual acuity, because we aimed to collect a patient cohort that represents clinical 
practice. This way, any predictive factors found in this study can be applied in the 
broadest possible way.  
 After the three loading injections, patients received on demand re-injections whenever 
signs for CNV activity were detected by clinical examination, funduscopy or FA. OCT 
was used when available.
Patients were excluded from this study if they had received prior treatments for active 
subfoveal CNV secondary to AMD. If both eyes were eligible for inclusion, the eye 
that received treatment first was chosen as the study eye. If both eyes started treatment 
simultaneously, the study eye was chosen at random.
Predictive factors
Questionnaires were used to collect information regarding disease history and 
environmental factors, which included smoking habits, body mass index and disease 
history. Venous blood for genotyping was drawn before onset of treatment. Genotyping 
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of SNPs in the CFH (Y402H; rs1061170), ARMS2 (A69S; rs10490924), VEGF-A 
(rs699947 and rs833069), KDR (rs2071559 and rs7671745), LPR5 (rs3736228), 
and FZD4 (rs10898563) genes was performed with TaqMan probes and primers, 
using assays developed by Applied Biosystems, and an ABI 7900HT system (Applied 
Biosystems, Nieuwerkerk a/d IJssel, the Netherlands) as described previously 17. Total 
CNV lesion size was measured on FA by dividing the total CNV lesion area by the 
optic disk area (DA). Total CNV lesion size was defined as the area of CNV, blocked 
fluorescence from hemorrhage or from other causes, pigment epithelial detachment and 
fibrosis. Measurements were performed using the open source image processing tool 
ImageJ (version 1.47f; available at http://rsb.info.nih.gov/ij) 22. The multiple imputation 
function in SPSS using all available factors was applied to impute missing values when 
needed to maintain statistical power. The outcome variable was available for all patients.
Outcome
The main outcome measure in this study is non-response. We based non-response 
on a functional outcome, namely the change in visual acuity. We chose not to use an 
anatomical response as seen on OCT because, from a patient’s perspective, vision is the 
only relevant outcome. An definition often used to define non-response is the loss of 
at least 15 ETDRS letters. This approach, however, tends to underestimate the number 
of non-responder in patients with a low visual acuity, as the amount of vision that 
can be lost is limited (floor effect). In contrast, patients with a high baseline visual 
acuity have greater potential to lose vision and the possibility of improvement is limited 
(ceiling effect).  To avoid this floor-ceiling effect, we defined non-response as a loss of 
30% of letters or more from baseline, which roughly corresponds with a loss of three 
EDTRS lines from the mean baseline visual acuity in this cohort. In table 1 we show 
the cut-off points for being non-responder with respect to baseline visual acuity. When 
baseline visual acuity was 20/640 or lower, a loss of 0 letters or more was considered 
non-response as visual acuity from that point was deemed too low to expect any more 
vision loss and changes in visual acuity would become too small to measure accurately. 
Because patients were treated according to an on demand schedule, follow-up and total 
number of injections varied among patients. To achieve a comparable and standardized 
evaluation of the response to ranibizumab, we analyzed the data to identify non-
responders after the first three consecutive monthly ranibizumab injections. In the 
majority of patients the maximum change in visual acuity will have been reached after 
the first three monthly injections with ranibizumab, making it a good indication of long-
term response 19. Using this method, we calculated the cut-off point for non-response 
for each individual patient and classified each patient accordingly.  
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Table 1. Cut-off point for non-response with respect to baseline visual acuity
Baseline visual acuity 
(Snellen)
Baseline visual acuity 
(letters)
Cutoff point for  
non-response
(letters)
Cutoff point for  
non-response (Snellen)
20/20 85 59 20/65
20/25 80 56 20/76
20/32 75 52 20/89
20/40 70 49 20/105
20/50 65 45 20/123
20/63 60 42 20/145
20/80 55 38 20/170
20/100 50 35 20/200
20/125 45 31 20/235
20/160 40 28 20/276
20/200 35 24 20/324
20/250 30 21 20/381
20/320 25 17 20/448
20/400 20 14 20/526
20/500 15 10 20/618
20/640 10 10 20/640
20/800 5 5 20/800
20/1000 0 0 20/1000
For each individual the cutoff point for non-response was determined by calculating the visual acuity after 
a loss of 30% of letters from baseline. Patients with a visual acuity after treatment equal to or lower than 
the calculated value (last column), were considered non-responder. Patients with 20/640 or lower were 
considered non-responder when their vision remained stable, as more vision loss in this group was not to 
be expected.
Statistical analyses
Snellen and EDTRS visual acuity was converted to the logarithm of minimal angle 
of resolution (logMAR) visual acuity for the purpose of statistical analysis. Change in 
visual acuity was calculated as the difference between the vision at baseline and after 
three months of follow-up. 
The association of the environmental and genetic factors with the main-outcome measure 
was assessed with univariable logistic regression analyses. Variables were dichotomized or 
categorized when possible. Visual acuity prior to treatment was categorized into groups 
by taking the quartiles of the range of baseline visual acuity in this cohort (approximately 
0.00-2.00 logMAR). Thus, the following four groups were established: > 0.50 logMAR 
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(20/63), between 0.50 and 1.00 logMAR (20/63-20/200), between 1.00 and 1.50 
logMAR (20/200-20/640) and ≤ 1.50 logMAR (20/640). The various genotypes were 
assessed separately as well as cumulatively in association with non-response, taking into 
account any additive effects that may exist between risk alleles as described before 17. 
Factors that were possibly associated with non-response (overall P < 0.20) were included 
in multivariable logistic regression analyses. The model was reduced by stepwise 
elimination of factors with a P-value of > 0.15 until four variables remained 23, 24. The 
model’s ability to discriminate between non-responders and responders was estimated as 
the area under the curve (AUC) for the receiver operating characteristic (ROC) curve. 
The Hosmer-Lemeshow goodness-of-fit test was used to estimate the reliability of the 
model. The model was validated internally using bootstrapping techniques, yielding a 
shrinkage factor for the regression coefficients and the ROC AUC 25, 26.
To obtain a prediction rule that is easily applicable in clinical practice, the adjusted 
regression coefficients of the model were divided by the lowest coefficient and rounded 
to the nearest integer. Scores for each individual patient were obtained by assigning 
points for each variable and adding the results. Patients were grouped according to risk 
score and the absolute risk of non-response for each risk score group was calculated. All 
statistical analyses were performed using SPSS, version 20.0 (SPSS, Inc., Chicago, IL).
Results
Of the 391 patients that met the eligibility criteria, 47 (12.0%) could be classified as 
non-responder and 344 (88.0%) as responder. Mean change in baseline visual acuity was 
plus 7.6 ± 10.7 letters for responders and minus 21.2 ± 13.1 letters for non-responders 
(P < 0.001). Demographic and disease characteristics of responders and non-responders 
are summarized in Table 2 and genotype characteristics are shown in Table 3. Visual 
acuity measurements after 12 months were available for 254 patients and showed that 
non-response at three months (in 30 of 254 patients) was strongly associated with non-
response at 12 months (in 43 of 254 patients) (P < 0.001). Eight of the non-responders 
at 3 months, no longer met the criteria after 12 months, but only three of these patients 
actually gained visual acuity from baseline. 
Results of multivariable logistic regression analyses are presented in Table 4. The final 
reduced regression model included four independent predictive variables, that is age, 
baseline visual acuity, diabetes mellitus and accumulation of risk alleles in the CFH, 
ARMS2 and VEGF-A genes. Other risk allele combinations of were not of added value 
(data not shown). Though CNV lesion size was significant and CNV type was marginally 
significant in univariable analyses, these variables were no longer significantly associated 
with non-response in the multivariable regression analysis and were not of added value 
to the model and hence not included in the prediction model. 
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The Hosmer-Lemeshow goodness-of-fit test indicated an acceptable fit of the final 
prognostic model (P = 0.69), and the AUC was 0.77 (95% CI: 0.70 - 0.84) (Figure 1). 
This equals a discriminative ability of 77%, meaning that by using this prediction model 
77% of patients are correctly classified as responder or non-responder. Internal validation 
Table 2. Univariable analysis of predictor variables for non-response: demographic and disease 
characteristics
Variables Responders 
n (%)
Non-respon-
ders n (%)
OR (95%-CI) P-value
Total 344 (88.0) 47 (12.0)
Age >80 years 117 (34.0) 25 (53.2) 2.2 (1.2-4.1) 0.012 *
Male gender 151 (43.9) 20 (42.6) 0.9 (0.5-1.8) 0.862
VA prior to treatment (Snellen)
> 20/63 142 (41.3) 7 (14.9) 1.0 < 0.001 *
20/63 - 20/200 124 (36.0) 20 (42.6) 3.3 (1.3-8.0) 0.009 *
20/200 - 20/640 74 (21.5) 14 (29.8) 3.8 (1.5-9.9) 0.006 *
≤ 20/640 4 (1.2) 6 (12.8) 30.4 (7.0-133.0) < 0.001 *
Disease history
Hypertension (n=273) 143 (58.6) 18 (66.7) 1.4 (0.6-3.3) 0.420
Diabetes (n=273) 39 (16.0) 10 (37.0) 3.1 (1.3-7.3) 0.009 *
Myocardial infarction (n=122) 10 (9.2) 1 (7.7) 0.8 (0.1-7.0) 0.860
Angina pectoris (n=122) 9 (8.3) 1 (7.7) 0.9 (0.1-8.0) 0.944
Stroke or TIA (n=122) 9 (8.3) 0 (0.0) 0.0 (0.0-inf.) 0.999
Environmental factors
Smoking ≥ 20 packyears (n=149) 33 (25.2) 7 (43.8) 2.3 (0.8-6.7) 0.123
BMI  > 30 (n=272) 38 (15.6) 5 (20.0) 1.4 (0.5-3.8) 0.566
Angiographic characteristics
Occult with no classic 190 (55.2) 18 (38.3) 1.0 0.177
RAP 20 (5.8) 2 (4.3) 1.1 (0.2-4.9) 0.945
Minimally classic 34 (9.9) 8 (17.0) 2.5 (1.0-6.2) 0.050 *
Predominantly classic 65 (18.9) 11 (23.4) 1.8 (0.8-4.0) 0.156
Unknown
Lesion size (DA) (n=295)
< 2
2 - 4
4 - 6
> 6
35
93
78
40
48
(10.2)
(35.9)
(30.1)
(15.4)
(18.5)
8
6
14
4
12
(17.0)
(16.7)
(38.9)
(11.1)
(33.3)
2.4
1.0
2.8
1.6
3.9
(1.0-6.0)
(1.0-7.6)
(0.4-5.8)
(1.3-11.0)
0.057
0.058
0.045
0.515
0.011
*
*
OR=odds ratio; VA=visual acuity; TIA=transient ischemic attack; BMI=body mass index; RAP=retinal 
angiomatous proliferation; DA=disk areas. 
Values from certain variables were missing for some of the patients; n=total number of patients included 
in analysis.
*P-value ≤ 0.05, indicating statistical significance. The P-values behind the reference categories, represent 
the overall P-values for the prognostic factor. All P-values are derived from univariable logistic regression 
analysis.
Predicting non-response to ranibizumab in patients with neovascular age-related macular 
degeneration
63
Table 3. Univariable analysis of predictor variables for non-response: genotype
 Genotype variables Responders 
n (%)
Non-respon ders
n (%)
OR (95% CI)
 
P-value
 
CFH (Y402H) (n=391)              
  TT 67 (19.5) 7 (14.9) 1.0   0.646  
  CT 165 (48.0) 22 (46.8) 1.3 (0.5-3.1) 0.594  
  CC 112 (32.6) 18 (38.3) 1.5 (0.6-3.9) 0.361  
ARMS2 (A69S) (n=391)              
  GG 115 (33.4) 12 (25.5) 1.0   0.558  
  TG 144 (41.9) 22 (46.8) 1.5 (0.7-3.1) 0.316  
  TT 85 (24.7) 13 (27.7) 1.5 (0.6-3.4) 0.368  
VEGF-A (rs699947) (n=375)              
  CC 75 (22.7) 8 (18.2) 1.0   0.738  
  CA 158 (47.7) 21 (47.7) 1.2 (0.5-2.9) 0.616  
  AA 98 (29.6) 15 (34.1) 1.4 (0.6-3.6) 0.436  
VEGF-A (rs833069) (n=368)              
  TT 143 (44.0) 15 (34.9) 1.0   0.528  
  TC 137 (42.2) 21 (48.8) 1.5 (0.7-3.0) 0.290  
  CC 45 (13.8) 7 (16.3) 1.5 (0.6-3.9) 0.420  
KDR (rs2071559) (n=369)              
  AA 72 (22.2) 15 (34.1) 1.0   0.133  
  AG 166 (51.1) 16 (36.4) 0.5 (0.2-1.0) 0.046 *
  GG 87 (26.8) 13 (29.5) 0.7 (0.3-1.6) 0.419  
KDR (rs7671745) (n=364)              
  GG 109 (33.7) 16 (39.0) 1.0   0.771  
  GA 176 (54.5) 20 (48.8) 0.8 (0.4-1.6) 0.473  
  AA 38 (11.8) 5 (12.2) 0.9 (0.3-2.6) 0.841  
LPR5 (rs3736228) (n=364)              
  TT 191 (59.5) 24 (55.8) 1.0   0.829  
  CT 83 (25.9) 13 (30.2) 1.2 (0.6-2.6) 0.550  
  CC 47 (14.6) 6 (14.0) 1.0 (0.4-2.6) 0.974  
FZD4 (rs10898563) (n=372)              
  AA 114 (34.8) 15 (34.1) 1.0   0.826  
  AG 159 (48.5) 20 (45.5) 1.0 (0.5-1.9) 0.901  
  GG 55 (16.8) 9 (20.5) 1.2 (0.5-3.0) 0.630  
Risk allele accumulation in CFH, 
ARMS2, VEGF-A (n=375)              
mean number of risk alleles ± SD 3.1 ± 1.2 3.4 ± 1.0 1.3 (1.0-1.7) 0.105  
Values from certain variables were missing for some of the patients; n=total number of patients included 
in analysis.
*P-value ≤ 0.05, indicating statistical significance. The P-values behind the reference categories, represent 
the overall P-values for the prognostic factor. All P-values are derived from univariable logistic regression 
analysis.
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using bootstrapping techniques yielded an over-optimism of 0.03. The shrunk AUC was 
0.75 (shrinkage factor of 0.86). 
Figure 1. Area under the curve of the receiver operating characteristic curve of the prediction model for 
non-response.  
The ROC curve is a plot of the true-positive rate (sensitivity) versus the false-positive rate (1 − specificity) 
evaluated at consecutive cut-off points for the predicted probability. The AUC provides a quantitative 
summary of the discriminative ability of a predictive model. A useless predictive model, such as a coin flip, 
would yield an AUC of 0.50. When the AUC is 1.00, the model discriminates perfectly between subjects 
who do and subjects who do not develop a prognostic outcome. The AUC of our prediction model for 
non-response was 0.77. The prediction model contains the predictors: age, diabetes, accumulation of risk 
alleles in the CFH, ARMS2 and VEGF-A genes and baseline visual acuity.
We developed a clinical prediction rule by assigning points to each predictive factor 
based on its regression coefficient (Table 4). We assigned 1 point for each risk allele in 
the CFH, ARMS2 or VEGF-A genes, 2 points for diabetes mellitus, 2 points for age of 
over 80 years, 3 points for a baseline visual acuity between 20/63 and 20/200, 4 points 
for baseline visual acuity between 20/200 and 20/640 and 9 points for a baseline visual 
acuity of 20/640 or less. We divided risk scores into 3 groups. 
The last group consisted of the 5% highest scoring individuals. The remaining 95% 
was divided into two groups consisting of the 50% lowest scoring individuals and 
the individuals in between the lowest and highest scoring groups. This resulted in the 
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following 3 risk score groups: 0-6, 7-10 and 11-19 points. The absolute risk for being a 
non-responder increased as the risk score increased (Figure 2). 
Figure 2. Absolute risk of non-response per risk score group
Discussion
Health care costs are ever rising  and to reduce the number of costly and unnecessary 
treatments we need reliable prediction rules. The current study describes the first step 
towards a clinical prediction rule that helps identifying non-responders to intravitreal 
injections with ranibizumab for age-related macular degeneration. 
In this study, the independent predictors of non-response were: age, diabetes mellitus, 
baseline visual acuity and accumulation of risk alleles in the CFH, ARMS2 and VEGF-A 
genes. The association of advanced age and certain risk alleles with a reduced treatment 
response is in line with earlier reports 17, 18, 20, 21. New correlations include the association 
of non-response with a low baseline visual acuity as well as with diabetes mellitus. The 
relation with a low baseline visual acuity is in contrast with other reports 18, 20, 21 and 
is most likely a consequence of the novel definition of non-response in this study that 
corrects for the floor-ceiling effect. The reason for this association is probably a greater 
degree of photoreceptor damage in the group of patients with low visual acuity. The 
increased risk for non-response to ranibizumab for diabetes patients has not been shown 
before although earlier reports suggested an association between diabetes and incident 
geographic atrophy secondary to AMD as well as incident neovascular AMD 27, 28
In previous subgroup analyses of the large ranibizumab trials, total CNV lesion size and 
CNV type were considered important predictors of treatment response 18, 20, 21. In this 
study, however, lesion size and CNV type were only associated with non-response in 
univariable analyses. The adding of baseline visual acuity to the model seemed to take 
away much of the effect size, indicating that baseline vision already accounts for much 
of the predictive value of these factors. Considering visual acuity at baseline is a much 
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more convenient measure in clinical practice and less prone to inter-observer variation, 
the inclusion of baseline vision into a prediction model instead of the CNV lesion type 
or the lesion size seems an obvious choice. 
This study focussed on a prediction model of functional non-response. Hence, we used 
visual acuity to define non-response. We defined non-response as a loss of 30% of letters 
from baseline. When using definitions of non-response employed in other studies, such 
as for example a loss of 15 letters, the results from the model were very similar, yielding 
the same predictive factors as in our prediction model. Only baseline visual acuity showed 
a reversed association, which most probably represents the neglected floor-ceiling effect, 
underestimating non-response in patients with low visual acuity. 
This study is based on clinical practice and therefore included patients with low baseline 
visual acuity. In most trials these patients are not included because the anticipated 
treatment effect is small. Our prediction model shows baseline VA as a strong predictor 
of non-response, which supports the notion that patients with low baseline vision 
indeed benefit less from treatment. However, the possibility exists that there is an 
over-representation of individuals with low vision in our non-responders group due 
to how we defined non-response. To assess the effect of baseline vision on the non-
response prediction model, we repeated the analyses with the exclusion of patients with 
baseline visual acuity <20/400. This did not lead to the selection of different predictors 
for the final model, nor did it change the parameter estimates of the univariable and 
multivariable analyses. The accompanying AUC was now 0.73. The absolute risk of 
non-response in the highest risk group decreased to 26% due to the removal of 10 non-
responders on account of the new exclusion criterion. This indicates that the prediction 
model presented here is applicable to populations with various ranges of vision and that 
the other predictors presented here are related to non-response independent of baseline 
vision.
Non-response in this study was determined after 3 months of treatment, because previous 
studies clearly demonstrated that virtually all visual gain can be expected in this period5, 
6. Furthermore, response after 3 months appears to be strongly correlated with long-
term response19. The current study corroborated the correlation between non-response 
after 3 and 12 months. Also, the factors associated with non-response after 3 months 
were similarly associated with non-response after 12 months. The associations from this 
study likely translate to long-term predictions, although 8 out of 47 non-responders at 
3 months could be considered responders at 12 months. Therefore, validation of the 
model with long-term outcomes is warranted. 
This study has some potential limitations that should be discussed. The presence of 
subretinal tissue, cystoid macular edema and reduced central retinal thickness on 
OCT has been linked with an increased risk for non-response to anti-VEGF 29, 30. 
Unfortunately, baseline OCT scans were not available for the majority of patients in 
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this study. We believe that these predictive factors should also be included in a future 
improved version of the prediction rule. 
A loss of vision of 30% is comparable to the natural course of disease, however, we cannot 
be sure that the non-responders in this study would not have lost more vision  without 
treatment. To estimate the consequences of such potential misclassification of non-
response, we will need efficiency trials that compare conventional treatment strategy to 
treatment strategy based on a prediction model, once more advanced prediction models 
become available. 
A major strength of the current study is the combination of various new and known 
predictors of non-response into a prediction model for non-response. There have been 
many previous studies focusing on single predictive factors. This study incorporates 
many of these predictor variables into a practical tool. The current model is not yet 
advanced enough to be the determining factor to discontinue treatment. The chance of 
non-response for high-risk individuals (namely, older patients with low baseline vision, 
diabetes and an unfavourable genetic profile), is approximately 50%, compared to the 
generally accepted 10% in the overall population. This absolute increase is of such 
significance that it should be taken into account by the clinician and the patient in their 
shared decision making on the treatment strategy.  
We need to continue the search for additional risk factors to refine the prediction model. 
In that sense, this model might very well serve as a guideline for future prediction models. 
Every predictor of response adds to a more accurate identification of patients with a 
heightened risk of non-response and a prediction rule can assist in making the decision 
to stop treatment. This is important not only to restrict the burden of a prolonged 
unsuccessful anti-VEGF treatment for patients and their family members, but also to 
apply a very costly treatment to those patients most likely to benefit. Finally, clinical 
prediction rules will become even more useful with the availability of new treatment 
modalities. Patients with a high-risk for non-response to ranibizumab may be offered an 
alternative therapy at an early stage. 
In conclusion, the combination of different genetic and environmental risk factors from 
this study can predict non-response to intravitreal ranibizumab treatment to certain 
extent. This study is an important step towards developing a straightforward prediction 
rule to help identify those AMD patients that are at an increased risk for non-response 
to ranibizumab treatment. 
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Purpose: Intravitreal anti–vascular endothelial growth factor (VEGF) injections are 
currently the standard treatment for neovascular age-related macular degeneration 
(AMD), but a broad range of response rates has been observed. We evaluated the 
association of single nucleotide polymorphisms (SNPs) in VEGF genes and their 
receptors (VEGFR) with the response rate to ranibizumab in 366 patients with 
neovascular AMD.
Methods: Design: Case series study. Participants: A total of 366 eyes of 366 patients 
with neovascular AMD. Visual acuity (VA) was determined at baseline, after 3 monthly 
ranibizumab injections, and after 1 year of treatment. Genotyping of 126 SNPs in the 
genes encoding VEGF family members VEGFA, VEGFB, VEGFC, VEGFD (FIGF), 
and placental growth factor (PGF); VEGF receptors VEGFR1 (FLT1), VEGFR2 
(KDR), and VEGFR3 (FLT4); and the gene encoding pigment epithelium-derived 
factor (PEDF) (SERPINF1) was performed. Main Outcome Measures: The changes in 
VA after 3 injections and after 1 year of treatment and their association with VEGF and 
VEGFR genotypes.
Results: Univariate analyses of variance (ANOVAs) revealed a significant effect of SNP 
rs4576072 in the VEGFR2 gene on VA change after 12 months (F[1,235] = 14.05; P = 
0.02). A stepwise linear regression analysis returned a model (P  = 0.01) with SNPs 
rs4576072 and rs6828477 in the  VEGFR2  gene as independent predictors for VA 
change after 12 months, with a mean increase in VA of 0.26 on the logarithm of the 
minimum angle of resolution (logMAR) scale in patients with 3 contributing minor 
alleles compared with a loss of 0.03 logMAR in patients with no minor allele.
Conclusion: Polymorphisms in the VEGFR2/KDR gene significantly influence visual 
outcome in patients receiving ranibizumab treatment for neovascular AMD. This study 
shows that genetic variation partially explains the wide range of response to ranibizumab 
treatment, which in the future might help clinicians tailoring medical interventions to 
individual needs.
Polymorphisms in Vascular Endothelial Growth Factor Receptor 2 Are Associated with Better 
Response Rates to Ranibizumab Treatment in Age-related Macular Degeneration
75
Introduction
In neovascular age-related macular degeneration (AMD), newly formed choroidal blood 
vessels (choroidal neovascularization [CNV]) invade the subretinal and intraretinal 
spaces, causing exudation, hemorrhage, and subsequently visual loss. Drugs such 
as ranibizumab targeting vascular endothelial growth factor (VEGF) are effective 
in preserving and improving visual acuity (VA). Although many patients respond 
favorably to anti-VEGF treatment, some patients lose vision despite optimal therapy. 
Several studies have suggested that genetic factors influence the response to anti-VEGF 
treatment.1-15 For example, poor response rates were demonstrated for patients carrying 
the complement factor H (CFH) Y402H genotype5-7, 9, 10, 16 or polymorphisms in age-
related maculopathy susceptibility 2 (ARMS2).1, 12  Moreover, a cumulative effect of 
high-risk alleles in the  CFH,  ARMS2, and  VEGFA genes was associated with poor 
response rates to ranibizumab treatment and a younger age of onset of neovascular 
disease.11 However, the effect of genetic variants on treatment response is still not clear.
Ranibizumab is a humanized monoclonal antibody fragment that binds all isoforms of 
VEGFA, which is an important pro-angiogenic factor that plays a central role in the 
development of CNV. In addition to VEGFA, the VEGF family comprises VEGFB, 
VEGFC, VEGFD (FIGF), and placental growth factor (PGF). The VEGF members are 
ligands of 3 tyrosine kinase receptors: VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 
(FLT4). Vascular endothelial growth factor A binds to VEGFR1 and VEGFR2; VEGFB 
and PGF bind only to VEGFR1. Vascular endothelial growth factor R2 mediates most 
cellular responses to VEGF, whereas VEGFR1 might modulate VEGFR2 signaling and 
act as a decoy receptor competing with VEGFR2 for VEGF. Vascular endothelial growth 
factor R2 and VEGFR1 are both inhibited by the anti-angiogenic pigment epithelium-
derived factor (PEDF). Vascular endothelial growth factor C and VEGFD are ligands 
for VEGFR3 involved in lymphangiogenesis.17
The purpose of this study was to determine whether polymorphisms in genes encoding 
VEGF family members, VEGF receptors, and PEDF influence visual outcome in patients 
treated with ranibizumab for neovascular AMD. Although several studies have analyzed 
a limited number of single nucleotide polymorphisms (SNPs) in the VEGFA and KDR 
genes2, 4, 6, 7, 14 a comprehensive analysis of SNPs across all VEGF and VEGFR genes has 
not been performed. Therefore, we genotyped 126 tag-SNPs in the VEGFA, VEGFB, 
VEGFC, VEGFD (FIGF), PGF, VEGFR1 (FLT1), VEGFR2 (KDR), VEGFR3 (FLT4), 
and PEDF (SERPINF1) genes in 366 patients with AMD who have been treated with 
ranibizumab for at least one year.
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Methods
Study Population
This multicenter study included 366 eyes of 366 unrelated patients aged 50 years or 
older with active subfoveal CNV secondary to AMD. All participants were enrolled in 
the European Genetic Database (EUGENDA), a multicenter database for the clinical 
and molecular analysis of AMD, between 2008 and 2010. The study was performed 
in accordance with the tenets of the Declaration of Helsinki. The approval of the local 
ethics committee was obtained for both centers, and written informed consent was 
provided by all participants.
Inclusion and Exclusion Criteria
All patients had active subfoveal or juxtafoveal CNV due to AMD confirmed by 
spectral-domain optical coherence tomography and fluorescein angiography (FA) with 
indocyanine green. Further criteria in the study eye were a best-corrected VA equivalent 
to ≥20 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters and no previous 
treatment for exudative AMD, such as photodynamic therapy or intravitreal injections 
in the study eye. Exclusion criteria included any previous ophthalmic surgery, except for 
cataract removal, diabetic retinopathy, and progressive glaucoma.
Diagnostics and Treatment
All patients were treated for at least 12 months with ranibizumab on a pro re nata 
regimen. Patients initially received 3 consecutive, monthly intravitreal injections of 
0.5 mg ranibizumab. After this first series of treatments, patients were monitored in 
monthly visits. Evaluations included spectral-domain optical coherence tomography, 
best-corrected VA, and fundus examination. Visual acuity was measured with Snellen 
charts in 288 patients and with ETDRS charts in 78 patients. A logarithm of the 
minimum angle of resolution (logMAR) score was recorded alongside each ETDRS 
measurement. Fluorescein angiography and indocyanine green were used only in 
unclear cases. Recurrence or persistence of CNV activity was defined as fluid seen by 
optical coherence tomography or leakage seen on FA, loss of ≥5 letters in ETDRS VA, 
or new macular intraretinal or subretinal hemorrhage. Recurrences were treated again 
with a series of 3 consecutive, monthly ranibizumab injections. For lesion type, all FA 
performed at baseline was graded by 2 independent graders.
Genotyping
The Tagger algorithm18  was used to select tag SNPs from HapMap to capture all 
SNPs of minor allele frequency 0.05 with an  r2  of 0.8 in the VEGFA, VEGFB, 
VEGFC, VEGFD (FIGF), PGF, VEGFR1 (FLT1), VEGFR2 (KDR), VEGFR3 (FLT4), 
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and PEDF (SERPINF1) genes. Tag SNPs were genotyped with 4 multiplex iPLEX Gold 
SNP Genotyping assays (Sequenom Inc., San Diego, CA).
Statistical Analysis
All statistical analyses were performed using the Statistical Package for the Social Sciences 
(version 21; IBM Corp., New York, NY). Visual acuity assessed with Snellen charts 
was converted to logMAR for statistical analyses. Levene’s test for equality of variances 
was used to test variability of VA changes between Snellen and ETDRS measurements. 
Improvement in VA was calculated for each patient as the increase of VA between 
baseline and after 3 months (1 month after the third injection) and after 12 months’ 
follow-up. To identify potential confounders, we computed univariate analyses of 
variance (ANOVAs) for the dependent variable “change in VA after 12 months” with 
the factors age (P > 0.89), gender (P > 0.97), baseline VA (P > 0.27), smoking status 
(P > 0.86), lesion type (P = 0.096 after Bonferroni correction), and number of injections 
within 12 months (P > 0.48). Only the factor of lesion type showed a trend toward 
statistical significance and was kept as a potential confounder. For each of the 126 tag 
SNPs, we computed ANOVAs with the factor “minor allele” (present, absent) and the 
dependent variable “change in VA after 3 months/12 months.” Lesion type (occult, 
predominantly classic, minimally classic, retinal angiomatous proliferation) was used 
as a covariate to control for lesion type–related effects on the outcome variable. The 
threshold for statistical significance was set to  P < 0.05. The resulting  P  values were 
corrected for multiple comparisons using Bonferroni’s approach.
As a second step to identify SNPs with an influence on visual outcome, we performed 
a multivariate stepwise linear regression analysis. Accordingly, we defined change in VA 
after 12 months as the dependent variable and the 126 analyzed SNPs (coding for the 
presence [1] or absence [0] of minor alleles of the respective SNP) as the independent 
predictor variables.
Results
The characteristics of the 366 patients included in the study are summarized in Table 1. 
All patients were treated for neovascular AMD with ranibizumab on a pro re nata regimen. 
After 3 initial injections, retreatment followed an optical coherence tomography–guided 
pro re nata regimen. Visual acuity was measured at baseline, at 3 months (1 month after 
3 injections), and at 12 months. 
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Table 1. Clinical Characteristics of the Study Population (n = 366)
Characteristics  
Sex 164 men (44.8%)
202 women (55.2%)
Eyes (n = 366) 51% right, 49% left
Age, yrs  
mean ± SD (range) 76.8±7.5 (54–97)
Type of CNV 60% occult
12% predominantly classic
21% minimally classic
7% retinal angiomatous proliferation
No. of intravitreal injections  
Mean ± SD (range) 6.0±3.3 (3–12)
VA (logMAR) at baseline  
Mean ± SD 0.64±0.36
VA after 3 intravitreal injections (logMAR)  
Mean ± SD 0.55±0.41
VA after 1 yr (logMAR)  
Mean ± SD 0.59±0.42
CNV = choroidal neovascularization; logMAR = logarithm of the minimum angle of resolution; SD = 
standard deviation; VA = visual acuity.
After correcting for multiple testing, univariate ANOVAs revealed a significant effect of 
SNP rs4576072 in the VEGFR2 gene on VA after 12 months (F[1,235] = 14.05; P = 0.02, 
Bonferroni corrected for multiple comparisons). The analysis of all remaining SNPs did 
not yield a significant effect on the outcome variable at Bonferroni-corrected thresholds 
(Table 2, available at www.aaojournal.org).
The stepwise multivariate regression analysis returned a regression model (R  = 0.21; 
adjusted  R2  = 0.04;  P  = 0.010) with the SNPs rs4576072 (standardized regression 
coefficient beta = 0.174; P = 0.012) and rs6828477 (beta = 0.148; P = 0.032) as only 
contributing predictor variables ( Table 2, available at www.aaojournal.org). All remaining 
SNPs did not significantly improve the model (P > 0.1) and were removed. The influence 
of the contributing rs4576072 and rs6828477 SNP genotypes on VA improvement at 3 
and 12 months is shown in Table 3. For each patient, we also calculated the number of 
minor alleles (0–4) in the 2 SNPs that were identified by multiple regression to influence 
VA improvement after 12 months. None of the patients had a genotype with 4 minor 
alleles. The mean increase in VA on the logMAR scale was 0.26 (±0.30) in patients with 
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3 contributing minor alleles (n = 18), 0.08 (±0.35) in patients with 2 minor alleles (n = 
91), and 0.02 (±0.32) in patients with 1 minor allele (n = 178) (Fig 1). Patients with no 
minor allele contributing had an average decrease of VA of 0.03 (±0.36).
Table 3. Improvement of Visual Acuity on the Logarithm of the Minimum Angle of Resolution Scale 
Depending on the Genotype of Vascular Endothelial Growth Factor Receptor 2 Single Nucleotide 
Polymorphisms rs4576072 and rs6828477.
SNP 
Genotype No. Age, yrs Baseline VA
VA Improvement 
after 3m
VA Improvement 
after 12m
(%)
(Mean  
± SD)
(Mean logMAR 
± SD)
(Mean logMAR  
± SD)
(Mean logMAR  
± SD)
rs4576072      
 TT 259 (71) 77.1±7.5 0.63±0.37 0.07±0.27 0.00±0.33
 CT 96 (26) 76.4±7.9 0.66±0.33 0.12±0.31 (P = 0.019) 0.13±0.35 (P = 0.004)
 CC 11 (3) 74.3±5.6 0.65±0.33 0.18±0.27 (P = 0.058) 0.14±0.28 (P = 0.182)
 CT or CC 107 (29) 76.2±7.7 0.66±0.33 0.13±0.30 (P = 0.007) 0.13±0.34 (P = 0.002)
rs6828477  
 TT 122 (33) 77.3±8.6 0.58±0.33 0.09±0.27 0.00±0.35
 CT 193 (53) 76.4±7.5 0.65±0.33 0.07±0.29 (P = 0.779) 0.06±0.33 (P = 0.147)
 CC 51 (14) 77.0±8.6 0.75±0.39 0.10±0.30 (P = 0.991) 0.06±0.36 (P = 0.035)
 CT or CC 244 (67) 76.5±7.8 0.67±0.36 0.08±0.29 (P = 0.815) 0.06±0.35 (P = 0.137)
logMAR = logarithm of the minimum angle of resolution; SD = standard deviation; SNP = single 
nucleotide polymorphism.
P values given (Mann–Whitney U) when compared with TT genotype.
A more detailed analysis (Table 4) revealed that the presence of at least 1 minor allele 
of rs4576072 or rs6828477 was associated with an improvement of VA that further 
increased with the presence of a second minor allele of rs6828477 but not of rs4576072. 
This was also confirmed when formally testing for differences in VA improvement 
after 12 months between different combinations of genes. Mann–Whitney  U  tests 
revealed significant differences (corrected for multiple comparisons). Differences in VA 
improvements after 3 months did not pass the statistical threshold after correction.
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Table 4. Improvement of Visual Acuity after 3 and 12 Months on the Logarithm of the Minimum Angle 
of Resolution Scale for All Allele Combinations of the Vascular Endothelial Growth Factor Receptor 2 
Single Nucleotide Polymorphisms rs4576072 (Minor Allele T) and rs6828477 (Minor Allele T).
  rs4576072  
rs6828477 TT CT CC
TT 0.07±0.26 0.11±0.28 0.26±0.24  
CT 0.06±0.27 0.11±0.33 0.13±0.31  
CC 0.07±0.29 0.22±0.31 ./.  
  VA improvement after 3 mos (mean logMAR ± SD)  
  rs4576072
rs6828477 TT CT CC
TT −0.03±0.36 0.03±0.33 0.13±0.25  
CT 0.02±0.31 0.16±0.35 0.15±0.31  
CC −0.02±0.34 0.33±0.29 ./.  
  VA improvement after 12 mos (mean logMAR ± SD)      
logMAR = logarithm of the minimum angle of resolution scale; SD = standard deviation; VA = visual 
acuity.
Figure 1. Improvement of visual acuity (VA) on the logarithm of the minimum angle of resolution 
(logMAR) scale after 12 months in patients receiving ranibizumab for neovascular age-related macular 
degeneration depending on the number of minor alleles in the single nucleotide polymorphisms 
rs4576072 and rs6828477 in theVEGFR2 gene. *P < 0.05 obtained by nonparametric testing (Mann–
Whitney U test).
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Other individual factors, such as age, sex, smoking, baseline VA, and number of 
injections, did not show significant effects on VA improvements after 3 or 12 months 
(P > 0.1 for each comparison).
Discussion
In this cohort study, we evaluated the association of SNPs in VEGF and VEGFR 
genes with the response to ranibizumab treatment in patients with neovascular AMD. 
We identified 2 SNPs (rs4576072 and rs6828477) in the  VEGFR2  gene that were 
independently associated with a significantly better visual outcome after 1 year. The 
difference in VA between patients with minor alleles and those with no minor allele 
was already apparent after 3 injections but increased to approximately 3 lines after 1 
year. These patients gained initially more letters and did not lose vision in the course 
of treatment within the first year. Visual acuity increased gradually with the number of 
minor alleles of both SNPs. The differences in VA, which were in the range of 1 to 3 
lines, were clinically relevant because a gain of 1 line on the ETDRS chart is perceived 
by most patients as a subjective improvement.19
The 2 SNPs had a significant influence on the variability in treatment response to 
ranibizumab. Therefore, they represent predictive factors for the therapeutic response 
to anti-VEGF treatment beyond other individual factors, such as CNV characteristics, 
diagnostics, adherence to treatment, underdosing, or delay of treatment, which all 
interfere with the therapeutic outcome.20, 21 Therefore, this is the first study of AMD to 
show a correlation between polymorphisms in the VEGFR2 gene and visual outcome in 
ranibizumab therapy.
Considered separately, the presence of at least 1 C-allele of SNP rs4576072 led to an 
improvement of 0.13 logMAR compared with wild-type. This trend toward improved 
visual outcome was already observed after 3 injections and not influenced by age or 
VA at baseline. A similar but weaker effect was seen for SNP rs6828477. In line with 
previous findings, the CNV type showed no association with response to ranibizumab 
treatment.7, 11
Other pharmacogenetic studies of anti-VEGF therapy in AMD have demonstrated 
that risk alleles in CFH and ARMS2 are associated with vision loss or a higher number 
of injections,3, 7, 10, 11, 13, 16 although other studies could not confirm these findings.9, 12, 
15 Although the VEGFA gene confers only a minor genetic risk for the development of 
AMD,22 genetic variants in VEGFA have been demonstrated to significantly influence 
the outcome of ranibizumab treatment in AMD.2, 4, 6 The latter association was not 
confirmed in this study because none of the tag-SNPs across the VEGFA  gene were 
significantly associated with change in VA after treatment.
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The effect of ranibizumab treatment is mediated primarily through VEGFA and its main 
receptor VEGFR2. Ranibizumab binds and inactivates VEGFA, which constitutes a key 
component of neovascularization. In this study, we identified 2 polymorphisms located 
in different haplotype blocks of the VEGFR2  gene that are independently associated 
with the outcome of ranibizumab treatment. Several studies have evaluated SNPs in 
VEGFR2 but so far failed to find significant associations with treatment response. This 
may be due to the limited sample size in those studies or the limited number of SNPs 
that have been analyzed.4, 7, 11, 14 In contrast, the present study tested for a broad range 
of SNPs in a relatively large cohort of subjects (n = 366 eyes), which facilitated the 
identification of significant associations between genetic factors and treatment response. 
We did not detect a significant association with genetic variants in other VEGF or 
VEGFR genes. Although this finding is in agreement with other studies,7, 14 there is 
evidence that variants in the VEGFA gene affect treatment outcome.2, 8
This is the first study to demonstrate a highly significant effect of polymorphisms in 
VEGFR2 on the therapeutic outcome of ranibizumab treatment by systematically 
analyzing tag SNPs across the VEGF and VEGFR genes. Further studies are now needed 
that clarify the pathophysiology underlying these gene-treatment associations with 
respect to the 2 candidate SNPs and to other genetic variants that are in high linkage 
disequilibrium with these SNPs. Hints for a putative pathophysiologic mechanism stem 
from data obtained in patients with metastatic pancreatic adenocarcinoma, in whom 
response to anti-VEGF therapy was related to VEGFR gene polymorphisms. Here, 
a synonymous SNP in VEGFR1 caused increased VEGFR1 expression and increased 
downstream signaling by a shift in codon use.23 It has been suggested that increased 
VEGFR1 concentrations can sequester VEGF, thereby decreasing its proangiogenic 
effects transduced via VEGFR2 and subsequently limiting the benefits of additional 
VEGF neutralization by bevacizumab. In line with these findings, we hypothesize that 
theVEGFR2 SNPs identified in this study may lead to altered expression or functional 
activity of VEGFR2, leading to an increased benefit of VEGF neutralization by 
ranibizumab on visual outcome. Whether such effects are responsible for treatment 
effects in AMD needs to be elucidated in future studies.
The findings need to be replicated in other cohorts and in a larger sample of subjects 
to confirm a putative diagnostic predictor for treatment response. In this study, VA at 
baseline and the initial gain of VA after 3 injections were comparable to other trials.24 
However, we observed some loss of VA after this initial gain after 12 months.
In conclusion, this study is the first to systematically analyze tag SNPs across the VEGF 
and VEGFR genes. This approach identified 2 SNPs in VEGFR2 that are independently 
associated with improved treatment response to ranibizumab in neovascular AMD. In 
the future, such data may help to identify high-risk patients and to individualize therapy.
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Purpose: To investigate the role of single nucleotide polymorphisms (SNPs) located in 
the neuropilin-1 (NRP1) gene in treatment response to anti-vascular endothelial growth 
factor (VEGF) therapy for neovascular age-related macular degeneration (nvAMD).
Methods: Four SNPs in the NRP1 gene (rs2229935, rs2247383, rs2070296 and 
rs2804495) were genotyped in a study cohort of 377 nvAMD patients who received 
the loading dose of three monthly ranibizumab injections. Treatment response was 
assessed as the change in visual acuity after three monthly loading injections compared 
to baseline.
Results: SNP rs2070296 was associated with change in visual acuity after three months 
of treatment. Patients carrying the GA or AA genotypes performed significantly worse 
than individuals carrying the GG genotype (p=0.01). A cumulative effect of rs2070296 
in the NRP1 gene and rs4576072 located in the VEGF receptor 2 (VEGFR2 or KDR) 
gene, previously associated with treatment response, was observed. Patients carrying 
two risk alleles performed significantly worse than patients carrying zero or one risk 
allele (p=0.03) and patients with more than two risk alleles responded even worse to the 
therapy (p=3x10-3). The combined effect of these two SNPs on the response was also 
seen after six and twelve months of treatment.
Conclusion: This study suggests that genetic variation in NRP1, a key molecule in 
VEGFA-driven neovascularization, influences treatment response to ranibizumab in 
nvAMD patients. The results of this study may be used to generate prediction models 
for treatment response, which in the future may help tailor medical care to individual 
needs.
A genetic variant in NRP1 is associated with worse response to ranibizumab treatment in neovascular 
age-related macular degeneration
89
Introduction
Age-related macular degeneration (AMD) is the leading cause of blindness in the Western 
world.1 The neovascular, or wet, form of AMD (nvAMD) is the most aggressive, being 
responsible for around 90% of the vision loss caused by the disease.2 
The first choice therapy for nvAMD consists of intravitreal injections of anti-vascular 
endothelial growth factor (VEGF) drugs. Although this treatment has dramatically 
changed the prognosis of the disease with a significant mean improvement in visual 
acuity (VA),3 a high variability in response rates has been described. Approximately ten 
percent of the treated patients do not respond to anti-VEGF therapy and still lose more 
than 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters two years after 
the start of treatment,3, 4 which is comparable to the natural course of the disease.5 
To date, several studies have suggested that genetic variants can influence this variability 
in treatment response.6-16 These studies have mainly focused on single nucleotide 
polymorphisms (SNPs) located in AMD-associated loci, but also common variants 
in VEGF family members, cytokines and proteins involved in development and 
maintenance of the retinal vasculature have been explored. Not all studies showed 
consistent results,9, 16 however, due to a high variability in study designs it is difficult 
to reliably compare the outcomes of these studies. Therefore, the relevance and basis of 
the genetic component of this diverse response to treatment still needs to be elucidated.
Recently, two SNPs in the VEGF receptor 2 (VEGFR2 or KDR) gene, which encodes 
the main receptor of VEGFA on vascular endothelial cells,17 have been associated with 
better anti-VEGF response rates.12 Consequently, other molecules involved in this 
pathway are also potential candidates to influence treatment response. Neuropilin-1 
(NRP1) is a co-receptor of VEGFA that binds to the predominant isoform, VEGFA165,
18 
and forms a complex with VEGFR2, which enhances the transduction of downstream 
signaling.19-22 Recent studies have implicated NRP1 signaling pathways in pathological 
neovascularization of the retina23 and NRP1 has been described to be involved in 
VEGFA-mediated vascular leakage.19 Indeed, NRP1 has been shown to affect the 
evolution of the choroidal neovascularization in AMD24 and has been proposed as a 
new target molecule for AMD treatment.25 Moreover, NRP1 seems to play a role in 
the cancer prognosis when treated with anti-VEGF compounds,26 which makes this 
molecule a compelling candidate for being involved in response variation.
This study aimed to determine whether genetic variants in the NRP1 gene influence 
treatment response to anti-VEGF therapy in patients with nvAMD.
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Patients and Methods
Study Population
The study cohort comprised 377 eyes of 377 Caucasian treatment-naïve patients aged 50 
years or older with active choroidal neovascularization secondary to AMD. A total of 145 
patients were treated at the Department of Ophthalmology of the Radboud university 
medical center, Nijmegen, the Netherlands; 182 at the University of Cologne, Germany 
and the remaining 50 patients at the McGill University Health Center, Montreal, 
Canada. The patients from the German and Dutch clinics were enrolled between 2008 
and 2010 in the European Genetic Database (EUGENDA), a multicenter database for 
the clinical and molecular analysis of AMD. 
The study was performed in accordance with the tenets of the Declaration of Helsinki 
(7th revision). Approval of the local ethics committees was obtained for all three centers 
and written informed consent was acquired from all participants. 
The diagnosis of active nvAMD was determined by retinal specialists based on 
ophthalmic examination, spectral-domain optical coherence tomography (OCT) 
(Spectralis HRA+OCT, Heidelberg Engineering, Heidelberg, Germany) or fluorescein 
angiography (FA) (Spectralis HRA+OCT, Heidelberg Engineering, Heidelberg, 
Germany; or Imagenet, Topcon Corporation, Tokyo, Japan). Exclusion criteria included 
any previous ophthalmic surgery, except for cataract removal, and retinal disorders other 
than AMD. If both eyes received treatment, the first eye to receive treatment was chosen 
as the study eye. If treatment started simultaneously, the study eye was chosen randomly. 
All patients were treated between 2007 and 2009 with three consecutive monthly 
intravitreal injections of 0.5 mg ranibizumab (Lucentis; Novartis Pharmaceuticals UK 
Limited, Frimley, Surrey, UK). Visual acuity was assessed in all cases before treatment 
(baseline) and after the three loading monthly injections. After the loading dose, 
patients were followed on a monthly basis and treated on a pro re nata regimen at 
the clinics of Nijmegen and Cologne. At the clinic of Montreal, the patients were 
further managed through a treat-and-extend regimen. OCT, best-corrected VA, fundus 
examination and FA were used alone or in combination to evaluate the effectiveness of 
the treatment. Recurrence or persistence of the choroidal neovascularization was defined 
as fluid seen by OCT, loss of VA of 5 ETDRS letters or more, leakage seen on FA, or 
new macular hemorrhage or fluid. In case of persistence or recurrence of the choroidal 
neovascularization, patients received three consecutive monthly ranibizumab injections. 
If available, VA was collected after 6 and 12 months of treatment. For 304 patients, 
Snellen VA measurements were collected retrospectively and 73 patients were followed 
up prospectively using ETDRS VA. Treatment response was defined as the change in 
visual acuity after the three first months of treatment compared to baseline. Long-term 
treatment response was defined as the change in visual acuity after six and twelve months 
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of treatment. Age at first ranibizumab injection, gender and other baseline variables 
were collected using questionnaires or retrieved from the patient files.
Genotyping
The SNPs rs2229935, rs2247383, rs2070296 and rs2804495 were selected from the 
major haploblocks of the NRP1 gene for genotyping (see Supplemental table 1, which 
details the chromosomal location of the SNPs). Two SNPs, rs2070296 (p.Ala179=) and 
rs2229935 (p.Tyr422=), were located in the coding region of NRP1. 
Genotyping of the SNPs was performed using competitive allele-specific KASP 
genotyping chemistry (LGC, Hoddesdon, UK). Primers and probes were developed by 
LGC, (see Supplemental table 1, which describes the probes used). Quality control of 
the genotyping assays was assessed using duplicate DNA samples in each run, achieving 
a concordance of 100% of the results. 
Sanger sequencing of exon 4 of the NRP1 gene (NM_003873.5) was performed in 
eleven patients for which genotyping by KASPar of SNP rs2070296 was not successful. 
Primers were designed using Primer3 software (see Supplemental table 1, which describes 
the primers used).27 Polymerase chain reaction was performed, and the amplicons 
were sequenced using an automated sequencer (BigDye Terminator, version 3, 3730 
DNA analyzer; Applied Biosystems). Sequences were assembled and analyzed using 
ContigExpress (Vector NTI Advance, Version 11.0, Life Technologies). 
Statistical Analysis
Statistical analysis was performed using IBM SPSS Statistics for Windows, Version 20.0 
(Armonk, NY: IBM Corp). ETDRS and Snellen visual acuity records were converted to 
the logarithm of Minimal Angle of Resolution (logMAR) for the purpose of statistical 
analysis. Change in VA after three, six and twelve months was calculated as the difference 
between VA at baseline and VA at the different time points.
Deviation of the genotype frequencies from those expected under Hardy-Weinberg 
equilibrium was assessed by a χ2 test. To determine the influence of the baseline 
variables on the change in VA after three months Spearman correlation was used for the 
continuous variables, and Kruskal-Wallis or Mann-Whitney U tests were performed for 
the categorical variables. 
The association of the different SNPs with the change in VA after three, six and twelve 
months was assessed using Mann-Whitney U tests. Bonferroni procedure was applied to 
correct for four tests (p-values ≤ 0.01 were considered statistically significant).
In order to analyze the combined effect of NRP1 rs2070296 and KDR rs4576072 on 
the change in VA after three, six and twelve months, patients were combined into three 
groups of approximately equal size (carriers of less than two, two risk alleles, or more 
than two risk alleles), and a Mann-Whitney U test was performed. Only the patients 
that were successfully genotyped for rs4576072 in a previous study12 were included in 
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the analysis (n=353). The rs4576072 major allele (T) has been reported to lead to a 
worse response to therapy,12 therefore, this allele was considered the risk allele.
Results
Demographics and ophthalmological details of the patients are described in Table 1. 
Older age at first injection (p-value=0.01), having a better baseline VA (p-value<10-3) 
and having diabetes mellitus (p-value=0.02) were associated with worse response after 
three months of treatment (see Supplemental table 2, which describes the results of 
the association tests). The type of choroidal neovascularization showed a trend towards 
statistical significance (p-value=0.06). These baseline variables were not associated with 
the SNPs of interest (p-value>0.05, lowest p-value=0.22) (see Supplemental table 3, 
which describes the results of the association tests).
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Table 1. Characteristics of the study cohort.
Demographics  
  Age at first injection (years), mean (SD) 77.11 (7.46)
  Female gender, n (%) 215 (57.0)
Disease history
Hypertension (n=259)a, n (%)b 154 (59.5)
Diabetes mellitus (n=259)a, n (%)b 47 (18.1)
Other environmental factors
BMI (kg/m2) (n=258)a, median (quartiles) 25.39 (23.52 - 28.49)
Ophthalmological details
Baseline VA (logMAR), median (quartiles) 0.543 (0.398 - 1.000)
Equivalent baseline VA (ETDRS letters)c, median (quartiles) 57.9 (35.0 - 65.1)
  Change in VA after 3 months (logMAR)d, median (quartiles) 0.097 (0.000 - 0.259)
Equivalent change in VA after 3 months (ETDRS letters)c,d, median 
(quartiles) 4.8 (0.0 - 12.2)
Change in VA after 6 months (logMAR)d, median (quartiles) (n=262) 0.090 (-0.097 - 0.223)
Equivalent change in VA after 6 months (ETDRS letters)c,d, median 
(quartiles) 4.5 (-4.9 - 11.2)
Change in VA after 12 months (logMAR)d, median (quartiles) (n=240) 0.040 (-0.192 - 0.204)
Equivalent change in VA after 12 months (ETDRS letters)c,d, median 
(quartiles) 2 (-9.6 - 10.2)
  Type of CNV (n=335)a
  Occult with no classic, n (%)b 199 (59.4)
  RAP, n (%)b 21 (6.3)
  Minimally classic, n (%)b 42 (12.5)
  Predominantly classic, n (%)b 73 (21.8)
  Lesion size (DA) (n=285)a
  <2, n (%)b 92 (32.3)
  2-4, n (%)b 91 (31.9)
  4-6, n (%)b 43 (15.1)
  >6, n (%)b 59 (20.7)
SD, standard deviation; n, number of patients; VA, visual acuity; logMAR, logarithm of the Minimum 
Angle of Resolution; ETDRS, Early Treatment Diabetic Retinopathy Study; CNV, choroidal 
neovascularization; RAP, retinal angiomatous proliferation; DA, disk areas.
a For the remaining patients no data were available. 
b Valid percentage.
c ETDRS letters equivalents were calculated in the following manner: ETDRS letters = 85 – 
logMAR/0.02 for logMAR values.
d Change in VA after 3, 6 and 12 months was calculated in the following manner: VA prior to treatment - 
VA after 3, 6 or 12 months of treatment.
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Over 90% of patients were successfully genotyped for SNPs rs2229935, rs2247383, 
rs2070296 and rs2804495 (Table 2). None of the SNPs showed deviations from 
Hardy-Weinberg equilibrium in the study cohort (p-value=0.81, 0.93, 0.98 and 0.41 
respectively). The GA or AA genotypes of SNP rs2070296 were found to be associated 
with a significantly reduced improvement in VA after three months (p-value=0.01) 
compared to the GG genotype, showing a linear trend for the three genotype groups 
(Figure 1A). The SNPs rs2229935, rs2248383 and rs2804495 were not found to be 
associated with treatment response (Table 2). 
Table 2.  Association of genotypes in NRP1 with response to ranibizumab treatment.
SNP n (%) ΔVA after 3 months (logMAR), median (quartiles)a P-value
b
rs2229935
CC 203 (57.2) 0.100 (0.000 - 0.301) Reference
CT 132 (37.2) 0.079 (0.000 - 0.198) 0.12
TT 20 (5.6) 0.085 (-0.075 - 0.273) 0.50
CT or TT 152 (42.8) 0.079 (0.000 - 0.198) 0.11
rs2247383
CC 123 (35.2) 0.097 (-0.077 - 0.273) Reference
CT 169 (48.4) 0.097 (0.000 - 0.242) 0.94
TT 57 (16.3) 0.090 (-0.064 - 0.238) 0.69
CT or TT 226 (64.8) 0.097 (0.000 - 0.242) 0.84
rs2070296
GG 270 (71.6) 0.100 (0.000 - 0.287) Reference
GA 98 (26.0) 0.079 (-0.097 - 0.195) 0.04
AA 9 (2.4) 0.000 (-0.097 - 0.040) 0.04
GA or AA 107 (28.4) 0.040 (-0.097 - 0.184) 0.01
rs2804495
TT 167 (49.1) 0.098 (0.000 - 0.240) Reference
TG 147 (43.2) 0.097 (0.000 - 0.273) 0.74
GG 26 (7.6) 0.138 (-0.088 - 0.300) 0.84
TG or GG 173 (50.9) 0.097 (0.000 - 0.279) 0.72
SNP, single nucleotide polymorphism; N, number; VA, visual acuity; logMAR =  logarithm of the 
Minimum Angle of Resolution.
a Change in VA after 3 months (logMAR) was calculated in the following manner: VA prior to treatment - 
VA after 3 months of treatment. b P-values were calculated using Mann-Whitney U tests.
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Figure 1. Effect of genetic variants in NRP1 and KDR on response to ranibizumab treatment in nvAMD. 
(A) Change in visual acuity after three months of ranibizumab treatment stratified by NRP1 rs2070296 
genotype. (B) Change in visual acuity after three months of ranibizumab treatment stratified by the 
number of risk alleles in NRP1 rs2070296 (A) and KDR rs4576075 (T). The median change in visual 
acuity for each group is depicted in both figures.
A combined analysis of NRP1 rs2070296 and the previously associated SNP rs4576072 
in KDR12 revealed a decrease in the change in VA after 3 months depending on the 
number of risk alleles (Figure 1B). Patients who carried two risk alleles responded 
significantly worse to therapy than carriers of one or zero alleles (median of 0.090 
logMAR or 4.5 ETDRS letters gained versus 0.196 logMAR or 10 ETDRS letters 
gained, p-value=0.03), and carriers of more than 2 alleles had even worse response rates 
(median of 0.020 logMAR or 1 ETDRS letter gained, p-value=3x10-3) (Figure 1B, Table 
3).  
Besides the variability in treatment regimens after the first loading injections, we 
evaluated if the effect of rs2072096 in NRP1 remained significant after six and twelve 
months of treatment. This SNP was not associated with the change in VA after 6 and 12 
months (Table 4). However, the combined effect of this SNP in NRP1 and rs4576072 
in the KDR gene did influence long term response (Figure 2, Table 5).
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Table 3.  Combined effect of the risk alleles in NRP1 rs2070296 (A) and KDR rs4576072 (T) on response 
to ranibizumab treatment. 
Number of risk 
alleles N (%)
ΔVA after 3 months (logMAR), 
median (quartiles)a P-value
b
<2 79 (22.4) 0.196 (0.000 – 0.321) Reference
2 201 (56.9) 0.090 (0.000 – 0.204) 0.03
>2 73 (20.7) 0.020 (-0.097 – 0.180) 3x10-3
N, number of patients; VA, visual acuity; logMAR, logarithm of the Minimum Angle of Resolution.
a Change in VA after 3 months (logMAR) was calculated in the following manner: VA prior to treatment - 
VA after 3 months of treatment. b P-values were calculated using Mann-Whitney U tests.
Figure 2. Effect of genetic variants in NRP1 and KDR on long term response to ranibizumab treatment in 
nvAMD. 
(A) Change in visual acuity after six months of ranibizumab treatment stratified by the number of risk 
alleles in NRP1 rs2070296 (A) and KDR rs4576075 (T). (B) Change in visual acuity after twelve months 
of ranibizumab treatment stratified by the number of risk alleles in NRP1 rs2070296 (A) and KDR 
rs4576075 (T). The median change in visual acuity for each group is depicted in both figures.
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Discussion
We evaluated the role of four SNPs located in NRP1 (rs2229935, rs2247383, rs2070296 
and rs2804495) in response to anti-VEGF treatment. The SNP rs2070296 was found 
to be significantly associated with a fewer gain in letters. Depending on the genotype, 
patients showed a different response following an additive model in which the minor 
allele (A) leads to worse response to treatment. In median, the nine patients that carried 
the homozygous AA genotype didn’t improve their VA and performed five ETDRS 
letters (one line) worse than the homozygous GG group. Since a recent study showed 
that most patients perceive one line of the ETDRS chart as an improvement,28 this 
difference could be clinically relevant. This effect was not seen after six and twelve 
months of treatment. Nevertheless, the dilution of the effect seen in the change of VA 
after the loading dose of three ranibizumab injections, could be due to variability in the 
treatment regime and progression of the disease, which makes the comparison of the 
long term response difficult.
We defined treatment response as change in visual acuity after three consecutive loading 
injections compared to baseline. Visual acuity is an important functional outcome 
measure, which is most relevant for patients, and therefore, it has been extensively used to 
evaluate treatment response in nvAMD.7, 12, 29-36 Most patients achieve the largest change 
in VA after the three first monthly injections3 and this time interval can be predictive 
of long term response.37 Therefore, this finding not only expands the knowledge of the 
mechanisms that underlie the variability in the response, but also could be implemented 
in future prediction models. Despite that, we encourage the evaluation of the effect of 
this SNP using also anatomic features defined by OCT. The patients from our study 
cohort were treated between 2007 and 2009, and at that time, OCT scans were not 
implemented routinely during treatment regimes.
Although our study detected a significant association of rs2070296 with anti-VEGF 
treatment response, further studies are required to confirm our findings and to 
determine whether this SNP or other genetic variants in NRP1 are driving the effect. A 
more extensive analysis of additional genetic variants in NRP1 could reveal other SNPs 
associated with variability in the response. Furthermore, examination of low frequency 
and rare variants could reveal variants with a higher impact on the trait and major 
clinical relevance. 
The NRP1 gene has also been implicated in treatment response to anti-VEGF therapy in 
cancer. A SNP in the 3’UTR of NRP1 has been associated with better progression-free 
survival in recurrent ovarian cancer treated with bevacizumab (Avastin; Genentech Inc., 
San Francisco, CA, USA),38 an anti-VEGF drug also used off-label for the treatment of 
nvAMD. NRP1 is expressed in endothelial cells and up-regulated in numerous tumor 
cell types,39-48 which has been associated with poorer outcomes in several cancers such as 
breast cancer,42 osteosarcoma46 and nasopharyngeal carcinoma.48 Therefore, the interest 
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in developing new therapies targeting NRP1 in cancer is increasing.49  Moreover, an 
improved effect of an anti-VEGF drug combined with anti-NRP1 antibodies has been 
described in tumor treatment.50 In addition, NRP1 has been proposed as a potential 
biomarker for treatment response in advanced gastric cancer treated with bevacizumab.26 
In a recent study, Raimondi et al. described that NRP1 promotes angiogenesis in a 
VEGFR2/VEGFA independent manner. In this novel mechanism, NRP1 forms a 
complex with ABL1 that leads to the activation of paxillin in a fibronectin dependent 
manner which enhanced motility in vitro and angiogenesis in vivo. Moreover, in a mouse 
model of oxygen-induced retinopathy, treatment with Imatinib (an ABL1 inhibitor 
used for the treatment of leukemia) reduced angiogenesis. Consequently, Imatinab was 
proposed as a new therapy for nvAMD targeting NRP1.25 
The wide range of response to anti-VEGF therapy observed in nvAMD patients has 
drawn much attention in the pharmacogenetic research field. The findings described 
in this study, together with the findings of Hermann et al.12 and Lotery et al.,9 suggest 
that variants in components of the neovascularization pathways play an important 
role in treatment response to anti-VEGF therapy in AMD. The study by Hermann et 
al. showed that rs4576072 in KDR is associated with response after twelve months of 
treatment.12 In the current study we demonstrated a significant cumulative effect of this 
SNP and SNP rs2070296 in NRP1 in the response to ranibizumab treatment after the 
three loading injections, and also after six and twelve months of treatment. This finding 
is specifically interesting for the development of prediction models based on relevant 
clinical parameters, environmental and genetic factors, which would allow patients to 
be grouped for different regimen doses or therapies.
In summary, our findings suggest that genotyping of SNPs in NRP1, in combination 
with SNPs in other genes as KDR, could be used as a rapid preclinical tool for selection 
of the optimal treatment for individual patients, which besides anti-VEGF treatment 
could also involve targeting of NRP1. In the future, genetic testing of such variants may 
help to predict outcome of nvAMD treatment, and to tailor medical care to individual 
needs.
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Supplemental table 2. Influence of the baseline variables on response to ranibizumab treatment.
    ΔVA after 3 months (logMAR)a
  P-valueb Correlation coefficient/ median (quartiles)
Demographics
  Age at first injection 0.01 -0.130
  Gender 0.38
Female: 0.079 (0.000 - 0.222)
Male: 0.100 (-0.020 - 0.300)
Disease history
Hypertension (n=259)c 0.91
Yes: 0.104 (0.000 - 0.250)
No: 0.079 (0.000 - 0.301)
Diabetes mellitus (n=259)c 0.02
Yes: 0.000 (-0.204 - 0.176)
No: 0.107 (0.000 - 0.301)
Other environmental factors
BMI (kg/m2) (n=258)c 0.22 -0.077
Ophthalmological details
  Baseline VA (logMAR) <10-3 0.195
  Change in VA after 3 months (logMAR) NA NA
  Type of CNV (n=335)c 0.06
Occult with no classic: 0.097 (0.000 - 0.204)
RAP: 0.107 (-0.048 - 0.301)
Minimally classic: 0.000 (-0.099 - 0.176)
Predominantly classic: 0.100 (0.045 – 0.311)
 
Lesion size (DA) (n=285)c 0.23
<2: 0.100 (-0.015 – 0.296)
2-4: 0.090 (0.000 – 0.222)
4-6: 0.100 (0.000 – 0.300)
>6: 0.000 (-0.097 – 0.176)
VA, visual acuity; logMAR = logarithm of the Minimum Angle of Resolution; NA, not applicable; n, 
number of patients; CNV, choroidal neovascularization; RAP, retinal angiomatous proliferation; DA, disk 
areas.
a Change in VA after 3 months (logMAR) was calculated in the following manner: VA prior to treatment - 
VA after 3 months of treatment.
b P-values were calculated using Spearman correlations for the independent continuous variables and 
Kruskal-Wallis tests or Mann-Whitney U tests for the categorical variables.
c For the remaining patients no data were available.
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Supplemental table 3. Influence of NRP1 SNPs on potential confounding factors.
Potential confounding factors of ΔVA after 3 months (logMAR)
  Age at first injection (years)
Baseline VA 
(logMAR)
Diabetes mellitus Type of CNV
  P-valuea P-valuea P-valuea P-valuea
rs2229935 0.23 0.23 0.38 0.22
rs2247383 0.89 0.30 0.37 0.93
rs2070296 0.50 0.34 0.30 0.30
rs2804495 0.85 0.47 0.79 0.39
VA, visual acuity; logMAR, logarithm of the Minimum Angle of Resolution; CNV, choroidal 
neovascularization.
a P-values were calculated using Kruskal-Wallis tests for continuous outcome variables and χ² test for 
categorical outcome variables.
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Anti-vascular endothelial growth factor (VEGF) therapy has become the mainstay of 
neovascular age-related macular degeneration (nAMD) treatment and has substantially 
improved visual prognosis. The first-line anti-VEGF agent used in the Netherlands is 
bevacizumab because of its superior cost-effectiveness compared to ranibizumab and 
aflibercept.1 Even though bevacizumab is generally effective, approximately 10% of 
patients are non-responders. The effectiveness and working mechanism of bevacizumab 
is comparable to ranibizumab, both being VEGF-A antibodies.2 The therapeutic 
mechanism of aflibercept is slightly different, which functions as a decoy receptor for 
VEGF-A, VEGF-B and placental growth factor. Therefore, aflibercept seems like a 
more promising alternative than ranibizumab in case of non-response to bevacizumab. 
Although aflibercept is an effective treatment for nAMD,3 its role as a secondary 
treatment option requires further investigation. Here we report the treatment response 
to aflibercept in nAMD-patients who did not respond to bevacizumab treatment. 
This prospective, single-arm, open-label, clinical trial was approved by the local 
ethical committee (NL44122.091.13) and was registered at the Dutch trial register 
(NTR4188). We included 10 eyes of 9 patients (table) that were non-responder to 
bevacizumab. Inclusion criteria were: inadequate response to bevacizumab treatment 
defined as a persistent central retinal thickness (CRT) of ≥300 µm on optical coherence 
tomography (OCT); having received at least 3 bevacizumab injections within 1 year 
before inclusion in this study; active nAMD as seen on fluorescein angiography and 
OCT; maximally 2 years since start of bevacizumab treatment; 1- 3 months since the 
last bevacizumab injection; and best-corrected visual acuity (BCVA) at baseline between 
20/25 and 20/320. Patients were excluded if they had: signs of subretinal fibrosis, 
scarring or geographic atrophy involving the center of the macula; pigment epithelial 
detachment with a height of ≥150 µm; or any other retinal diseases. 
Aflibercept was administered as 3 consecutive monthly injections at a dose of 2 mg 
(0.05 ml). At every visit we measured CRT on OCT (Spectralis HRA+OCT, Heidelberg 
Engineering) and ETDRS BCVA. One month after the last injection response was 
evaluated. All statistical comparisons were made in SPSS using a paired t-test.
CRT decreased significantly after switching to aflibercept with a mean of 102 ± 96 µm 
after 3 months (p=0.008) (figure). The largest decrease was seen after 1 month  (90 ± 
83 µm, p=0.007). BCVA increased correspondingly with 6.7 ± 11.4 ETDRS letters, 
this was however not significant (p=0.096). The change in CRT was substantial in 7 
eyes, with a decrease of >50 µm. In 7 out of 10 eyes there was a functionally relevant 
improvement of >5 ETDRS letters. 
Switching to aflibercept in patients with neovascular age-related macular degeneration not 
responding to bevacizumab: a pilot study
111
Table. Baseline characteristics
n=10 eyes of 9 patients
Male, n (%) 4 (44%)
Age, median (range) 75 (55-87)
   
Eye included, n (%)  
Right eye 4 (40%)
Left eye 6 (60%)
   
Nr of bevacizumab injections, median (range) 6 (3-11)
   
CRT at baseline in µm, mean (SD) 540 (110)
BCVA at baseline in letters, mean (SD) 57.6 (18.7)
CRT=central retinal thickness; BCVA=best corrected visual acuity
Figure. Course of central retinal thickness after switching to aflibercept
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In this study there was a clear anatomical benefit of switching to aflibercept. Most eyes 
also improved functionally, however not significantly, likely due to a lack of power. The 
3 month BCVA changes we found were good compared to other prospective studies on 
switching to aflibercept after non-response to previous anti-VEGF treatment, where it 
ranged between 0 and +7 letters after 6 months (3 month data not available for most 
studies).4 In these previous studies anatomical response varied between -127 and -15 
µm, however, most find CRT changes of <50 µm. An explanation for our good results 
could be that patients in our study were switched relatively early, sometimes as soon 
as after 3 months of bevacizumab treatment, leaving more room for improvement. In 
conclusion, this study provides additional evidence that switching to aflibercept may 
be beneficial after non-response to bevacizumab, resulting is anatomical as well as 
functional improvement.
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Purpose: Treatment of diabetic macular edema (DME) has moved from laser towards 
anti-VEGF therapy. However, it is unclear how frequent non-response to anti-VEGFs is 
and what is the best management for these non-responders. We assessed the effectiveness 
of primary bevacizumab treatment for DME in daily clinical practice and of alternative 
treatments in non-responders. 
Methods: We reviewed the medical charts of DME-patients treated with bevacizumab 
and recorded whether patients switched treatment during the first year. The course 
of visual acuity (VA) and central retinal thickness (CRT) was determined. In non-
responders, VA and CRT were assessed prior to and following alternative treatment. 
Results: We included 94 eyes of 69 patients. Mean VA improved from 20/76 to 
20/62 (p=0.124) and CRT decreased by 36 µm (p<0.001) over 1 year. Nineteen eyes 
(20%) switched treatment due to non-response. Six eyes switched to ranibizumab. 
Two responded with ≥50 µm decrease in CRT. Eight eyes switched to intravitreal 
triamcinolone. Seven responded well, decreasing ≥50 µm in CRT. 
Conclusions: The effectiveness of bevacizumab in DME-patients in daily clinical 
practice is moderate. About 20% of patients require alternative treatment due to non-
response. Compared to ranibizumab, switching to triamcinolone was the preferred 
alternative treatment with clear improvement in most patients.
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Introduction 
Diabetic retinopathy is a common complication of diabetes mellitus and is the leading 
cause of visual impairment in the working-age population.1 Approximately 64% of 
vision-threatening diabetic retinopathy is due to diabetic macular edema (DME), 
making it the primary cause of vision loss in diabetics.2 The global prevalence of DME is 
~7% in all diabetic patients and the cumulative incidence can reach up to 29% in long-
term type I diabetic patients.2, 3 The number of people affected with diabetes mellitus is 
rising each year making DME an increasingly important health concern.4 
DME results from a disruption of the blood-retina barrier at the level of the retinal 
capillaries resulting in excessive vascular permeability and leakage of fluid into the retina. 
Retinal hypoxia leading to increased vascular endothelial growth factor (VEGF) levels 
and inflammation may both contribute to DME.5 The role of VEGF in the etiology of 
DME led to a number of clinical trials evaluating anti-VEGFs in the treatment of DME. 
From 2007 to 2014 several randomized controlled trials (RCTs) have demonstrated that 
anti-VEGF therapy is more effective in improving visual acuity (VA) and reducing retinal 
thickness than laser surgery alone.6-13 Moreover, there appears to be no added benefit 
of laser surgery in combination with anti-VEGF therapy [ref BOLT, DRCRN(Protocol 
I), Pan-American, Solaiman, Restore].8, 10, 11, 14, 15 Consequently, anti-VEGF therapy has 
replaced laser surgery as the primary treatment for center-involved DME. 
Three anti-VEGF agents are currently available for treatment of DME: ranibizumab, 
bevacizumab and aflibercept. The protocol T study, a large RCT from the Diabetic 
Retinopathy Clinical Research Network (DRCRN), compared the effectiveness of these 
three agents and concluded that for patients with baseline VA of over 20/40, the three 
agents were equally effective in improving vision. For patients with visual acuity below 
20/50 aflibercept resulted in better visual improvement, yielding 5-6 ETDRS letters 
more than ranibizumab or bevacizumab.16 Regarding anatomical effects, both aflibercept 
and ranibizumab were significantly better at reducing central retinal thickness (CRT) 
compared to bevacizumab and more often resulted in CRT of <250 µm. Before the 
protocol T study had shown the superiority of aflibercept in DME-patients with visual 
acuity below 20/50, bevacizumab was the first choice treatment for all DME patients in 
the Netherlands due to its favorable cost-effectiveness profile.17 
Although all three anti-VEGF agents have improved visual prognosis of the average 
DME-patient, there are still patients with suboptimal response or non-response. In the 
protocol T study 1/3 of aflibercept and ranibizumab treated eyes and almost 2/3 of 
bevacizumab treated eyes had not achieved a CRT of <250 µm after 1 year, indicating 
persistent edema.16 The protocol I study that evaluated the effectiveness of ranibizumab 
showed that of the patients with persistent edema after 6 months, 40% still have 
persistent DME after 3 years.18 So it seems there is a substantial number of patients not 
responding, or only partially responding, to anti-VEGF therapy. 
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Non-response is an everyday problem in clinical practice and many ophthalmologists 
are faced with the dilemma of what to do in case DME persists despite continuous 
anti-VEGF treatment. At the moment, there are no clear guidelines for defining non-
response. This means it is unclear to many ophthalmologists which patients are the non-
responders requiring an alternative treatment strategy and it is also unclear how frequent 
non-response is in clinical practice. Several studies have tried to address the issue of 
non-response, but even within the same study the frequency of non-response may vary 
greatly depending on de definition used. 
Although there is no consensus as to what should be considered non-response, there are 
some alternative treatments to consider when non-response is suspected. Mainly, the 
choice is between switching to a different anti-VEGF agent or switching to steroids. The 
prospective REEF study showed that switching from bevacizumab to ranibizumab in 
refractory DME patients resulted in anatomical improvement of >10% CRT reduction 
in 75% of patients after 3 months.19 Retrospective studies have shown similar benefit 
of switching to ranibizumab in refractory DME cases.20, 21 Intravitreal steroids, such 
as triamcinolone acetonide (TAC) or long-acting dexamethasone implants may pose 
another alternative treatment.22, 23 Steroids are able to improve visual acuity and CRT 
compared to sham treatment, but the effect is mostly seen in pseudophakic patients.10 
In phakic patients anti-VEGF results in superior visual acuity due to cataract formation 
in the steroid treated group. Phakic patients treated with TAC require cataract surgery 
in ~60% of cases. Also, 30-40% of TAC treated patients experience a rise in intraocular 
pressure of ≥10 mmHg within 2 years.10, 24 Because of these common side-effects, 
intraocular steroids are usually not a first choice treatment, but may be considered in 
non-responders. Switching from bevacizumab to steroids in non-responders has been 
evaluated in several small sized studies.25-27 These studies have shown good short-term 
anatomical response, however, the effect on visual acuity in all studies was less outspoken 
and changes in vision could not be sustained over the study periods.
So far, no clear guidelines exist for secondary treatment and it is unclear whether non-
responders should be switched to a different anti-VEGF or to a steroid. Here we assess the 
response to primary bevacizumab treatment in DME-patients in daily clinical practice, 
report the frequency of treatment switching and describe the effect of switching non-
responders to the alternative treatments ranibizumab or TAC.  
Methods
Population
We reviewed the charts of patients that were treated with bevacizumab for DME at the 
department of ophthalmology of the Radboud university medical center in Nijmegen 
between October 2009 and March 2014. Inclusion criteria were: central diabetic macular 
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edema, no previous intravitreal treatment for DME in the study eye, a completed loading 
dose of three consecutive bevacizumab injections 4-6 weeks apart and optical coherence 
tomography (OCT) imaging available at baseline and at least one follow-up moment. 
Treatment
All patients were treated with intravitreal injections (IVI) of 1.25 mg in 0.05 ml 
bevacizumab. Patients received a loading phase of 3 consecutive injections 4-6 weeks 
apart, followed by a monitoring phase where injections could be administered on a 
pro re nata (PRN) basis. The decision for re-injection with bevacizumab was based on 
persistent fluid or retinal thickening on OCT. Patients switched treatments at the treating 
physicians discretion after non-response to bevacizumab, which entailed an increase 
or insufficient decrease in CRT despite treatment. Change in VA was not considered 
in determining non-response. Focal/grid photocoagulation for microaneurysms or 
panretinal photocoagulation for proliferative diabetic retinopathy could be performed 
at the treating ophthalmologist’s discretion. The studied alternative treatments were 
ranibizumab and TAC. The choice for either drug was not based on any predefined 
criteria but according to the preference of the ophthalmologist. Ranibizumab was 
administered as 3 consecutive monthly IVIs of 0.5 mg in 0.05ml and TAC as a single 
dose of 2mg in 0.05. 
Clinical data collection
We extracted patient characteristics such as type and duration of DM, insulin use and 
duration of DME from the medical history. CRT was measured on OCT (Spectralis 
HRA+OCT, Heidelberg Engineering) using automatic volume measurements with 
manual correction of retinal boundary segmentation errors. CRT and best corrected 
Snellen VA were assessed at baseline, 3, 6 and 12 months. At every time point we 
recorded whether a patient had switched treatments and the nature of the alternative 
therapy. For patients that switched treatments, VA and CRT were also collected prior to 
and after the alternative treatment. 
Statistical analysis
Snellen VA was converted to the logarithm of the maximum angle of resolution (logMAR) 
to enable statistical analysis. Descriptive statistics were used with eyes as independent 
units. All other analyses were performed using linear mixed models to account for the 
dependency between eyes of the same patient.28, 29 The primary outcome was change in 
CRT over 1 year of treatment. The difference in course of CRT and VA between non-
responders and the remaining patients was assessed by testing for interaction between 
switching treatment and time. Finally, we evaluated  CRT and VA before and after 
switching to a different treatment modality. All analyses were performed in SPSS version 
22 and a p-value of <0.05 was considered statistically significant. 
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Results
Overall response to bevacizumab
We included 94 eyes of 69 patients. The baseline characteristics are presented in table 
1. The complete cohort showed a mean decrease in CRT of 36 ± 127 µm over 1 year 
(p<0.001). VA improved from 0.58 ± 0.38 logMAR (Snellen 20/76) to 0.49 ± 0.40 
logMAR (Snellen 20/62), albeit not significantly over time (p=0.124). Response to 
treatment of the complete cohort is summarized in table 2. The median number of 
injections was 6 (interquartile range 3-9).  
Table 1. Patient baseline characteristics
Variable  
94 eyes of 69 patients  
   
Male, n (%) 37 (54%)
   
Age at first injection in years, mean (SD) 63 (13)
   
Eye included, n (%)  
OD 28 (41%)
OS 16 (23%)
ODS 25 (36%)
   
Type of diabetes mellitus, n (%)  
DM I 8 (12%)
DM II 59 (86%)
Unknown 2 (3%)
   
Duration DM in years, median (IQR)* 12 (5-21)
   
Duration of DME in months, median (IQR) 8 (2-21)
   
Insulin user, n (%) 42 (61%)
*duration DM missing for n=7 eyes; SD= standard deviation; OS= oculus sinister; OD= oculus dexter; 
DM= diabetes mellitus; IQR= inter quartile range; DME= diabetic macular edema
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Table 2. Treatment outcomes
  Baseline 3 months 6 months 1 year p-value
  n=94 eyes n=83 eyes n=74 eyes n=66 eyes  
CRT in µm, mean (SD) 474 (124) 426 (139) 437 (136) 441 (154) <0.001
Change from baseline in µm, mean (SD) -49 (85) -42 (89) -36 (127)  
   
  n=94 eyes n=89 eyes n=81 eyes n=74 eyes  
logMAR, mean (SD) 0.58 (0.38) 0.51 (0.36) 0.51 (0.36) 0.49 (0.40) 0.124
Snellen equivalent 20/76 20/65 20/65 20/62  
Change from baseline in logMAR, mean (SD)
-0.07 
(0.24)
-0.06 
(0.27)
-0.07 
(0.34)  
Improvement >= 0.3 logMAR, n (%) 14 (16%) 13 (16%) 15 (19%)  
Worsening >= 0.3 logMAR, n (%)   2 (2%) 6 (7%) 6 (9%)  
CRT= central retinal thickness; SD=standard deviation; 0.3 logMAR is equivalent to 15 Early Treatment 
Diabetic Retinopathy Study (ETDRS) letters.
Bevacizumab non-responders
During one year of bevacizumab treatment, the non-response rate was 20% with 19 
eyes of 17 patients switching treatment. Three eyes switched after 3 months, another 3 
eyes after 6 months and the remaining 13 eyes after 1 year. These 19 eyes experienced 
a mean increase in CRT of 23 ± 101 µm from baseline during bevacizumab treatment 
up until the moment they switched (p=0.277) (figure 1). This was significantly worse 
compared to patients that did not switch, who experienced a CRT reduction of 50 ± 
127 µm after 1 year (p=0.001) (figure 1). However, when correcting for baseline CRT 
this was no longer significant, but a clear trend was still present (p=0.077). The 19 
non-responder eyes had higher baseline CRT (534 ± 130 µm compared to 459 ± 119 
µm for the remaining eyes; p=0.018). At the time of switching, the mean CRT had 
increased to 557 ± 116 µm. The non-responders lost 0.03 ± 0.17 logMAR (from Snellen 
VA 20/74 to 20/80) during bevacizumab treatment, while the remainder that did not 
switch treatments improved 0.09 ± 0.36 logMAR over 1 year (from Snellen VA 20/78 
to 20/59) (figure 2). This change in VA was not significantly different between both 
groups (p=0.472). There was also no difference in baseline VA between switchers and 
non-switchers (p=0.918). 
In most non-responder eyes that switched treatment (16 of 19) CRT had not decreased 
more than 50 µm despite bevacizumab treatment. One eye did show a good response 
during the loading phase of bevacizumab (reduction from 658 to 456 µm in CRT), 
however, because further decrease in CRT could not be achieved, this patient was 
switched to ranibizumab after 1 year of treatment. Two eyes decreased 62 µm and 58 
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µm in CRT after the bevacizumab loading phase respectively, but still had active and 
extensive macular edema (CRT of 524 µm and 766 µm respectively). One eye was 
therefore switched to ranibizumab after 1 year and the other to subconjunctival TAC 
after 6 months. 
Figure 1. Course of central retinal thickness for non-responders that switched treatment versus those that 
did not switch treatment
Figure 2. Course of visual acuity for non-responders that switched treatment versus those that did not 
switch treatment
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Switch to ranibizumab
Twelve non-responders were switched to ranibizumab. Six of these eyes were lost to 
follow-up after referral to an independent outpatient clinic. In general, the response to 
ranibizumab was poor as shown in figure 3.  Two of 6 eyes responded well to ranibizumab 
with a reduction in CRT of more than 50 µm (eye 2 and 6 in figure 3). The mean 
decrease in CRT after 3 ranibizumab injections was limited ( -10 ± 100 µm (p=0.900)). 
One eye that initially responded well during the bevacizumab loading phase  did not 
respond to ranibizumab (eye 4 in figure 3) and increased in CRT. The other eye that had 
responded favorably to bevacizumab also responded to ranibizumab (eye 6 in figure 3). 
Mean VA change was +0.08 ± 0.51 logMAR (p=0.539). However, only the 2 eyes that 
showed anatomical response experienced an increase in VA and the increase in mean 
VA was mostly driven by one patient whose VA increased with 1.30 logMAR (change 
in Snellen VA from 2/200 to 20/100). With the exclusion of this particular patient, the 
mean change in VA was -0.10 ± 0.14 logMAR. 
Of the 6 eyes that were lost to follow-up, of 3 eyes information could be retrieved. OCT 
imaging was not performed with Heidelberg OCT, thus they were not included in the 
analysis. In one eye the fluid had almost completely resolved, with only a few residual 
cysts left after 3 ranibizumab IVIs. Visual acuity in this eye increased from 20/70 to 
20/50. The other 2 eyes showed possible partial resolution of fluid, although different 
imaging modalities made direct comparison difficult. One of these eyes did not improve 
in VA, while the other improved from 20/100 to 20/70. 
Switch to triamcinolone
Seven non-responders were switched directly to TAC. Of the 6 eyes that switched to 
ranibizumab, 2 eyes were subsequently switched to TAC because of non-response to 
ranibizumab (eye 1 and 4 in figure 3 and eye 5 and 6 in figure 4). Thus, a total of 
9 eyes were treated with TAC because of  non-response to anti-VEGF therapy. One 
eye received TAC as a subconjunctival injection, so therefore was not included in the 
analyses. Of the 8 eyes that received intravitreal TAC, 7 responded well with a decrease 
in CRT of over 50 µm (figure 4). One eye did not respond to TAC (eye 8 in figure 4). 
The mean change in CRT was a reduction of  295 ± 171 µm (p<0.001). There was 
a corresponding mean improvement in VA in these patients of 0.11 ± 0.11 logMAR 
(p=0.045). Six out of 8 eyes experienced an increase in VA, one eye remained stable and 
one eye lost 0.04 logMAR. 
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Figure 3. Change in central retinal thickness after switching to ranibizumab
Figure 4. Change in central retinal thickness after switching to triamcinolone
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Discussion 
Overall, there was a moderate, but significant anatomical as well as a non-significant 
functional improvement from bevacizumab treatment for DME in this clinical setting. 
An alternative treatment because of insufficient response to bevacizumab was necessary 
in 20% of patients. Eyes that switched to TAC responded better with regard to CRT 
decrease and VA increase compared to eyes that switched to ranibizumab. 
In RCTs we usually see a greater effect of bevacizumab on CRT change, as well as VA 
after 1 year of treatment compared to our retrospective study.11, 12, 16, 30-33 The RCTs found 
decreases in CRT ranging between 50 and 180 µm and improved VA by approximately 
2 Early Treatment Diabetic Retinopathy Study (ETDRS) lines of vision. In our study 
the effect of bevacizumab was less successful with a mean CRT decrease of 36 µm and a 
little under 1 ETDRS line (0.08 logMAR) increase in VA. The limited effect observed 
in our study compared to RCTs may be caused by the large number of injections given 
in RCTs, i.e. approximately 9 IVIs on average in RCTs versus 6 in our study. But also 
the inherent differences between the highly controlled RCT setting and the daily clinical 
practice population will likely contribute. The improvement in VA we observed was 
in concordance with retrospective studies evaluating bevacizumab in clinical practice 
(range of 0-2 ETDRS lines of vision increase).15, 34-36 However, the effect on the CRT 
was somewhat lower than these retrospective studies where the reported reduction in 
CRT varies between 50-150 µm. The fact that our center is a tertiairy referral center 
with relatively complicated cases may have influenced the outcome. 
Some limitations are involved in clinical practice data, as in our study. This study 
was retrospective and thus uncontrolled. There was a loss to follow up of about 20%, 
either because the patient refused further treatment or the treatment was continued 
elsewhere. Also, the non-responder subgroups were small and follow-up was short. In 
the Protocol I study it was suggested that the effect of TAC may wane over time.10 
Therefore confirmation of results in bigger cohorts with longer follow-up is warranted. 
Recent evidence from the protocol T study suggests that aflibercept may be preferable 
as first-line anti-VEGF for patients with a ETDRS visual acuity below 20/50.16 In our 
cohort 59% of eyes presented with a VA of below 20/50 at baseline and therefore it could 
be expected that they would have fared better on aflibercept. This could potentially 
influence the percentage of non-responders in the current study and the effect of 
switching to a different treatment. Based on RCT data, bevacizumab still is the most 
cost-effective treatment,17 so studies of aflibercept in daily practice are required before a 
conscious decision can be made which anti-VEGF agent should be first-line treatment. 
In this study patients switched treatments when the ophthalmologist, in consultation 
with the patient, decided that response to bevacizumab was unsatisfactory. This was not 
based on predefined response criteria, but did mainly consider the persistence of fluid on 
OCT. This limitation possibly stems from the inconsistent literature on the definition of 
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non-response. Several studies have attempted to label lack of response or non-response [ref 
studies non-response zie samenvatting]. These criteria for non-response in literature may 
have been created for several reasons: to determine whether retreatment is indicated,16, 17 
as a way to perform statistical analyses comparing responders and non-responders,26, 37, 
38 or as a way to determine treatment effect.18, 39 Therefore not all published definitions 
may be suitable for determining non-response in clinical practice. Moreover, response 
may be based on CRT, VA or a compound measure. Because there is no consensus on 
which measure should be applied, the percentages of non-response in the same study 
may vary greatly depending on the definition used. For example in the BOLT study that 
evaluated bevacizumab, in report number 439 they defined non-responders as patients 
that did not show a reduction of ≥20% CRT at 4 months or 12 months, while in report 
number 540 non-response was defined as never achieving a CRT of <270 µm during 
24 months of treatment. The difference in the number of non-responders was 9% in 
report 4 and 57% in report 5. Therefore the exact definition applied may have quite an 
impact on clinical practice and non-response management. That this lack of consensus is 
challenging in clinical practice and could also be noted in this study. Although the group 
that had switched treatments was different with regard to course of CRT compared to 
the remaining patients, there was substantial overlap in response. Also, there was no 
significant difference in change in VA between the two groups, indicating that the non-
response criteria based on OCT practiced in this study might not be very relevant to 
the patient who is mostly concerned with visual gains. OCT features, such as CRT, are 
often incorporated in non-response definitions. However, the correlation between CRT 
and VA is only moderate and in some individuals non-response on OCT may even be 
accompanied by good visual response and vice versa.37, 41, 42 It is clear there is still room 
for optimization of secondary DME treatment and a consensus on a relevant definition 
of non-response would be a good first step. 
Regardless of whether the non-response criteria applied here were optimal, it was 
striking how switching to TAC seemed more effective than switching to ranibizumab. 
It has been suggested in the FAME study43 that chronic edema may be especially prone 
to steroid treatment, however chronic edema was defined as having DME for over 3 
years and none of the patients that were switched to TAC had DME for more than 
2 years. So it does not seem the effect can be explained by a chronic character of the 
edema. It could however imply different mechanisms at work as a cause for DME in 
these bevacizumab non-responders. In DME, fluid leakage originates from the retinal 
capillaries where change in permeability of retinal endothelial cells results in macular 
edema.44 There may be multiple causal pathways for this increased permeability, such 
as hypoxic or inflammatory pathways, and thus different treatment approaches may 
be in order. Anti-VEGF therapy targets the hypoxic or VEGF pathway, while steroids 
target the VEGF and the inflammatory pathway.45, 46 Depending on which pathway is 
most active in a patient presenting with DME, one treatment may yield better results 
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than the other. The study of Jeon et al26 suggests a beneficial effect of switching to TAC 
after bevacizumab, and links the response to TAC to the inflammatory marker IL-8 in 
the aqueous humor. Other inflammatory factors were also tested (VEGF, IL-2, IL-6, 
TNF-α, TGF-β2), but these were not associated. Possibly, the macular edema in the 
non-responders in this study was mediated more by inflammation as opposed to VEGF. 
Future studies are needed to investigate whether systemic inflammatory factors can be 
measured in advance to determine whether a patient’s first line treatment should be 
anti-VEGF or steroids. 
In conclusion we showed a moderate effect on CRT and VA in DME-patients treated 
with bevacizumab in daily clinical practice. Within 1 year, 20% of patients were 
considered non-responder and had to be switched to an alternative treatment. In our 
retrospective study, TAC was a better alternative treatment than ranibizumab.  
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Purpose: The discussion on the use of bevacizumab is still ongoing and often doctors 
are deterred from using bevacizumab due to legal or political issues. Bevacizumab is 
an effective, safe and cheap treatment option for neovascular age-related macular 
degeneration (AMD). However, bevacizumab is not registered for AMD. Therefore, in 
some countries ophthalmologists are forced to use the equally effective but expensive 
drugs ranibizumab and aflibercept. Here, we describe the economic consequences of 
this dilemma surrounding AMD treatment.
Methods: We modelled cost-effectiveness of treatment with ranibizumab (as-needed), 
aflibercept (bimonthly) and bevacizumab (as-needed). The drug with the most favourable 
cost-effectiveness profile compared to bevacizumab was used for threshold analyses. 
First, we determined how much we overpay per injection. Second, we calculated the 
required effectiveness to justify the current price and what a reasonable price is for a 
drug that leads to optimal vision. Finally, we estimated how much Europe overspends if 
bevacizumab is not first choice.  
Results: Bevacizumab treatment costs €27,087 per year, about €4,000 cheaper than 
aflibercept and €6,000 cheaper than ranibizumab. With similar effectiveness for all 
drugs as shown by meta-analysis, bevacizumab was clearly the most cost-effective. 
Aflibercept was chosen for threshold analyses. Aflibercept costs €943 per injection, but 
we determined that the acceptable price is actually €533. Alternatively, at its current 
price, aflibercept should yield about twice the visual gain. Even when optimal vision 
can be achieved, the maximum price for any treatment is €37,453 per year. Most 
importantly, Europe wastes €335 million on AMD treatment when choosing aflibercept 
over bevacizumab. 
Conclusion: Bevacizumab is undoubtedly the most cost-effective treatment for AMD, 
yet is not the standard of care across Europe. The registered drugs ranibizumab and 
aflibercept cause huge overspending with limited health benefits. Health authorities 
should take steps to implement bevacizumab into clinical practice as first choice. 
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Introduction
Bevacizumab is a cheap and effective anti-vascular endothelial growth factor (VEGF) 
drug for neovascular age-related macular degeneration (AMD). Yet, recently it was 
described how ophthalmologists in the UK are deterred from prescribing this drug.1 
Instead doctors are being forced to prescribe the much more expensive ranibizumab or 
aflibercept by the General Medical Council, which opposes the use of off-label drugs 
such as bevacizumab when registered drugs are available. Even the National Institute 
for Health and Care Excellence (NICE), which holds cost-effectiveness in high regard, 
recommends the registered drugs over bevacizumab.2, 3 The article describes the many 
political and legal issues involved in the development of such guidelines that seemingly 
ignore cost-effectiveness completely. This, however, does not occur solely in the UK. In 
fact in many other European countries bevacizumab is not allowed for ophthalmological 
indications. Europe is wasting money by not addressing this problem adequately as 
anti-VEGF treatment accounts for a large proportion of total health care expenditures.4 
AMD is a major health concern, affecting almost 200 million people globally within 
the next five years. Over 11 million will have developed end-stage AMD and about 2.8 
million of these people will reside in Europe.5 Two-thirds will be neovascular AMD 
cases, requiring multiple anti-VEGF treatments. In the neovascular end-stage of AMD, 
increased VEGF levels cause newly formed blood vessels to grow into the retina and 
leak fluid, lipids and proteins, leading to rapid and severe vision loss. Anti-VEGF agents 
that can be injected in the eye have been developed to inhibit these neovascularisations 
and with great success. Pivotal randomized controlled trials (RCT) have shown the 
superiority of anti-VEGF treatment over placebo improving both vision and quality 
of life in general.6-8 Now, anti-VEGF therapy has become the mainstay of neovascular 
AMD treatment. Treatment in clinical practices worldwide is dominated by three anti-
VEGF agents: ranibizumab, aflibercept and bevacizumab. 
Ranibizumab (Lucentis, Genentech Inc./Novartis) and aflibercept (Eylea, Bayer) are both 
registered for neovascular AMD. A large non-inferiority RCT comparing aflibercept 
and ranibizumab showed no discernible difference in effectiveness.9 Bevacizumab 
(Avastin, Genentech Inc./Roche) is not registered for use in AMD. The property rights 
of bevacizumab and ranibizumab are both owned by Roche, the parent company of 
Genentech, and although bevacizumab was originally developed as a cancer treatment, 
it has similar properties as ranibizumab, both being VEGF-A antibodies. RCTs have 
shown that there is no meaningful difference between the two agents in effect on visual 
acuity.10-13 However, although the three agents are equally effective in conserving vision, 
there are large differences in costs. Bevacizumab is a factor 20 cheaper than ranibizumab 
and aflibercept, i.e. about €50 and €1,000 per injection. As the EU member states are 
aiming towards containment of expenditures to health care and efficient allocation of 
resources one would expect that bevacizumab would be first choice in AMD treatment. 
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However, wide differences exist across Europe in rules and legislations surrounding the 
use of this off-label drug and so its use in clinical practice is not self-evident.
In this article we describe how much we are overspending on registered anti-VEGF drugs 
and we provide the economic arguments for AMD treatment decisions, pricing and 
innovation. We provide insight into the costs involved in ranibizumab, aflibercept and 
bevacizumab treatment and show the economic consequences of not allowing bevacizumab 
in ophthalmology. Supported by a cost-effectiveness analysis we will discuss why bevacizumab 
is the only reasonable first line treatment in AMD from a public health perspective. 
Methods
Model development
To estimate the economic consequences for society of prescribing ranibizumab or 
aflibercept instead of bevacizumab we developed a patient-level decision analytic 
model evaluating effectiveness, quality of life and costs. Three treatment strategies were 
compared: ranibizumab administered as-needed, aflibercept administered bimonthly 
and bevacizumab administered as-needed. The as-needed regimen includes a loading 
phase of three consecutive monthly injections, followed by injections on an as-needed 
basis, depending on clinical evaluation. The bimonthly regimen also includes a loading 
phase, followed by injections every two months. These regimens reflect daily care in 
clinical practice most closely, but are also supported by evidence from RCTs. 
The model estimated the mean costs and benefits for a hypothetical group of patients. 
AMD patients with specific baseline characteristics entered the model individually and 
progressed through all three treatment strategies in the model over one year. Each patient 
was assigned a baseline visual acuity and change in visual acuity for each of the treatment 
strategies. The outcomes were averaged across a large sample of patients (n=100). We 
employed a 1-year time horizon since this time span is most extensively studied and 
allows for the most accurate effect estimates. The model assumed treatment of the best 
seeing eye, which is known to be most strongly predictive of quality of life.8, 14 
Effectiveness and quality of life
To determine the effectiveness of each drug a meta-analysis was conducted; seven RCTs 
were included (table 1).9-13, 15, 16 The results are presented in table 2. Data were pooled 
with a random effects meta-analysis. Effectiveness was defined as change in visual acuity 
from baseline in ‘early treatment for diabetic retinopathy study’ (ETDRS) letters after 1 
year of treatment. ETDRS letters are scored on a letter chart with letters of decreasing 
size from top to bottom. The number of letters a patient can read on the letter chart 
determines the visual acuity. Baseline visual acuity was derived from a meta-analysis of 
the baseline ETDRS letter scores of all included RCTs. 
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Table 2. Results of meta-analysis
Variable
Baseline visual acuity (ETDRS letters) mean (SD) 52.1 (14.1)
Change in visual acuity (ETDRS letters) mean (SD)  
Ranibizumab 4.7 (15.9)
Aflibercept 8.4 (14.7)
Bevacizumab 5.4 (8.8)
   
Number of injections  
Ranibizumab 6.2  
Aflibercept 7.0  
Bevacizumab 7.0  
ETDRS=early treatment for diabetic retinopathy study; 
SD=standard deviation. 
Based on their visual acuity after 1 year of treatment, patients were assigned a utility 
score which was derived from literature (table 3).17 We assumed that this utility score 
remained constant throughout the 1-year time horizon of the model. Utility scores 
represent the quality of life of a patient with a certain health status, or in this case with 
a certain visual acuity score. Utility scores vary from 1 to 0, with 1 indicating a perfect 
health state and 0 indicating death. The use of utility scores allows the calculation of 
quality adjusted life years (QALYs). One QALY equals one year lived in perfect health. 
Table 3. Utility value per visual acuity category
Visual acuity 
category
Visual acuity range Utility value Standard error Distribution
1. 20/20-20/25 0.84 0.027 Beta
2. 20/30-20/40 0.80 0.024 Beta
3. 20/50-20/100 0.71 0.029 Beta
4. ≤ 20/200 0.59 0.027 Beta
Derived from Brown et al. 200217
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Costs
Costs were calculated from a societal perspective, including both direct and indirect 
costs. Direct medical costs included the costs of the drugs, medical visits and ophthalmic 
examinations. Drug costs were obtained from the Dutch National Health Care 
Institute18 and costs for ophthalmic examinations were obtained from the department of 
Ophthalmology of the Radboudumc. The mean number of injections for ranibizumab 
and bevacizumab in a year was estimated from published RCTs. The number of 
injections for aflibercept was set at 7, corresponding with a bimonthly regimen. Indirect 
costs included the costs of low vision aids and nonmedical costs. The costs of low vision 
aids were based on a database from the Low Vision Totaal vision clinic containing 550 
patients with various forms of maculopathy and their use of vision aids. Per visual acuity 
category the mean costs for low vision aids per person were calculated. Nonmedical 
costs, including caregiver costs, adapted housing and transportation, were derived from 
literature.19 Table 4 provides an overview of all estimated costs. Costs are estimated 
in 2014 euro (€), using index prices according to the Dutch pharmaco-economic 
guidelines20 and presented in euro or equivalent pound (£) when appropriate  (currency 
rate €/£ January 1st 2015: 0.77661).
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Table 4. Direct and indirect costs for neovascular AMD treatment
  Unit Costs (€) SE Distribution Source 
Aflibercept Per injection 943.48 Fixed DNHCI
  Average per year: 7.0  
   
Ranibizumab Per injection 979.14 Fixed DNHCI
  Average per year: 6.2  
   
Bevacizumab Per injection 44.45 Fixed DNHCI
  Average per year: 7.0  
   
Medical visit Per visit 140.42 Fixed Radboudumc
  Per year: 12  
   
Optical coherence 
tomography
 
Per measurement 33.39 5.0 Gamma Radboudumc
Per year: 12  
   
Fluorescein 
angiography
 
Per measurement 111.33 10.0 Gamma Radboudumc
Per year: 1  
   
Visual acuity 
measurement
 
Per measurement 12.19 2.0 Gamma Radboudumc
Per year: 12  
   
Fundus photograph Per measurement 39.0 10.0 Gamma Radboudumc
  Per year: 1  
   
Low vision aids* If 20/20-20/25 218.24 85.95 Gamma Low Vision Totaal
(One-time) If 20/30-20/40 451.69 74.97  
  If 20/50-20/100 1020.00 53.74  
  If ≤20/200 1065.87 73.76  
   
Nonmedical costs# If 20/20-20/25 1141.69 327.09 Gamma Brown et al.19 
(One-time) If 20/30-20/40 6165.32 1947.80  
  If 20/50-20/100 19477.18 2599.00  
  If ≤20/200 42318.61 3822.44  
SE=Standard error; DNHCI=Dutch National Health Care Institute, www.medicijnkosten.nl, 2014; 
Radboudumc = Department of Ophthalmology of the Radboudumc
*Low vision aids includes (electronic) loupes, loupe glasses, filter glasses, loupe lamp, monitor loupes; 
#Nonmedical costs include caregivers costs for inside activities of daily living (ADL), outside ADL and 
transportation costs and residence costs.
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Analysis
We developed the decision analytic model using ARENA software (version 14.00.00 
Rockwell Automation, Inc). The three treatments were compared in terms of mean 
costs, mean effects (in QALYs) and incremental cost-effectiveness ratios (ICERs). 
The ICER represents the extra costs that are incurred in order to gain one additional 
QALY, comparing one treatment over the other. The ICER is calculated by dividing the 
estimated difference in costs between two treatments by the difference in QALYs.21 
Whether a treatment may be considered cost-effective depends on how much a society 
would be willing to pay for a QALY. We used a willingness-to-pay (WTP) threshold 
of €80,000 per QALY, the highest cost-effectiveness threshold recommended by The 
National Health Care Institute.22 This means that a strategy is deemed cost-effective 
compared to another strategy when it costs €80,000 or less to gain an extra QALY, i.e. 
the ICER is lower than €80,000 per QALY. Bevacizumab was used as the comparator 
in all cases. Probabilistic sensitivity analyses were performed to assess the impact of 
uncertainty on the outcomes.23 This means that we assigned distributions to model 
parameters, to reflect the uncertainty in the estimation of that parameter when possible. 
All distributions are listed in tables 3 and 4. Parameter values were sampled at random 
from the assigned distributions, using Monte Carlo simulation. After each sample, 100 
patients were simulated using these parameter values, which was repeated 1000 times. 
Cost-effectiveness acceptability curves were plotted, which show the probability that an 
anti-VEGF drug is the most cost-effective over a range of WTP thresholds. 
To answer our question of what an acceptable price is for innovative treatments in AMD, 
we performed threshold analyses for the drug with the most favourable cost-effectiveness 
profile compared to bevacizumab. Threshold analyses determine under what conditions 
the drug will become the most cost-effective treatment compared to bevacizumab, i.e. 
under which circumstances the ICER will drop below the WTP threshold of €80,000 
per QALY. First, the acceptable price for one injection was calculated by determining 
the total acceptable costs for a treatment at an ICER of €80,000 and subtracting all 
remaining costs except for drug costs and dividing by the total number of injections. 
Second, we determined how effective the drug should be to justify the current difference 
in costs compared to bevacizumab. Third, we calculated the acceptable costs for an 
innovative treatment that leads to optimal visual acuity. When varying quality of life 
gains, indirect costs were reduced as quality of life gains increased. The reduction in 
indirect costs per 0.01 QALY was estimated through linear regression in the modelled 
patient population. Similarly, we used linear regression to determine the number of 
QALYs gained per ETDRS letter to translate quality of life changes to visual acuity 
changes. 
Overspending was defined as the amount of extra money paid for health care that 
cannot be justified by the WTP threshold of €80,000, i.e additional treatment costs 
without an equivalent health benefit. Overspending in Europe was calculated based 
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on the overpricing of the registered drug compared to bevacizumab and the number of 
expected injections. The number of injections in the UK was derived from incidence 
data of new patients requiring treatment for neovascular AMD (102 per 100,000)24 
and the assumption that most patients in real-world clinical practice will receive on 
average 5 injections in the first year.25-28 From the department of ophthalmology of 
the Radboudumc, where bevacizumab is first choice, we could estimate that 80% 
of injections for AMD are with bevacizumab, while the other 20% are mostly with 
aflibercept reserved for non-responders. All estimates were then extrapolated to the 
entire European Union, which has a population of approximately 200 million aged over 
50 years.29
Reporting in this economic evaluation was based on the Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS) statement.30
Results
Costs-effectiveness
Ranibizumab was dominated by bevacizumab in the cost-effectiveness model, meaning 
it was more expensive without yielding additional QALYs. Aflibercept yielded 0.015 
extra QALYs compared to bevacizumab. Assuming a threshold of €80,000 for one QALY 
gained, bevacizumab was the most cost-effective treatment in 100% of simulations 
Figure 1. Acceptability curve of the three anti-VEGF treatments
The acceptability curve shows the probability of a treatment being cost-effective over a range of 
willingness-to-pay thresholds. The curve shows that bevacizumab is the most likely to be cost-effective 
until a willingness-to-pay threshold of €407,250 is reached, after which aflibercept is most likely to be 
cost-effective.  
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(figure 1). Using aflibercept instead of bevacizumab means paying €278,099 per QALY 
gained (table 5). Using ranibizumab would mean paying money without any health 
benefits. 
Table 5. Differences in effectiveness and costs between treatments
The ICERs show that we pay €278,099 per QALY if we use aflibercept instead of bevacizumab and that 
ranibizumab is dominated by bevacizumab, meaning it is more costly, but does not yield any health 
benefit.
 
Mean costs
€ (95-%CI)
Difference 
in costs
Δ€
Mean 
effectiveness 
QALY (95-%CI)
Difference in 
effectiveness 
ΔQALY
ICER
Δ€/ΔQALY
Ranibizumab € 33,137 (28,883-37,926) € 6,050 0.69 (0.66-0.73) 0.000 Dominated
Aflibercept € 31,119 (26,979-35,766) € 4,032 0.71 (0.67-0.74) 0.015 € 278,099
Bevacizumab* € 27,087 (22,818-31,789) - 0.69 (0.66-0.73) - -
QALY=quality-adjusted life year; ICER=incremental costs-effectiveness ratio; 95%-CI=95%-confidence 
interval; *Bevacizumab is comparator
Threshold analyses 
Because aflibercept was more promising in terms of cost-effectiveness, we chose this 
drug to show what would be necessary in order for it to be a justifiable alternative 
to bevacizumab. The current acquisition costs of aflibercept are €943. For aflibercept 
to meet the standard criteria of cost-effectiveness, this should be reduced to €533 per 
injection. This means aflibercept is currently €410 overpriced. Because WTP thresholds 
may vary across countries, the relation between the price for one aflibercept injection and 
WTP is shown in figure 2. At a willingness to pay of £30,000 (€38,629), the threshold 
practised by NICE, aflibercept should cost no more than  £347 (€447) per injection.
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Figure 2. Acceptable costs per aflibercept injection
Which price is acceptable for one aflibercept injection depends on what society is willing to pay. The 
graph shows that at a willingness-to-pay of €80,000 per QALY aflibercept should cost no more than 
€533. To reach the NICE threshold for cost-effectiveness, the costs should be reduced to £347.
We also reversed the question by estimating how well aflibercept should work to justify 
the current pricing. The difference in total costs between aflibercept and bevacizumab 
was €4,032. Taking into account that indirect costs will decrease as effectiveness 
increases, we calculated that aflibercept should at least render an additional 0.041 QALYs 
compared to bevacizumab. Linear regression showed that 0.004 QALYs corresponded 
to approximately 1 letter on ETDRS chart. This implies that aflibercept should at least 
render an additional visual gain of 10.3 letters compared to bevacizumab, which is a 
change from baseline of 15.7 letters instead of the current 8.4 letters.   
New drugs are constantly being developed and one day these may be highly effective in 
restoring vision. The maximum utility to be reached in neovascular AMD was established 
to be 0.84 in the highest visual acuity group.17 Bevacizumab treatment leads to a mean 
utility score of 0.69, implying that at maximum 0.15 QALYs can be gained each year. 
To remain within the €80,000 WTP threshold, total costs for the new treatment should 
not exceed €38,813 during the first year. Since indirect costs for this new treatment will 
be lower when effectiveness increases, we re-calculated the indirect costs to be €1,360 
(table 4) when vision is optimally restored. After subtracting indirect costs, the direct 
medical costs of a treatment that accomplishes perfect vision in AMD should not exceed 
€37,453 per year. 
No excuses. Bevacizumab should be first choice in AMD
147
Financial consequences
In the UK alone the number of eyes with neovascular AMD requiring treatment will rise 
to 32,000 within the next 5 years.24 These patients will require on average 5 injections 
in their first year, summing up to 160,000 injections in total. The UK does not have 
bevacizumab as their first choice treatment since the NICE guidelines recommend 
the registered drugs instead. Assuming that 80% of patients could be treated with 
bevacizumab instead, we have calculated that the UK is overspending over €52.5 
million (£38.7 million) each year on new neovascular AMD patients. For Europe we 
estimate that approximately 204,000 new AMD patients will require roughly 1 million 
injections. Treating 80% of these people with bevacizumab instead of aflibercept, would 
save Europe approximately €335 million yearly. 
Discussion
Bevacizumab is undoubtedly the most cost-effective treatment for neovascular AMD. 
That aflibercept and ranibizumab are not cost-effective compared to bevacizumab does 
not come as a surprise and has been investigated before.31-33 We estimated that each 
injection of aflibercept is €410 overpriced and that Europe overspends €335 million on 
health care if aflibercept is first choice treatment instead of bevacizumab. The waste of 
implementing ranibizumab as first choice will be even bigger. An important remark here 
is that these costs are not accompanied by a substantial health benefit. Visual acuity gains 
of aflibercept were estimated to be approximately 3 letters compared to bevacizumab, 
corresponding to 0.01 QALYs. A difference this small will not be perceived by the 
individual patient.34 
The major strength of our model is that it gives a clear view of the total costs involved 
in choosing one drug over the other. This article presents the absolute overspending 
associated with aflibercept treatment and can thus contribute to budgetary discussions. 
Some possible limitations should also be discussed. First, we assumed treatment of the 
best-seeing eye in our model since we know that the vision related quality of life in an 
individual is mostly determined by the vision in the eye that sees best. Treating the 
worst-seeing eye will have little impact on quality of life.8 Modelling the best-seeing 
eye will therefore lead to conservative estimates, and cost-effectiveness is probably 
even poorer in real-life. Second, we did not consider adverse events of any kind. A 
recent Cochrane review evaluated the evidence for systemic safety of ranibizumab and 
bevacizumab (n=3,665) and they found no relevant differences except for gastrointestinal 
events.35 Interestingly, the authors recommend that health care authorities refrain 
from prohibiting bevacizumab on account of theoretical safety issues. Evidence for 
safety of aflibercept is still lagging behind, but in the large RCT of aflibercept versus 
ranibizumab no differences in safety were noted.9 Third, nonmedical costs were derived 
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from an American source. It is unsure whether these are fully representative of the 
European setting. Also, the larger the differences of nonmedical costs between vision 
categories, the more favourable the cost-effectiveness of aflibercept becomes. This is 
because when the cost differences between the vision categories become bigger, small 
differences in effectiveness become more valuable. So there will be some variation in 
results, depending on how you estimate these nonmedical costs. In our model, the cost 
differences were substantial. Nonetheless, aflibercept did not come close to being cost-
effective. Finally, we only estimated costs and effects for the first year of treatment. After 
this year, patients are still treated, but the number of injections and their effectiveness 
are unknown. Arguably, in the following years costs are still made, but vision is expected 
to deteriorate. Hence, the actual overspending is probably underestimated. So regardless 
of these limitations, it is clear that ranibizumab and aflibercept are grossly overpriced.
Europe is divided when it comes to its health care policies regarding the use of off-label 
drugs. As we know now, the General Medical Council and the NICE guidelines in the 
UK dissuade ophthalmologists from using bevacizumab, as it lacks proper appraisal. 
Unfortunately, the UK is not the only country where the use of this cheap alternative is 
held back by outmoded legislation. In countries such as Germany, Switzerland, Belgium, 
and until recently France, the use of bevacizumab in ophthalmology is not allowed 
because the health authorities declare that off-label use of drugs should be avoided when 
a registered alternative is available. But in the case of bevacizumab, should there not be 
an exception to the rules seeing the immense benefits? 
The discussion here is not only about overpaying for a drug when a cheaper alternative 
is available. Some may argue that even a little gain in quality of life is reason enough to 
use one drug over the other. This seems ethical, but is actually the opposite. Health care 
funds are not an infinite resource. Investing in one part of health care, means having less 
resources left for other types of health care. For the National Health Services (NHS) in 
the UK this has been meticulously researched by Claxton et al.36, 37 They published new 
methods for estimating NICE cost-effectiveness thresholds which was accompanied 
by a calculator to estimate the overall loss of QALY based on the additional costs of 
approving a new technology. Knowing that a year’s worth of aflibercept treatment costs 
€4,032 more than bevacizumab, this means an additional investment of €129 million 
to treat the AMD-population. This money has to come from somewhere. The calculator 
shows us that this additional investment requires redistribution of health care, resulting 
in a total of 7,346 QALYs lost because of reduction of resources in other types of health 
such as respiratory diseases and mental health. So not only does the use of aflibercept 
over bevacizumab lack a substantial health benefit, it in fact results in loss of overall 
health within the society.        
A simple solution would seem to register bevacizumab for use in AMD. However, only 
Roche, who has the ownership rights to bevacizumab, can request such a registration and 
Roche also owns its more costly alternative ranibizumab. Roche states that bevacizumab 
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is not manufactured or approved for intraocular use and they wish to focus on developing 
bevacizumab further for oncological indications and not for ophthalmology. They do not 
comment on the fact that registration of the much cheaper bevacizumab would surely 
cost them money, since this would of course lead to a reduction of their ranibizumab 
sales. However, we cannot rely on commercial companies to actively contribute to 
financial sustainability in health care and this should be the task of the health care 
authorities. The registration and patent policies will probably not change anywhere in 
the near future, but fortunately ranibizumab’s patent will be ending in 201838 and if not 
extended, this will hopefully lead to an influx of cheaper generic alternatives. And who 
knows, maybe this will impel Roche to register bevacizumab after all. 
In conclusion, since AMD is such a prevalent and debilitating disease, there is a large 
demand for treatments. Value based pricing in health care means that drugs should be 
priced the same as equivalent drugs that are available, or should at least be priced in 
accordance with their health benefits.39 It is clear that aflibercept and ranibizumab do 
not adhere to those rules. New drugs are continuously being designed and as long as 
policy makers are negligent of cost-effectiveness and sustainability of health care, it is 
a lucrative market for pharmaceutical companies. The question remains whether the 
development of these new agents is truly justified, considering the availability of the 
cheap and effective bevacizumab. Developing a new drug at the cost of below €40,000 
per year will be a challenging task. The awareness of the importance of cost-effectiveness 
to keep health care sustainable is growing and new drugs should be critically appraised 
on their added value. In the case of neovascular AMD treatment there are no excuses. 
Bevacizumab should be first choice. 
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Purpose: This study investigated whether pain from intravitreal injections (IVIs) can 
be reduced by injecting with a 33G needle instead of the commonly used 30G needle. 
Additionally, several pain-related psychological factors were explored as predictors of 
outcome. 
Methods: This randomized crossover trial included 36 patients who received injections 
with both needles in randomized order. After the injection, patients rated IVI-pain on 
a 0-10 scale. Prior to injection, distress and pain expectations were assessed. Afterwards, 
patients rated the IVI-procedure and anticipated consequences. In addition, we assessed 
the force necessary to penetrate the sclera for both needles in porcine eyes.
Results: The 33G needle did not result in lower IVI-pain (2.8 vs. 3.1, p=0.758), but 
tended to cause less vitreal reflux (0 vs. 5 times, p=0.054). Factors related to more pain 
were: distress, expecting IVI-pain and discomfort, dissatisfaction with the preparation 
procedure, anticipating negative consequences, and female gender. Patients regarded 
povidone-iodine disinfection as particularly unpleasant. Exploration of the needles’ 
mechanical properties showed that 33G needles penetrate the sclera more easily.
Conclusion: The thinner 33G needle does not reduce IVI-pain, but may limit scleral 
damage. Future efforts could be aimed at optimizing patient information, reducing 
distress, and the use of better tolerable disinfectants. 
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Introduction
Intravitreal injections (IVIs) are used with increasing frequency in ophthalmic practice 
and they have become a significant part of standard eye care. It was estimated that over 
1 million injections were performed in 2009.1 At present that number has multiplied 
and will only increase as the indications for IVIs expand. Currently, the large majority of 
IVIs relate to anti-VEGF agents that are mainly used in neovascular age-related macular 
degeneration (AMD), diabetic macular oedema (DMO) and macular oedema secondary 
to retinal vein occlusion (RVO). 
From the patient’s perspective, an eye injection can be a frightening prospect. To 
improve IVI experience, it is important that the injection procedure is as comfortable 
and pain free as possible. Factors that have been associated with a higher pain experience 
in IVIs are female gender, older age, and negative treatment results.2 However, these are 
non-modifiable factors and efforts to increase patient comfort should focus elsewhere. 
The needle, and more specifically the size of the needle, seems to be a logical candidate. 
Currently, a 30G needle, with an outer diameter of 0.31 mm, is most commonly used 
for intraocular injections with non-viscous, soluble agents such as VEGF-inhibitors. 
There is evidence suggesting that the size of the needle is associated with pain experience 
during IVI, but results have been inconsistent.2-4 One study found no difference in pain 
of a 33G guarded-needle in comparison to a regular 30G needle5, however, due to the 
difference in technique, it is hard to draw conclusions from this study regarding needle 
gauge. No study up to date has assessed the potential benefit of a 33G needle in pain 
reduction in a suitable study design. This needle has an outer diameter of only 0.21 
mm, which is a reduction of 32% compared to its 30G counterpart. Additionally, it is 
well recognized that psychological factors such as distress prior to surgical procedures 
can be a major influence on pain experience.6-8 Likely, this also plays a role in IVIs and 
patients regularly mention negative expectations, such as a fear of injection and/or fear 
of negative results.9 Controlled efforts to diminish distress in IVIs, however, have been 
limited,10 so its role in pain management in IVIs remains unclear.
The goal of this study was to investigate whether IVI pain scores can be reduced by 
replacing the 30G needle with an ultrathin 33G needle. We employed a crossover design 
allowing all participants to be their own control to account for interpersonal differences 
in pain perception. We measured the difference in force necessary to penetrate the sclera 
between 30G and 33G needles. Finally,  we explored effects on secondary outcomes of 
complications during the IVI and the influence of patient’s distress, anticipated pain, 
anticipated consequences of the IVI, and overall visit experience on the level of pain 
from an IVI. 
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Methods
Design and Population
We included 36 patients for this randomized, crossover trial. Patients who were scheduled 
for at least two consecutive IVIs with VEGF-inhibitors within 6 weeks were eligible. 
Patients and researchers were both masked for needle size. Because of the nature of the 
intervention and the difference in appearance of the needles, the surgeon performing 
the IVI could not be masked.  We performed this study in accordance with the tenets of 
the Declaration of Helsinki and the Dutch Medical Research Involving Human Subjects 
Act (WMO) and acquired an informed consent from all participants. The local ethics 
committee declared to have no objection to this trial. This clinical trial was registered at 
the Netherlands Trial Register (NTR3770).
Injection procedure
All patients received a total of two injections up to 6 weeks apart, one with the 30G 
needle [0.31x13 mm, BD Medical] and another with the 33G needle [0.21x13 mm, 
TSK laboratory]. Both needles were of the same tri-beveled design, developed for 
optimal penetration. We randomized the order in which these needles were used. All 
IVIs were administered according to clinic protocol and by the same surgeon. Twenty to 
30 minutes prior to injection the preparations started with an eye drop of oxybuprocain, 
povidone-iodine 5% and tetracain 1%. After another 10 minutes patients received an 
additional povidone-iodine 5% drop and after 20 minutes a tetracain 1% eye drop. 
Immediately prior to injection patients received a last drop of tetracain 1% and the 
eyelids were disinfected with povidone-iodine 10%. An eyelid speculum was inserted to 
keep the eye open during injection. The conjunctiva was gently displaced using a pair of 
surgical forceps and the injection was placed in a straight angle in the upper temporal 
quadrant, 3.5 mm from the limbus in pseudophakic eyes and 4 mm from the limbus in 
phakic eyes. At the end of the procedure the povidone-iodine was rinsed out with sterile 
saline solution. The surgeon recorded the occurrence of reflux and any irregularities 
during the procedure. 
Data collection
The primary outcome was pain score on a 0-10 numeric rating scale (NRS).11 
Immediately after each injection, patients were asked to score the amount of pain they 
felt during the intraocular injection with anchors of 0 meaning ‘no pain’ to 10 ‘worst 
pain ever experienced’. 
As secondary outcome variables, distress, anticipations regarding pain and consequences 
of the IVI, and visit experience were assessed. Thirty to 60 minutes prior to the injection 
procedure, patients were asked to fill out the Hospital Anxiety and Depression Scale 
(HADS)12-15 to determine distress over the last week (anxiety and depression subscale 
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possible scores ranging from 0-21). Internal consistency for composite scores was 
assessed using Cronbach’s α to indicate whether the individual questions measure a 
similar concept and a composite score is indeed acceptable. Internal consistency of the 
HADS depression and anxiety subscales was considered good with Cronbach’s α of .61 
and .71 respectively during the first visit, and 0.75 and 0.81 during the second visit. 
Additionally, patients were asked to rate several items on 0-10 NRS regarding distress 
at that moment and expectations of the injection regarding painfulness and discomfort 
(Table 1a). An overall composite score for distress was calculated by averaging the scores 
from the tension, anxiety, and nervousness questionnaire items. The items showed good 
internal consistency, with a Cronbach’s α of 0.94 during the first visit and 0.89 during 
the second. The number of preceding injections and indication for injections were 
extracted from the patient file.
Following the injection procedure, participants scored on 0-10 NRS how they perceived 
several aspects of the clinic visit and what they believed the consequences of the IVI on 
ocular function would be (Table 1b). Two specific aspects of the clinic visit were scored 
separately. The preparations surrounding the injection included the time spent in the 
preparation room and administration of the eye drops starting 20-30 minutes prior to 
injection. The procedure surrounding the injection consisted of the time spent in the 
procedure room, disinfection with povidone-iodine, insertion of the eyelid speculum, 
and the injection itself. Regarding the consequences of the injection we distinguished 
between expectations of negative consequences, such as worsening of disease or risk 
of complications, and expecting the disease to contribute to the improvement of the 
disease, either in terms of improved eyesight or slowing down the disease process. Lastly, 
patients were asked in an open question what aspect of the overall clinic visit they 
perceived as least pleasant.
Penetration force measurements
We measured the force required for scleral penetration for both needles, to gain insight 
in mechanically relevant differences between the 33G and the 30G needle. We used 
a material testing machine Z2.5 (Zwick/Roell, Ulm, Germany) with a load cell of 20 
Newton. Recently enucleated porcine eyes were mounted on a custom-built container 
to prevent excessive movement during needle penetration. We measured penetration 
force requirements of 33G, 30G and 27G needles. The 27G needle was included as 
a control since it has previously been shown to require a higher maximum force to 
penetrate the sclera as compared to the 30G needle.16 The needle was attached to a 
syringe with luer lock, which in turn was secured to the load cell. The needle was then 
lowered unto the porcine eye with a constant speed of 1 cm/second until the sclera 
was penetrated. Measurements were repeated 10 times for each gauge, using another 
location on the sclera with a fresh needle. Maximum force to penetration was recorded 
for each single test. 
Chapter 6
160
Statistical analysis
The required sample size was calculated based on a paired-samples t-test on the pain 
scores of the 33G versus the 30G needle. The standard deviation of the difference was 
estimated to be 2.0 and the correlation between consecutive pain scores 0.5.2, 17 In order 
to demonstrate a difference in pain score of at least 1.0 on a 0-10 NRS, a sample size of 34 
was required (α=0.05, β=80%). All variables were checked for normal distribution. The 
primary outcome measure showed a skewed distribution. The difference in pain score 
between needles was calculated using the Wilcoxon ranks test. Explorative associations 
between pain scores and psychological variables were assessed using linear mixed models 
to account for the dependency between the measurements from the first and second 
visit. Differences in adverse events were analysed with the Fisher’s exact test. Maximum 
force between the 30G and the 33G needle were compared using an independent t-test. 
All statistical analyses were performed in SPSS 20.0 (SPSS Inc., Chicago, IL).
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Table 1a. Psychological questionnaire prior to injection
Question Scoring scale
1. Please indicate on the scale how much 
tension you are feeling right now?  0 “no tension” - 10 “worst tension ever experienced”
2. Please indicate on the scale how anxious you 
are feeling right now?  0 “not anxious” - 10 “most anxious ever experienced”
3. Please indicate on the scale how nervous you 
are feeling right now?  0 “not nervous” - 10 “most nervous ever experienced”
4. Please indicate on the scale how much pain 
you are feeling right now?  0 “no pain” - 10 “worst pain ever experienced”
5. Please indicate on the scale how painful you 
expect the injection is going to be?  0 “no pain” - 10 “worst pain ever experienced”
6. Please indicate on the scale how 
uncomfortable you expect the injection is 
going to be?  
0 “very comfortable” - 10 “very uncomfortable”
 
Table 1b. Psychological questionnaire after the injection procedure
Question Scoring scale
1. Please indicate on the scale how painful you 
thought the injection was at the moment you 
received it?  
0 “no pain” - 10 “worst pain ever experienced”
2. Please indicate on the scale how much pain 
you are still feeling right now?  0 “no pain” - 10 “worst pain ever experienced”
3. Please indicate on the scale how you 
experienced your current visit to the clinic 
and the approach of the clinic personnel and 
treating surgeon?  
0 “very unpleasant” - 10 “very pleasant”
4. Please indicate on the scale how you 
experienced the preparation before the 
injection?  
0 “very unpleasant” - 10 “very pleasant”
5. Please indicate on the scale how comfortable 
or uncomfortable your thought the procedure 
surrounding the injection was?  
0 “very comfortable” - 10 “very uncomfortable”
6. Please indicate on the scale to what extent 
you expect the injection is going to have 
negative consequences for your health?  
0 “not at all” - 10 “to large extent”
7. Please indicate on the scale to what extent 
you expect the injection is going to contribute 
to curing/improving your eye condition?  
0 “not at all” - 10 “to large extent”
8. Please indicate briefly what you thought was 
least pleasant regarding the entire procedure 
surrounding today’s injection, from the moment 
you entered the clinic.
 
All questions were scored on 0-10 NRS. Patients were asked to mark the place on the NRS scale that 
according to them most represented how they felt. 
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Results
Patient characteristics
After randomization, 13 (36%) patients received the first injection with the regular 30G 
needle and the second injection with the ultrathin 33G needle; in the remaining 23 
patients, the 33G needle was the first needle used. The baseline characteristics for the 
two groups are described in Table 2. All patients received treatment with bevacizumab. 
Common reasons for IVI were neovascular AMD (39%), DMO (22%), RVO (17%), 
and macular oedema from various causes (11%). 
Table 2. Baseline characteristics of the two randomization groups
 
Start with 30G needle Start with 33G needle 
(n=13) (n=23)
Gender, n (%):    
Male 9 (69) 14 (61)
Female 4 (31) 9 (39)
     
Mean age (SD) 71.3 (14.5) 66.3 (11.3)
     
Eye, n (%):    
OD 5 (38) 7 (30)
OS 7 (54) 15 (65)
ODS 1 (8) 1 (4)
     
Median nr injections (range) 4 (1-56) 8 (1-29)
     
Indication for injection, n (%):    
AMD 8 (62) 6 (26)
DME 2 (15) 6 (26)
RVO 3 (23) 3 (13)
Other 0 (0) 8 (35)
SD= standard deviation; OD= oculus dexter; OS= oculus sinister; ODS= oculus dexter and sinister; 
AMD= age-related macular degeneration; DME= diabetic macular edema; RVO= retinal vein occlusion.
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Pain
The mean pain score did not differ significantly between IVIs with the ultrathin 33G 
needle (2.8 ± 2.3) and the 30G needle (3.1 ± 2.6) (p=0.758). There was no significant 
order effect, as there was no difference between the first and second injection mean pain 
scores (3.0 ± 2.4 and 2.9 ± 2.5 respectively, p=0.786), nor was the outcome different 
between randomization groups. Also, the expectation of pain and distress preceding 
the second injection was not influenced by the type of needle used in the previous visit 
(Distress composite score: p=0.739; NRS pain expectation: p=0.361). 
Evaluation of IVI procedure
Patients were generally satisfied with the procedure and gave high ratings to the overall 
experience of the current visit (8.7 ± 1.1). In 37 (51%) of in total 72 visits, patients 
did not report any negative aspects. The most unpleasant element was the application 
of povidone-iodine disinfectant in 19 (26%) visits, the IVI itself in 7 (10%) visits, the 
insertion of the eyelid speculum in 6 (8%) visits and the waiting period was considered 
most unpleasant in 3 (4%) visits.
Complications
No serious complications were reported during the study. The surgeon did report some 
minor events: there was a trend towards significant difference in vitreal reflux, which was 
reported 5 times during injections with the 30G needle compared to 0 times during the 
33G needle injections (p=0.054). Secondly, subconjunctival bleeding occurred twice 
during the 30G needle injections versus 3 times for the 33G needle (p=1.000). The 
surgeon did not report an influence of needle size on ease of injection. Specifically, 
the surgeon indicated there was no discernible difference in force required to enter the 
vitreous cavity, nor did he notice difference in resistance during injection of the drug.
Predictors of pain
Overall, patients reported low levels of distress directly prior to the injection with 2.4 ± 
1.9 on the 0-10 distress composite score. Also distress scores in the preceding week were 
low with 4.5 ± 3.3 on the HADS anxiety subscale. An overview of the scores from the 
psychological questionnaires per visit are reported in Table 3. The associations between 
demographic and psychological factors and IVI pain levels are presented in Table 4. 
Higher pain scores were associated with more distress prior to injection, expecting more 
pain, female gender (even though distress scores between men and women were similar), 
a less positive rating of the preparations before the injection procedure, a negative 
experience from the procedure preparations, expecting more negative consequences 
from the treatment, and low scores on believing the injections would contribute to 
health. 
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Penetration force measurements
The mean maximum force required for penetration was 0.55±0.12 and 0.45±0.06 
Newton for the 30G and the 33G needle respectively. This difference was statistically 
significant with p=0.025. The 27G needle required approximately twice the maximum 
force to penetration (1.08±0.37 Newton) compared to the 30G needle, this finding is 
in line with the report by Pulido and co-workers.16  
Table 3. Psychological factor scores per visit.
Variable Visit 1Mean (SD)
Visit 2
Mean (SD)
Female gender pain score 4.0 (3.0) 4.3 (2.9)
Male gender pain score 2.4 (1.9) 2.2 (2.0)
HADS scores
HADS depression score 4.2 (2.8) 4.6 (3.3)
HADS anxiety score 4.4 (3.1) 4.5 (3.5)
HADS total score 8.6 (5.0) 9.1 (5.9)
Questions prior to IVI
Distress composite score 2.8 (2.0) 2.2 (1.8)
1. Tension prior to injection 3.2 (2.1) 2.7 (2.2)
2. Anxiety prior to injection 2.5 (2.6) 1.7 (1.7)
3. Nervousness prior to injection 2.8 (2.3) 2.2 (1.9)
4. Pain at this moment 0.9 (1.3) 0.8 (1.3)
5. Pain expected from injection 3.3 (2.2) 3.2 (2.7)
6. Discomfort expected from injection 4.9 (2.6) 4.7 (2.7)
Questions after IVI
2. Pain directly after injection 2.7 (2.2) 3.2 (2.6)
3. Experience of current visit 8.8 (1.0) 8.7 (1.2)
4. Experience of preparations before the injection 8.1 (1.9) 8.2 (1.8)
5. Discomfort of procedure surrounding injection 4.3 (2.8) 4.3 (2.1)
6. Expected negative consequences on health 2.3 (2.2) 1.7 (1.8)
7. Contribution to improvement of disease 5.7 (2.2) 5.9 (2.4)
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Table 4. Psychological and demographic predictors of pain from intravitreal injections.
Variable Parameter estimate (SE) p-value
Age in years -0.01 (0.03) 0.603
Number of injections 0.01 (0.03) 0.664
Male gender Ref.
Female gender 1.84 (0.62) 0.005*
HADS scores
HADS depression score 0.13 (0.10) 0.197
HADS anxiety score 0.32 (0.09) 0.001*
HADS total score 0.16 (0.05) 0.005*
Questions prior to IVI
Distress composite score 0.33 (0.16) 0.039*
         1. Tension prior to injection 0.28 (0.14) 0.046*
         2. Anxiety prior to injection 0.28 (0.15) 0.081
         3. Nervousness prior to injection 0.27 (0.14) 0.065
4. Pain at this moment 0.36 (0.24) 0.142
5. Pain expected from injection 0.49 (0.10) 0.000*
6. Discomfort expected from injection 0.28 (0.11) 0.013*
Questions after IVI
2. Pain directly after injection 0.63 (0.10) 0.000*
3. Experience of current visit -0.34 (0.27) 0.214
4. Experience of preparations before the injection -0.65 (0.14) 0.000*
5. Discomfort of procedure surrounding injection 0.20 (0.11) 0.091
6. Expected negative consequences on health 0.38 (0.14) 0.007*
7. Contribution to improvement of disease -0.27 (0.13) 0.041*
Numbers in front of the variables refer to the question number. 
SE= standard error; HADS= Hospital Anxiety and Depression Scale; 
IVI= intravitreal injection
All p-values were derived from mixed models with “pain from IVI” as the dependent variable. * p-value < 
0.05
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Discussion
Previous studies on needle size in diabetic insulin therapy showed that larger needles 
are associated with more pain.18-20 Studies comparing needle sizes in IVI have been 
inconsistent with respect to pain scores. One study found that patients experienced 
less pain when injected with 29G or 30G needles as compared to 26G or 27G needles3 
and another showed patients rated a 31G needle as less painful than a 30G needle.4 
By contrast, a third study reported no difference in pain levels between 27G, 30G and 
32G needles.2 None of these studies used a crossover design to account for the large 
variability in pain perception between patients. One study by Eaton et al.5 did compare 
a guarded 33G needle with the regular 30G needle in patients who were receiving 
bilateral injections. This study did not find a significant difference in pain, but used 
a 0-4 Likert scale to measure pain, which could explain why they noted only small 
differences in pain score. Moreover, a different technique was employed for each of 
the needles (use of a guarded 33G needle without speculum versus regular injection 
technique with a 30G needle and eyelid speculum), which makes it difficult to assess 
the exact role of needle size in pain perception. The current crossover study comparing 
a 30G and an ultrathin 33G needle used the same injection technique for both needles. 
The IVI pain scores were low to moderate and could not be reduced any further with 
the ultrathin 33G needle.
We subsequently explored which factors were predictive of IVI related pain. Psychological 
factors such as distress and expectations are known to influence pain experience.6-8 In this 
study, we could corroborate the relevance of these factors in IVIs. In general, patients 
reported low distress scores and patients were overall satisfied with the procedure 
as a whole. Psychological factors that were associated with higher pain experience 
were: distress prior to injection, expecting pain and discomfort from the injection, 
dissatisfaction with the preparations before IVI, expecting negative consequences from 
the injection, and not expecting the IVI to contribute to improvement of disease. 
Possibly, in a subset of patients, the subjective experience of the injection procedure 
could be improved by focussing more on patient communication to reduce distress and 
manage patient expectations. 
 A noticeable item that came up in the questionnaires was the povidone-iodine 
disinfectant. Many patients specifically mentioned this as very unpleasant, which was 
also reflected in the lower scores given to the procedure surrounding the injection. 
Despite rinsing the eye after each injection with sterile saline solution, patients still 
complained about irritation from the disinfectant. Reducing the povidone-iodine 
concentration from 10% to 5% or possibly even lower may be a straightforward way to 
reduce patient discomfort without increasing the risk of infection.21, 22 
Even though the 33G needles did not lower pain scores, these ultrathin needles may 
offer other advantages. We found no significant difference in complication rates, but we 
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did find a trend towards more vitreal reflux with the 30G needle. This was also seen in 
previous studies which noted less reflux with thinner needles.3, 23 Whether this is clinically 
relevant remains to be seen, since reflux from IVIs usually consist of liquefied vitreous 
and hardly affects the quantity of anti-VEGF delivered in the vitreous cavity.24-26 Reflux 
could, however, prevent a peak in intraocular pressure (IOP) directly after the IVI.23, 
27 Manual palpation after the procedure did not identify any patients with clear IOP 
increase in this study and no IOP related adverse events were reported. What the exact 
consequences are of a transient rise in IOP due to decreased reflux remains unknown. 
Increased reflux probably does indicate more scleral damage. The substantially smaller 
diameter of the 33G needle (0.21mm compared to 0.31mm) is surely less damaging to 
the eye wall, as already demonstrated in porcine eyes.28, 29 We investigated this assumption 
further by measuring the difference in maximum penetration force required to puncture 
the sclera in porcine eyes between both needles. We observed that the 33G needle 
required less force to penetrate the sclera as compared to the 30G needle. However, 
this difference was small and could not be felt by the surgeon performing the injection. 
We should keep in mind that long term studies on anti-VEGF treatment show that 32-
65% of patients still require IVIs after 4 years and the number of injections received in 
that period can accumulate to over 40 injections.30-33 It would be interesting to explore 
whether 33G ultrathin needles are better tolerated when such high numbers of IVIs are 
administered. 
An obvious strength in this study is the use of a crossover design where every case 
served as its own control. This prevents large interpersonal differences in pain perception 
as a cause of differences in pain scores. Moreover, in crossover studies, differences in 
pain scores are not dependent on baseline differences that may coincidentally arise 
from randomization. This crossover trial also includes some potential limitations that 
should be discussed. An apparent limitation would be that this trial was conducted 
with a relatively small sample size of 36 patients. This number was big enough to show 
a difference in pain score of at least 1.0 on a 0-10 NRS, which is the minimum to be 
considered a clinically relevant reduction in pain score.34, 35 However, this number is 
quite low with regard to the explorative analyses for pain correlations with psychological 
factors and results should be interpreted with caution. 
In conclusion, ultrathin 33G needles did not significantly reduce pain scores in this 
study. For now, there seems to be no clear benefit of IVIs with 33G needles. Also taking 
into account that 33G needles are more expensive (a price difference varying from 
€5.00 to €30.00 per 100 needles), there is no immediate reason to start using ultrathin 
33G needle for IVIs. The pain scores during IVI were low, and opportunities to improve 
patient experience appear to lie more in management of patient expectations, stress 
reduction and the use of better tolerated disinfectants.
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Purpose: Age-related macular degeneration (AMD) is the leading cause of blindness 
in the Western world. AMD is a multifactorial disorder but complement-mediated 
inflammation at the level of the retina plays a pivotal role. Oral zinc supplementation 
can reduce the progression of AMD but the precise mechanism of this protective effect 
is as yet unclear. 
Methods: We investigated whether zinc supplementation directly affects the degree 
of complement activation in AMD and whether there is a relation between serum 
complement catabolism during zinc administration and the complement factor H (CFH) 
gene or the Age-Related Maculopathy susceptibility 2 (ARMS2) genotype. In this open-
label clinical study, 72 randomly selected AMD patients in various stages of AMD 
received a daily supplement of 50 mg zinc sulphate and 1 mg cupric sulphate for three 
months. Serum complement catabolism— defined as the C3d/C3 ratio—was measured 
at baseline, throughout the three months of supplementation and after discontinuation 
of zinc administration. Additionally, downstream inhibition of complement catabolism 
was evaluated by measurement of anaphylatoxin C5a. Furthermore, we investigated the 
effect of zinc on complement activation in vitro. 
Results: AMD patients with high levels of complement catabolism at baseline exhibited 
a steeper decline in serum complement activation (p<0.001) during the  three month 
zinc supplementation period compared to patients with low complement levels. There 
was no significant association of change in complement catabolism and CFH and 
ARMS2 genotype. In vitro zinc sulphate directly inhibits complement catabolism in 
hemolytic assays and membrane attack complex (MAC) deposition on RPE cells. 
Conclusion: This study provides evidence that daily administration of 50 mg 
zinc sulphate can inhibit complement catabolism in AMD patients with increased 
complement activation. This could explain part of the mechanism by which zinc slows 
AMD progression.
This trial was registered with The Netherlands National Trial Register; NTR2605; 
http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2605
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Introduction
Worldwide, age-related macular degeneration (AMD) affects 30-50 million people and is 
the leading cause of blindness in the Western world.1-4 AMD is a complex, multifactorial 
disease that manifests clinically as a loss of central vision resulting in an inability to 
read, recognize faces or discriminate colors. The hallmark lesions of early stage AMD 
are drusen, which are pathological deposits of extracellular material that form between 
the retinal pigment epithelium and Bruch membrane.5 The late stages of AMD can be 
separated into geographic atrophy and neovascular AMD.5 In  patients with neovascular 
AMD, choroidal blood vessels invade the central retina and subretinal space causing 
a rapidly progressive loss of vision.5 Although the neovascular AMD accounts for 
10% of all AMD patients, it is responsible for the majority of AMD-related severe 
visual impairment.6-9 Despite the beneficial effects of intraocular injections of vascular 
endothelial growth factor A (VEGF-A) inhibitors,10, 11 a large percentage of neovascular 
AMD patients continue to lose vision.12, 13 In patients with geographic atrophy, loss 
of the RPE and photoreceptor cells in the central retina result in a progressive decline 
of vision at a much slower rate than neovascular AMD.5 Unfortunately, an effective 
therapy for treating geographic atrophy has yet to be developed. 
Pivotal studies performed during the past decade have changed our understanding of 
the molecular mechanisms underlying AMD. These findings have led to the exploration 
of a new therapeutic paradigm for managing AMD, namely the targeting of specific 
molecular components in the complement pathway.14, 15 The complement system 
is a major component of innate immunity with crucial roles in the first line defense 
against invading microorganisms, clearance of the apoptotic cells and modulation of 
the adaptive immune response.16 There are three pathways of complement activation: 
the classical, the lectin and the alternative pathway.16 The most important step of the 
alternative complement pathway activation is the formation of unstable C3 convertase 
C3bBb, which cleaves C3 to generate the active fragment C3b. Deposition of C3b on 
the target surface triggers the effector molecules C3a, C5a and the membrane attack 
complex (MAC), resulting in inflammation and cell lysis. The discovery that drusen 
contain proteins of the alternative complement pathway led to the hypothesis that 
drusen could be involved in local complement-mediated inflammation.17, 18 Moreover, 
the discovery of a strong association between AMD and genetic variants in CFH gene, a 
major inhibitor of the alternative pathway, provided a second line of evidence in support 
of the inflammation model.19-22 In addition to CFH, several other AMD risk variants 
have been found in genes underlying the alternative pathway.23-26 A third line of evidence 
supporting complement involvement in AMD came from studies that showed that 
AMD patients have higher levels of complement activation products in their blood.27-30 
However, it is likely to be several years before any of the complement inhibiting drugs 
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will be approved for routine use in clinical practice, assuming they are eventually found 
to be safe and effective.
In 2001, the data collected from the Age-Related Eye Disease Study (AREDS) 
revealed that patients who were treated with zinc—either alone or in combination 
with vitamins—had reduced progression to advanced AMD.31 Based on these results, 
AREDS recommends that persons who are older than 55 years of age and who are at 
risk for developing advanced AMD should consider taking vitamin supplements plus 
zinc.31 A report published by the Blue Mountains Eye Study, a population-based study, 
confirmed the beneficial effect of zinc in AMD patients.32 The large population-based 
Rotterdam Study supported the hypothesis of biological interactions between the CFH 
gene Y402H variant and zinc, β-carotene, lutein/zeaxanthin and omega-3 fatty acids and 
between the ARMS2 gene A69S variant and zinc and omega-3 fatty acids.33 As a result 
of these findings, the Rotterdam Study recommended that clinicians give dietary advice 
to young individuals who are at risk for AMD.33 More recently, AREDS2 demonstrated 
that addition of lutein, zeaxanthin and omega-3 long-chain polyunsaturated fatty acids 
to the AREDS formulation, did not further reduce risk of progression to advanced 
AMD.34 However, exploratory subgroup analyses demonstrated that addition of 
lutein and zeaxanthin to the AREDS formulation, resulted in a significant reduction 
of progression to advanced AMD for persons in the lowest quintile of dietary intake, 
suggesting different treatment effects within subgroups of AMD patients.34 Despite 
the widespread use of zinc and antioxidants among AMD patients, the mechanism by 
which zinc exerts its beneficial effects in AMD patients has not yet been identified. The 
design of optimal and appropriate therapies require a comprehensive understanding of 
the factors that drive and delay pathogenesis of AMD. To add to current knowledge 
we designed the present study to investigate whether zinc affects the activity of the 
alternative complement pathway in patients with AMD, which might explain how zinc 
slows AMD progression in subgroups of patients with AMD. Secondly, we correlate 
the response to zinc supplements to the CFH and ARMS2 genotype status. Lastly, we 
conducted an in vitro experiment to evaluate whether there is a direct effect of zinc on 
complement activation.
Methods
Study population of the clinical study
This study was performed in accordance with the Declaration of Helsinki and the 
Dutch Medical Research Involving Human Subjects Act. Prior to the study, we obtained 
approval from the local ethics committee (Commissie Mensgebonden Onderzoek 
regio Arnhem-Nijmegen, April 20th 2010) as well as written informed consent from 
all participants. This clinical study was registered with The Netherlands National Trial 
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Register (number NTR2605) shortly after recruitment began due to an administrative 
error. The authors confirm that all ongoing and related trials for this drug/intervention 
are registered. The protocol for this trial and supporting TREND checklist are available 
as supporting infromation (Protocol S1 and Checklist S1). The study participants were 
enrolled in EUGENDA (www.eugenda.org), a multicenter database for the clinical 
and molecular analysis of AMD, between March 2006 and August 2009. Patients with 
various stages of AMD were selected at random from the EUGENDA database and were 
included between June 2010 and February 2011. Follow-up ranged between 14 and 22 
months. All data were collected at the department of Ophthalmology of the Radboud 
university medical center. We excluded individuals who had a core body temperature 
above 38°C and/or received antibiotics at baseline. In addition, we excluded patients 
who were receiving intraocular anti-angiogenic treatment, individuals with atypical 
hemolytic uremic syndrome or membranoproliferative glomerulonephritis type 2 and 
patients who received local or systemic steroid therapy within the three months prior to 
the trial. A total of 72 AMD patients were included in this study (Figure 1).
Study design
To study the effect of zinc on complement activation in patients with AMD, 72 AMD 
patients received a daily oral supplement containing 50 mg zinc sulphate and 1 mg cupric 
sulphate in capsule form. The capsules were to be taken at home for a period of three 
months. These components were donated by Sanmed, Almere, the Netherlands. The 50 
mg dose of zinc was lower than in the original AREDS formulation and was chosen to 
minimize the chance of side-effects. Also, we chose zinc sulphate instead of zinc oxide 
(as used in the AREDS study), because most over-the-counter supplements contain 
zinc sulphate and in addition there is evidence that the bioavailability may be higher.35, 
36 The primary endpoint of the study was a change in serum complement catabolism 
during the three months of zinc supplementation. AMD patients have increased serum 
levels of C3 and the metabolic byproduct C3d, the most prominent marker of chronic 
activation of the alternative complement pathway.30 To correct for individual variations 
in the level of C3, complement activation was defined as the C3d/C3 ratio as described 
previously.30 Anaphylatoxin C5a levels are also elevated in AMD patients and promote 
choroidal neovascularization.28, 29, 37 In order to explore downstream inhibitory effects of 
zinc on complement catabolism, we additionally measured serum C5a levels during the 
study period. The second objective was to study the association of serum complement 
catabolism during zinc administration and genotypes of AMD risk variants in CFH or 
ARMS2. 
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Figure 1. Flow diagram of patient inclusion
During the course of the study, six venous blood samples were collected. One sample 
was collected prior to zinc supplementation and served as the baseline sample. Three 
samples were collected at the end of months 1, 2 and 3 of the three-month period of 
zinc supplementation. We collected a fifth blood sample two months after ending the 
zinc administration (i.e., at the end of month 5) to check for any reversible effects on 
complement activation. A final blood sample was collected in months 14-22. From one 
month prior to zinc supplementation through the end of month 5, the patients were 
prohibited to take any type of nutritional supplement; from month 5 onwards, the 
patients were free to take supplements at their own discretion. 
To identify clinical manifestations associated with intermittent infections, at every 
visit, we performed a general physical examination, measured the serum C-reactive 
protein (CRP) levels and administered a questionnaire that was aimed at identifying 
clinical manifestations associated with intermittent infections. At every visit, patients 
were asked whether they had been taking the zinc supplements daily to promote 
compliance. We also assessed the best-corrected visual acuity using Early-Treatment 
Diabetic Retinopathy Study (ETDRS) charts at every visit. In addition, we imaged 
the retinas using high-resolution spectral-domain optical coherence tomography (SD-
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OCT) to detect active neovascular manifestation of AMD. We performed color fundus 
photography at baseline to assist in AMD grading based on the 5-grade Clinical Age-
Related Maculopathy Staging (CARMS) classification scale.38 
Complement measurements and genotyping in AMD patients
Serum was prepared by coagulation at room temperature and after centrifugation 
the samples were stored at -80 °C within one hour after collection. C3 and C3d were 
measured in serum samples as described.39, 40 All C3 and C3d measurements in this 
study were performed  in a single experiment, except for the final sample in months 
14-22. C5a was measured by ELISA at a 1/10 dilution using a commercially available 
development kit (DuoSet) for human complement component C5a (R&D Systems, 
Minneapolis, USA). All the samples collected at baseline to month 5 were measured in 
a single run. 
The CFH (Y402H; rs1061170) and ARMS2 (A69S; rs10490924) SNPs were genotyped 
as described.41 
Serum zinc concentration was measured by atomic absorption spectroscopy with the 
spectrophotometer 1100 B from Perkin Elmer. CRP levels were measured by Abbott 
Architect C16000 system. The immunoturbidimetric test for CRP was provided by 
Abbott Diagnostics (Abbott Diagnostics). 
In vitro hemolytic assays and membrane attack complex (MAC) deposition on RPE cells 
We designed in vitro experiments to provide evidence of a direct effect of zinc on 
the complement pathway. Human serum was prepared from blood of several healthy 
volunteers after written informed consent had been obtained with the specific permit 
(418/2008) from the ethics committee of Lund University. Commercially available 
rabbit erythrocytes (Håtunalab, Bro, Sweden) were washed in 2.5 mM veronal buffer 
pH 7.3, supplemented with 70 mM NaCl, 140 mM glucose, 0.1% porcine gelatin 
and 7 mM MgCl2. Different concentrations (0-64 µM) of zinc sulphate (Merck) were 
pre-incubated with 2% serum in the same buffer for 1.5 h at 37°C, followed by 1 h 
incubation at 37°C together with the erythrocytes. The amount of lysed erythrocytes 
was determined from the amount of released hemoglobin at 405 nm using Cary 50 
MPR microplate reader (Varian). 
To study the effect of zinc on membrane MAC deposition on human RPE cells subjected 
to oxidative stress, RPE cells (ARPE-19, ATCC) were cultured in DMEM/F12 media 
(HyClone), supplemented with 10% FCS (Gibco) and antibiotics (HyClone). After 
detachment using trypsin, the cells were incubated in medium containing 10 mM H2O2 
for 2 h at 37°C, to mimic oxidative damage and make them amenable to attack from 
complement.42, 43 After washing with PBS, the cells were incubated with 5% human 
serum, together with 0-250 µM zinc sulphate, in the veronal buffer defined above , 
for 1 h at 37°C. The amount of MAC deposited on the RPE cells was detected using 
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a monoclonal C9 neoepitope antibody (aE11, Hycult), which only recognizes C9 in 
the C5b-9 complex, followed by a FITC-conjugated secondary antibody and flow 
cytometric analysis (Partec).
Statistical analysis
A sample size of 70 was calculated to detect a decrease in serum C3d/C3 of 10% after 3 
months, using the complement levels from a previous study to estimate variation,30 with 
α=0.05 and a power of 80%. 
Change in serum zinc, change in C3d/C3 ratio and change in C5a over the entire 
study period (0 to 14-22 months) were all modeled separately. Changes in serum zinc 
concentration were analyzed using a linear mixed-effects model with zinc concentration 
as the dependent variable. To make optimal use of repeated measures and to allow for 
correction of baseline differences, changes in C3d/C3 and C5a levels level were analyzed 
using linear mixed-effects models with C3d/C3 ratio or C5a as the dependent variable. 
The interaction between time and baseline complement levels was included in a linear 
mixed-effects model to study any baseline effects. To illustrate the effect of the baseline 
C3d/C3 ratio we plotted the course of the C3d/C3 ratio for 3 groups with different 
baseline ratios using the raw data. In a recent study we measured C3d/C3 levels in 150 
unaffected control subjects of 65 years and older,30 and we used the mean value (1.5) 
and standard deviation (0.6) to determine the cut-off points. The cut-off values for 
the different groups were selected by taking the mean C3d/C3 ratio and one standard 
deviation above and below the mean of the healthy control group. Our population was 
not large enough to create groups of individuals with two standard deviations above and 
below the mean. This resulted in the following three groups: 1. patients with baseline 
ratio ≥2.1 (n=16); 2. patients with ratios between 1.5-2.1 (n=29); and 3. patients with 
ratio <1.5 (n=31). Only very few subjects (n=3) had a baseline ratio more than one 
standard deviation below the mean, so these individuals were included in group 3. 
The associations between the complement levels throughout the study and CFH and 
ARMS2 genotype, age, gender, CRP level and zinc level were also studied using a linear 
mixed-effects model. In the final models for the change in zinc, C3d/C3 and C5a, only 
significant predictors were used (p < 0.05). For the final serum zinc and C5a models 
this meant the inclusion of time and baseline values as the independent variables. In 
the final C3d/C3 model the independent variables were time, baseline C3d/C3 and the 
interaction between time and baseline C3d/C3. 
To further explore the relationship between baseline complement catabolism and 
other patient characteristics at baseline, we assessed the associations of age and baseline 
visual acuity with baseline C3d/C3 ratio and C5a using the Pearson correlation and 
the Spearman’s rank correlation coefficient. The difference in baseline complement 
catabolism between different genotypes was assessed using one-way ANOVA.
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Because patients often display different stages of AMD in each eye, we created five 
groups for both eyes. These groups were based on the CARMS classification as follows: 
(CARMS grade 2:2), small drusen and/or RPE changes in both eyes; (CARMS 
grade 3:3), large drusen and/or drusenoid RPE detachment in both eyes; (CARMS 
grade 2: 4-5), small drusen and/or RPE changes in one eye and geographic atrophy 
or choroidal neovascularisation in the other eye; (CARMS grade 3:4-5), large drusen 
and/or drusenoid RPE detachment in one eye and geographic atrophy or choroidal 
neovascularisation in the other eye; and (CARMS grade 4-5:4-5), geographic atrophy 
or choroidal neovascularisation in both eyes. The association between baseline systemic 
complement catabolism and CARMS classification was tested using one-way ANOVA 
with a post-hoc Bonferroni correction. The correlation between baseline visual acuity 
and CARMS was tested using the Spearman’s rank correlation coefficient. 
Visual acuity changes during the course of the study were assessed by generalized 
estimated equations (GEE). The GEE model estimated the probability of low vision 
(LogMAR < 0.5) versus high vision (LogMAR > 0.5), with time and baseline C3d/C3 
ratio as predictors. Data for the hemolytic assay and the RPE cell assay were analyzed 
using one-way ANOVA with Dunnett’s multiple comparison test. 
Reported p-values are two-sided, and differences were considered to be statistically 
significant if lower than 0.05. All statistical analyses were performed using SPSS, version 
18.0.
Results
To evaluate the effect of receiving zinc supplements on systemic complement 
catabolism, AMD patients received oral zinc sulphate. The baseline characteristics of 
the study population are presented in Table 1. Serum zinc concentration increased 
significantly during the supplementation period (p<0.001) and returned to baseline 
levels two months after the zinc supplements were discontinued (Figure 2). The mean 
complement activation level, defined as the C3d/C3 ratio, in the 72 patients showed 
tendency to decline (albeit not significantly; p=0.149) during the three months of zinc 
supplementation (Figure 2). From month five onwards, 36 patients indicated they had 
been using over-the-counter zinc supplements, but generally in lower dosages than used 
in this study. 
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Table 1. The baseline characteristics of the study population.
Baseline characteristics AMD, n=72
Mean age — years ± SD 73.9 ± 8.3
Sex, male — No. (%) 29 (40.3)
Visual acuity OD — median  (1st-3rd quartile) 20/83 (20/400-20/25)
Visual acuity OS — median (1st-3rd quartile) 20/55 (20/333-20/26)
Mean C3d/C3 ratio ± SD 1.65 ± 0.69
Mean zinc level — µmol/l ± SD 13.33 ± 2.83
CFH (Y402H; rs1061170) genotypes, No. (%)
CFH TT genotype (wildtype) 1 (1.4)
CFH CT genotype 36 (50.0)
CFH CC genotype 34 (47.2)
ARMS2 (A69S; rs10490924) genotypes, No. (%)
ARMS2 GG genotype (wildtype) 19 (26.4)
ARMS2 TG genotype 30 (41.7)
ARMS2 TT genotype 22 (30.6)
Serum C-reactive protein (CRP), No. (%)
< 5 — mg/l 52 (72.2)
5 - 15 — mg/l 18 (25.0)
16 - 45 — mg/l 2 (2.8)
SD=Standard deviation, visual acuity in Snellen.
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Figure 2. Serum zinc concentration and C3d/C3 ratio throughout the study period. 
During the three months daily zinc supplementation, serum zinc concentration increased significantly 
(p<0.001). After zinc supplementation was discontinued, the serum zinc levels returned to baseline 
levels within 2 months. The C3d/C3 ratio showed non-significant decline during zinc supplementation 
(p=0.149). 
Exploration of effect of zinc supplementation on complement catabolism 
We conducted further exploratory analyses whether zinc supplementation may have 
different effects within patients with different levels of baseline complement catabolism 
defined as C3d/C3 ratio. In this analysis, we observed a strong interaction between 
baseline C3d/C3 ratio and change in C3d/C3 ratio during zinc supplementation 
(p<0.001). The AMD patients with relatively high baseline levels of serum complement 
catabolism exhibited a more pronounced decline in their C3d/C3 ratio during the 
administration of zinc sulphate, compared to those AMD patients with lower baseline 
levels. After the zinc supplementation period, the decline in C3d/C3 ratio remained at 
this lower level for the following two months. Measurements performed at least nine 
months later (in months 14-22) showed that complement activation had returned 
to baseline levels. The AMD patients who already had a relatively low C3d/C3 ratio 
at baseline showed no decline in C3d/C3 ratio throughout the treatment period. 
Figure 3 illustrates the course of serum C3d/C3 ratio over time in three groups with 
different baseline C3d/C3 ratios. The statistical model was not based on these cut-off 
points. There was no significant association between C3d/C3 ratio and age or gender 
throughout the course of the study. C5a levels decreased significantly over the three-
month supplementation period (p=0.019) (Figure 4). We observed a similar baseline 
effect for the course of C5a levels, however, the interaction between baseline and time 
was not significant and therefore not included in the final model (p=0.065).
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Association between the stage of AMD and serum complement catabolism
We further analyzed the clinical characteristics of AMD patients with a relatively high 
baseline complement catabolism. Higher baseline C3d/C3 ratio was significantly 
associated with younger age (r=-0.33, p=0.005) and better visual acuity (OD: r=0.25, 
p=0.031 and OS: r=0.36, p=0.002). Also, baseline C3d/C3 ratio was associated with 
the CARMS classification based on both eyes (p=0.010). Post hoc analysis revealed that 
patients with large drusen and/or drusenoid RPE detachment in one eye and geographic 
atrophy or choroidal neovascularization in the other eye (3:4-5) had higher baseline 
complement catabolism compared to geographic atrophy or choroidal neovascularization 
in both eyes (4-5:4-5) (Table 2). There was no association with baseline C5a and age 
(r=0.068, p=0.583), visual acuity (OD: r=-0.110, p=0.381 and OS: r=-0.023, p=0.855) 
or the CARMS classification based on both eyes (p=0.947). C3d/C3 ratio and C5a levels 
were measured in separate experiments and were not correlated (r=0.086, p=0.490). As 
expected, baseline visual acuity for each eye was strongly associated with the CARMS 
classification per eye (OD: r=-0.69, p<0.001 and OS: r=-0.65, p<0.001) (Table 3). 
Figure 3. The effect of zinc supplementation on patients with different level of complement catabolism at 
baseline. 
The patients with high serum complement catabolism had a steeper decline in C3d/C3 ratio during the 
administration of zinc sulphate (p<0.001). 
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Figure 4. C5a concentration throughout the study period. 
The C5a levels decreased significantly during the three months of zinc supplementation and returned to 
baseline level within 2 months after the cessation of zinc supplementation.
Table 2. Association between the stage of AMD and serum complement catabolism. 
Compared to the patients with intermediate AMD in one eye and late AMD in the other eye (CARMS 
stage 3:4-5), the patients who had late AMD in both eyes (CARMS 4-5:4-5) had significantly lower C3d/
C3 levels (p=0.006).
Clinical Age-Related Maculopathy Staging (CARMS)  
for both eyes
Mean C3d/C3 
ratio (SE) No. (%) p*
Grade 2 in both eyes (2 : 2) 1.64 (0.30) 4 (5.6) 1.000
Grade 2 in the first eye and grade 4 or 5 in the second eye  
(2 : 4-5) 1.69 (0.31) 9 (12.7)
1.000
Grade 3 in both eyes (3 : 3) 1.86 (0.17) 10 (14.1) 0.263
Grade 3 in the first and stages 4 or 5 in the second eye (3 : 4-5)     2.01 (0.20) 19 (26.8) 0.006
Grades 4 or 5 in both eyes (4-5 : 4-5) 1.32 (0.06) 29 (40.8) Ref. 
* p-value from one-way ANOVA with post hoc Bonferroni correction
Table 3. Visual acuity per CARMS classification grade. 
Baseline median visual acuity in Snellen per Clinical Age-Related Maculopathy Staging (CARMS) 
classification grade for the separate eyes. Visual acuity decreases as CARMS classification increases.
Clinical Age-Related Maculopathy Staging 
(CARMS)
Visual acuity, median (1st-3rd quartile)
OD OS
Grade 2 20/20 (20/25-20/20) 20/22 (20/40-20/20)
Grade 3 20/25 (20/40-20/21) 20/25 (20/50-20/20)
Grade 4 20/143 (20/200-20/40) 20/63 (20/200-20/40)
Grade 5 20/400 (20/1000-20/133) 20/267 (20/1000-20/80)
Visual acuity in Snellen
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Correlation between the serum complement catabolism and the genotype 
The baseline C3d/C3 ratios did not differ significantly between wildtype/heterozygous 
Y402H CFH genotype and the homozygous Y402H genotype (p=0.934) nor between 
ARMS2 genotypes (p=0.729). There was also no difference in baseline C5a between 
CFH (p=0.597) and ARMS2 genotypes (p=0.412). Change in C3d/C3 ratio or C5a 
levels were not related to CFH or ARMS2 genotypes. 
Intermittent infections and the C3d/C3 ratio
Serum CRP levels were measured at every visit and were not significantly associated with 
the C3d/C3 ratio (p=0.168) nor the C5a levels (p=0.942). Questionnaires demonstrated 
that antibiotics were prescribed in 10 patients during the study period. Use of antibiotics 
was not related to increased CRP levels, increased body temperature or elevated C3d/C3 
ratio (data not shown) in these individuals. 
Effect of zinc on complement catabolism in vitro 
To demonstrate the in vitro effect of zinc on the complement activity of human serum 
and to better understand the effect observed in vivo in the patients, we performed an 
alternative pathway hemolytic assay. Results showed that zinc sulphate inhibits the lysis 
of rabbit erythrocytes in a dose-dependent manner (Figure 5A). Retina is exposed to 
high levels of oxidative stress from light exposure and metabolic processes.44 We tested 
in vitro whether zinc could also protect the RPE from a oxidative stress related damage 
from the complement system. The test results show that the amount of MAC deposited 
on RPE cells exposed to oxidative stress can be reduced in a dose dependent manner 
by zinc sulphate (Figure 5B-C). In the negative controls, zinc and serum were omitted.
Figure 5. The effect of zinc on the hemolytic activity of human serum and on the membrane attack 
complex (MAC) deposition on retinal pigment epithelial (RPE) cells. (A) Zinc sulphate inhibits the lysis 
of rabbit erythrocytes in a dose-dependent manner. (B-C) the amount of MAC deposited on RPE cells 
exposed to oxidative stress can be reduced in a dose dependent manner by zinc. *p<0.05 and ***p<0.001.
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Discussion
In the past decade, it has become increasingly clear that complement-mediated 
inflammation plays a fundamental role in the etiology of AMD.18, 45 All current therapies 
for treating neovascular AMD are designed to reduce the ongoing VEGF stimulus—and 
hence inhibit the growth of new vessels—but do not address the underlying pathology. 
Moreover, no effective therapy has been developed for treating early AMD or geographic 
atrophy. The discovery of complement as a major contributing factor to AMD 
pathogenesis has sparked considerable interest in this system as a potential therapeutic 
target, and various complement inhibitors are currently being tested in clinical trials.14, 
15 
Our findings suggest that increased complement catabolism, defined as the C3d/C3 
ratio, in AMD patients can be reduced by the daily oral administration of 50 mg zinc 
sulphate. However, the effect of complement inhibition seemed to be limited to patients 
with a high baseline level of complement catabolism. The C3d/C3 ratio returned to 
its baseline value after the supplementation period, indicating a reversible effect of 
zinc supplementation on complement activation. Continuous zinc supplementation 
may therefore be necessary to inhibit complement activity over longer periods of 
time. Approximately 50% of patients indicated they had been using zinc supplements 
during the period before the last measurement. However, the zinc dosage and possibly 
compliance in these patients was apparently too low to exert a clear effect on complement 
levels. 
 We then linked the degree of serum complement activation to the clinical stages of AMD 
and found that the level of serum complement activation is correlated with patients 
having large drusen and/or drusenoid RPE detachment. It has been demonstrated that 
42% of patients with drusenoid RPE detachment progress to end-stage AMD and 
develop profound and irreversible visual loss within five years.46 The AREDS1 study 
showed that this group in particular benefits from zinc plus antioxidant supplementation. 
Our results suggest that this may be related to increased activation of the alternative 
complement pathway in this group, which would support the notion that patients with 
large drusen and/or drusenoid RPE detachment should receive supplements. Although 
correlation coefficients were modest, higher complement levels at baseline were mostly 
observed in younger patients with better visual acuity, corresponding with less advanced 
disease. This could indicate that the use of supplements should not be postponed until 
more advanced stages of the disease.
C5a showed a significant decrease during zinc supplementation, indicating that zinc 
inhibition of the complement pathway can also be detected further downstream. We 
observed a similar pattern of increased inhibitory effect in patients with higher baseline 
C5a levels, but this was not as profound as for the C3d/C3 ratio. This could be explained 
by the more unstable nature of C5a as compared to the C3d/C3 ratio which corrects for 
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intrapersonal fluctuations. C5a returned to its baseline value within 2 months after the 
supplementation period also suggesting a reversible effect of zinc on C5a. 
The exact role of genotype in the response to zinc and antioxidant supplements remains 
unclear. The Rotterdam study showed that high dietary zinc intake reduces the risk 
of AMD associated with the CFH Y402H variant, suggesting a relationship between 
zinc and this genotype.33 A recent subgroup analysis, utilizing data from the AREDS 
study, showed that the response to zinc and antioxidants may be influenced by CFH and 
ARMS2 genotype. Their results suggested that patients carrying the CFH Y402H risk 
allele have no benefit from zinc supplementation on the 10-year disease progression.47 In 
previous studies by AREDS study researchers on the interaction between genotype and 
treatment response, they found that the AREDS supplements may be less effective in 
reducing progression in carriers of the CFH risk allele.48 But in a later publication they 
could not corroborate the interaction and could not find any relation with response to 
zinc or antioxidants and genotype.49 Notably, a biochemical study of zinc and factor H 
showed that the interaction between zinc and the factor H protein was not influenced by 
the CFH Y402H variant.50 In our study, genotype did not have an effect on baseline or 
change of complement activation levels. Given the small number of study participants 
our study probably lacks the power to detect a possible interaction between CFH or 
ARMS2 genotype and zinc supplementation. 
Changes in C3 activation over time can also be caused by various factors related to 
immune defense in case of infection.51 Since serum CRP levels were not significantly 
associated with C3d/C3 ratio, it is unlikely that the observed change in complement 
catabolism can be ascribed to an intermittent infection. Data obtained from a general 
physical examination and a questionnaire aimed at identifying clinical manifestations 
of intermittent infections also did not point to an infectious cause for the change in 
complement levels in these AMD patients. Finally, it is unlikely that the study results 
were influenced by the statistical phenomenon of ‘regression to the mean’ because the 
C3d/C3 ratio returned to baseline levels for after discontinuation of zinc administration.
In further support of our hypothesis that zinc administration affects complement 
catabolism, we demonstrated in vitro that zinc sulphate directly inhibits complement 
activation in human serum in a dose-dependent manner. In addition, we demonstrated 
that during oxidative challenge the presence of zinc sulphate diminishes MAC deposition 
on RPE cells, thereby preventing complement-mediated cytolysis and apoptosis. This 
implies that zinc not only has the ability to reduce systemic activation of the alternative 
complement pathway, but may also diminish complement activation locally on RPE 
cells. Important to note is that zinc concentrations were in physiological levels,44, 52 
and therefore have biomedical significance. A previous biochemical study showed that 
oligomerization of the CFH protein occurs in the presence of zinc, theoretically leading 
to increased complement activation.53 A more recent biochemical study from researchers 
of the same study group demonstrated that factor H-C3b complexes are precipitated by 
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zinc which would inhibit complement activation.54 Thus we cannot pinpoint the exact 
molecular mechanism behind our observations, however, we can conclude that zinc 
inhibits systemic complement activation and local MAC deposition preventing RPE 
cell damage.
This study has some limitations that should be addressed. A relatively small number of 
subjects were included, and zinc was administered for a relatively brief period of time. 
Patient compliance was monitored through questionnaires, which could potentially 
underestimate zinc intake. However, a steep increase in serum zinc following the 
initiation of treatment indicated that supplementation had been successful. Because of 
the slow natural progression of AMD, this study was never designed to measure a direct 
protective effect of zinc on visual acuity. Larger patient cohorts and a longer period of 
zinc supplementation should also be studied to corroborate and extend our findings. 
In summary, in our study increased levels of serum complement catabolism correlates 
with the stage of AMD. Our study demonstrate that increased levels of complement 
catabolism can be normalized by the daily oral administration of 50 mg zinc sulphate. 
Findings from the present study might explain how zinc slows AMD progression in 
subgroups of patients with AMD. 
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The general aim of this thesis was twofold: [1] to identify areas in the treatment of 
neovascular age-related macular degeneration (nAMD) that are arguably in need of 
improvement, and [2] to assess different strategies to achieve such improvements. To 
achieve this overall aim, this thesis is structured around three more specific objectives: 1) 
to predict non-response to anti-VEGF treatment in patients with nAMD, 2) to evaluate 
and identify new areas for improvement of both the injection procedure and anti-VEGF 
treatment in clinical practice, and 3) to evaluate the cost- effectiveness of anti-VEGF 
treatment for nAMD. In this discussion, I will outline the main findings and put the 
results in a broader perspective. I will discuss what I believe is needed to improve non-
response prediction, how differences between clinical practice and randomized clinical 
trials (RCTs) can affect treatment protocols and policies, and how costs in nAMD 
treatment may be controlled. Finally, specific recommendations will be given for future 
research. 
The main findings of this thesis were the following:
• To predict non-response to anti-VEGF treatment in patients with nAMD (objective 
1), we developed a prediction model in chapter 3a which showed that non-response 
to anti-VEGF drug ranibizumab can be predicted with moderate accuracy on the 
basis of a specific set of clinical and genetic factors.  
• To identify new areas for improvement of both the injection procedure and anti-
VEGF treatment in clinical practice (objective 2), we showed in chapter 2 and 4b 
that there is still a gap between efficacy as reported  in clinical trials and that achieved 
in clinical practice, and in chapter 6 we showed that there are specific, practical ways 
to reduce the burden of the injection procedure.
• As for the cost- effectiveness of anti-VEGF treatment for nAMD (objective 3), 
we showed in chapter 5 that bevacizumab is the most cost-effective first choice 
treatment for AMD, but that it is not yet considered the standard of care across the 
globe.
Predicting non-response
In order to achieve objective 1 we developed a prediction model for early identification 
of non-responders. The main reasons for developing predict models for non-response 
were to reduce the treatment burden for patients and clinics and to control costs. 
Individualizing treatment decisions on the predicted level of response could reduce 
unnecessary, costly injections and help to keep the large patient flows manageable. 
Patients predicted to be non-responders can be diverted to other treatment strategies, 
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which can be either a second-line therapy, or withholding intraocular treatment 
combined with appropriate aftercare such as low vision measures. 
We were able to develop a model that predicted non-response with 77% accuracy, 
meaning that 77% of nAMD patients were correctly classified as either a responder 
or a non-responder based on several clinical and genetic predictors. Patients in the 
highest risk score group had a probability of being non-responder of ~50%. Whether 
this accuracy of prediction is sufficient to change treatment guidelines is not so 
straightforward. The prediction model from chapter 3a and the identified genetic 
response predictors in chapter 3b-c make an important contribution to clinical practice 
by creating the awareness amongst ophthalmologists that non-response is a frequent 
problem. In addition, they show that non-responders may carry specific genetic and 
clinical traits. Especially in patients over 80 years old, with diabetes and poor starting 
vision it may be wise to switch to an alternative treatment more promptly. However, 
the performance of our prediction model is not 100%, and, therefore, some patients 
will be falsely classified as non-responder. Withholding treatment from those predicted 
to be non-responders is not ethical as 50% of those patients will actually benefit from 
treatment. Hence, although our prediction model comprises  an important step towards 
personalized medicine, further improvements are needed before any type of prediction 
tool can be implemented into clinical practice, which I will discuss below. 
1) Improving management of non-responders
The first improvement relates to what the second-line treatment strategy for non-
responders should be. Without knowing what the effect of a second-line treatment is, it 
is difficult to estimate the value of a prediction model in clinical practice. To decide to 
withhold treatment when the model predicts non-response, it has to be very accurate as 
the consequence of not treating a nAMD patient can mean severe vision loss. However, 
when a good second-line treatment would be available, a non-responder could be 
offered that option, avoiding treatment delay. We evaluated the second-line treatment 
aflibercept in chapter 4a and observed adequate response from switching after non-
response. However, it is unclear whether the prediction model we generated is specific 
for ranibizumab or whether it can be applied to all anti-VEGF agents. Therefore, non-
responders may not necessarily show a good response to second line anti-VEGFs and all 
drugs should undergo similar modelling for comparison. 
2) Improving accuracy of prediction
The second improvement refers to the accuracy of the prediction model. This means 
finding new predictors for non-response, but possibly also better understanding the 
role of known predictors. Understanding how predictors relate to non-response, may 
help to more accurately measure these predictors. The only truly established factors 
that predict visual acuity are baseline vision and age.1-4 Low baseline visual acuity is 
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predictive of a greater gain in Early Treatment for Diabetic Retinopathy Study (ETDRS) 
letters, but of less gain in percentage of letters as shown in chapter 3a. Older age has 
also been consistently associated with poorer response, but the cause for this is unclear. 
Possibly the consistency of the vitreous plays a role, which is more liquefied in older 
age, leading to changes in pharmacokinetics. Indeed, vitreomacular adhesion caused by 
vitreous liquefaction has been associated with poor response in some studies,5, 6 although 
others could not corroborate this finding.7 Possibly, older age simply represents a more 
advanced disease or a longer disease duration, negatively influencing treatment effect. 
Genetics is an interesting area for finding new non-response predictors. AMD risk 
is largely genetically determined and many research groups have turned towards 
pharmacogenetics to explain the high variability in treatment response to anti-VEGF. The 
vast majority of pharmacogenetic studies have assessed single nucleotide polymorphisms 
(SNPs) known to be associated with the development of AMD. Of all assessed SNPs, 
very few have shown consistent associations with treatment response. The CFH Y402H 
SNP is the only SNP that has been evaluated in three separate meta-analyses. Each of 
these studies concluded that the C risk allele shows a poorer response with an odds ratio 
of ~1.6 comparing wildtype to homozygous risk allele carriers.8-10 Many other SNPs 
have been evaluated,11 among others in the genes ARMS2,12-14 HTRA1,12, 13, 15 C3,12, 13, 
16 and VEGF16, 17 but none of these have been convincingly shown to be independently 
associated with treatment response. Possibly this is because there truly is no association 
with response, but it is also likely that any role that these individual SNPs play is small. 
Still what is lacking in all these pharmacogenetics studies is the mechanism behind their 
effect on non-response. How would these AMD-susceptibility loci be associated with 
response to a treatment that is basically symptomatic? Possibly the SNPs are indicative 
of more severe disease, but some have hypothesized that the aberrant inhibition of 
the complement system induces VEGF, explaining a resistance to anti-VEGF.9, 18 Still, 
the biological relevance is unclear for most SNPs. In chapters 3b and 3c we therefore 
focused on SNPs with a biological relation to anti-VEGF treatment, namely SNPs in 
the VEGF pathway. We identified SNPs associated with visual acuity in the VEGFR2 
and NRP1 genes, coding for the VEGF receptor and the VEGF co-receptor respectively. 
Interestingly, although these SNPs in itself had small effects, jointly they could make 
up a difference of 10 letters on average. This may not be enough to turn a responder 
into a non-responder, but is does indicate how increased burden of the VEGF pathway 
is involved in treatment response. In combination with other predictors it could 
improve the accuracy of an updated prediction model. After chapter 3b was published, 
investigators from the CATT and IVAN study have tried to replicate the results of the 
identified SNPs in VEGFR2,19 but to no avail. Interestingly, neither the CATT nor 
the IVAN study has ever identified pharmacogenetic associations. Possibly, the strict 
treatment regimen leaves very little room for natural variability of response. This could 
indicate that genetic variants predispose to an increased vulnerability to undertreatment, 
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which is presumably more common in clinical practice settings as compared to trial 
settings. However, the possibility of false-negative findings should not be excluded, and 
all pharmacogenetic associations should be replicated in independent cohorts before 
including them in prediction models.20 
3) Improving the definition of non-response
The third and possibly most important issue standing in the way of accurate and 
meaningful non-response prediction is that non-response itself is poorly defined. There 
is currently no generally accepted definition of non-response, but two major subtypes 
may be considered: functional and anatomical. The functional type refers to response in 
terms of change in function of the retina, usually expressed as visual acuity. Anatomical 
response is determined by change of neovascular activity on imaging modalities, 
commonly defined by central retinal thickness (CRT) on optical coherence tomography 
(OCT). 
Functional response determined by visual acuity is the main outcome of RCTs as this 
outcome is necessary for the registration of a drug.21-23 Visual acuity is what determines 
the quality of life of a patient and therefore is the more relevant outcome to the 
patient.24 Nevertheless, there are some important limitations to using visual acuity to 
define response. We discuss in chapter 3a of this thesis how visual acuity is subject to the 
floor and ceiling effect when using an absolute value. We explain how patients with a 
low baseline vision are less likely to deteriorate in terms of visual acuity, simply because 
they have less vision to lose, and are therefore less likely to be classified as non-responder. 
The opposite holds for patients with high baseline VA. Eventual visual acuity, however, 
is usually higher in patients with good baseline vision than in patients with low baseline 
vision,2, 3 so an absolute cut-off value for non-response will not necessarily select those 
patients that are worst off.
Another disadvantage of visual acuity as measure of response is that many other factors 
besides the efficacy of the drug may influence its change over time. Visual acuity can 
be influenced by scarring,25 development of geographic atrophy26 and photoreceptor 
damage.27 These different causes of functional non-response likely represent different 
mechanisms, making accurate response prediction particularly difficult. In addition, 
contextual factors may play a role, such as treatment delay.28, 29
To avoid the difficulties of defining response as a loss of vision, many researchers and 
ophthalmologists opt for the use of OCT to identify non-responders. OCT features, 
such as CRT, are considered more objective measures compared to visual acuity. CRT, the 
mean thickness of the central 1 mm around the fovea, reflects the amount of intraretinal 
and subretinal fluid and is used to monitor anatomical response. A major drawback 
of using OCT to predict treatment response is that changes in retinal thickness are 
poorly correlated with changes in visual acuity.30-32 As described before, visual acuity is 
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influenced by other factors than purely presence of fluid on OCT, so even though the 
treatment is effective on OCT, the patient may not experience any gain in vision.  
When choosing critera for response it is also important to consider how the results should 
be interpreted. OCT measurements can be useful in etiological studies trying to explain 
the large variability in pharmacological response between patients. Visual acuity is a 
more appropriate measure to determine the value of a treatment to a patient. Therefore, 
we chose to use visual acuity as the outcome in chapter 3a for predicting non-response. 
However, it should be noted that both visual acuity and CRT may influence treatment 
strategy and thus both should be considered when trying to optimize treatment. 
Ultimately, neither functional nor anatomical response is sufficiently accurate to define 
all non-response. Probably, response is much more complicated than we think. Visual 
acuity is likely a composite measure, an accumulation of damage to the retina by multiple 
causes.33 Anatomical response could be a part of this. Fluid that does not resolve due to 
drug resistance could impair the ability to regain vision, but fluid itself also damages the 
retina and the photoreceptors, more so in some than in others. In addition, formation 
of fibrosis or geographic atrophy during treatment may be the cause of sustained vision 
loss.33 Visual acuity will capture all of these entities, but we are not yet sure how all of 
these fit together. Possibly, all are part of a different mechanism of disease and each leads 
to non-response, although through a different pathway. When predicting response in 
a patient cohort, different reasons for non-response will play a role. Likely, one simple 
prediction model will not suffice to capture the complexity of treatment response. 
Anatomical response through CRT will not be exhaustive, because it does not reflect all 
different types of non-response; on the other hand,  functional response through visual 
acuity might be too exhaustive. Maybe we should step away from trying to define non-
response as if it were a single entity and start by accurately classifying non-responders in 
their different subgroups. 
Response and non-response in clinical practice
In chapter 2 and 4b we showed that nAMD patients in Dutch clinical practice gain less 
vision than reported for patients in RCTs. The difference of visual gains is 5 ETDRS 
letters after 1 year and 10 letters after 2 years.21, 22, 34 Similarly, for patients with diabetic 
macular edema (DME), we showed that the difference between RCTs and clinical 
practice is apparent in terms of change in visual acuity as well as improvement on optical 
coherence tomography (OCT). Patients in our clinics gained 3.5 letters on average over 
1 year of treatment, while patients in RCTs can gain as much as 10 letters.35, 36 The 
decrease in central retinal thickness (CRT) was also less prominent. 
The observed effectiveness gap between trial data and clinical practice is a relevant 
difference. A change of 5 letters is the approximate minimum change in vision that can 
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be perceived by an individual and will likely affect quality of life.37 Therefore, these large 
differences between RCTs and clinical practice cannot be ignored. First, establishing that 
a treatment is not as effective as it could potentially be, means we should be evaluating our 
treatment procedures carefully to find out why we are not reaching greater effectiveness. 
Second, management of nAMD patients in clinical practice may be more complicated 
than anticipated from RCTs. Non-response may be more frequent than anticipated and 
the search for alternative treatments becomes a more pressing matter.  Third, when 
developing (inter)national treatment guidelines that rely on cost-effectiveness analyses, 
proper effectiveness estimates may make an important difference in which treatment 
should be preferred over the other. 
We can deduce from chapter 2 and 4b that reasons for underachievement in clinical 
practice could be that patients tend to receive fewer injection and do not always complete 
the loading phase. For current clinical practice this means that ophthalmologists should 
be conscious of how they establish retreatment in a patient. Lowering the threshold for 
determining active disease would help to avoid undertreatment and should improve 
vision outcomes for patients. Also, to reduce the chances for a patient of not receiving 
a completed loading phase, ophthalmologists should schedule three loading phase 
injections as soon as the diagnosis is made..
Although these are valuable observations for clinical practice, it does not yet fully explain 
the difference with RCT data. There may be many other reasons why effectiveness is 
reduced in the real-world. In clinical practice patients may present themselves with 
AMD or DME who would not fit the criteria for inclusion in RCTs. For example, many 
RCTs on AMD will not include patients with visual acuity below 20/320, but these 
patients are treated in clinical practice, albeit with more modest results.38 Additionally, in 
clinical practice follow-up may be more inconsistent and there may be more divergence 
from protocol. These can be related to practical issues leading to treatment delay, which 
are unfortunately often due to logistical issues such as arranging proper transport and 
waiting for approval by a third party payer.28, 29, 39 We were unable to identify such causes 
from our own study, so this could be a relevant subject for future research. 
Cost of anti-VEGF treatment
In chapter 5 we showed that bevacizumab is just as effective for AMD as the other 
anti-VEGF agents, that there is no proof that bevacizumab is less safe, and that it is 
substantially more cost-effective than either ranibizumab or aflibercept. Yet, many 
countries and ophthalmological societies have not adopted bevacizumab as first choice 
nAMD therapy. This is for an important part because of legislations that state that 
physicians are not allowed to prescribe off-label medication when equivalent registered 
alternatives are available.40 Therefore, our findings should be directed at the policy 
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makers in health care and not just ophthalmologists who need to operate within legal 
constraints. 
Registration of bevacizumab for AMD would solve much of the problem, but this 
registration can only be requested by the owner of the drug. Roche indicated that 
they will not further develop bevacizumab for intraocular use. Large investigator-
driven, government-issued trials proving the effectiveness of bevacizumab have already 
been conducted41, 42 so maybe a next step could be the formation of an independent 
government-issued committee to conduct the final assessment of the drug for registration. 
Off-label prescriptions are common, not only in ophthalmology, and account for about 
20% of prescriptions.43 In our aging population with increasing need of care, regulating 
registration independent from pharmaceutical companies could become an important 
method to limit health care expenses. 
Changing drug-registration policy will take time. An alternative solution could be to 
significantly reduce the price of ranibizumab and aflibercept. Drug manufacturers are 
free to ask any price for their drug and they are not obligated to be transparent regarding 
how this price was determined. Actual production costs are usually only a small part of 
the final price.44, 45 On the other hand, governments are not obligated to accept any price 
the manufacturer offers. Lower prices can be negotiated.46 As a last resort a government 
can issue a manufacturing licence to a different company, allowing them to produce 
the same drug at a much lower cost.46 Cost-effectiveness analyses that include a societal 
perspective like in chapter 5 can support governments to negotiate fair prices for all 
parties involved. 
Recommendations for future research to optimize AMD treatment
Prediction of non-response
A next step in finding new predictors and elucidating the role of genetics in treatment 
response could be to perform genome-wide association studies (GWAS). The GWAS 
assesses SNPs spanning the entire genome and provides a hypothesis free approach to 
identify genetic associations.47 It provides the unique opportunity to identify genetic 
associations in new regions, pointing to previously unknown mechanisms of treatment 
response. Therefore, the GWAS could be an important tool to help us better understand 
the underpinnings of treatment response. There are, however, some hurdles to overcome. 
A GWAS tests a large amount of SNPs at once leading to a high chance of finding false 
positive associations.48 To limit this phenomenon and to prevent the literature from 
overflooding with false associations, the GWAS requires a correction for multiple testing. 
Usually the significance threshold lies at p=5x10-8, assuming there are approximately 1 
million independent regions in the human genome. To reach this threshold, at least 
one of two things is needed: very large effect size, or big sample size. Both will be 
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challenging. The effect size, or odds ratio, of an average SNP identified in a GWAS is 
only 1.33.49 Treatment response in a disease as multifactorial as AMD is unlikely to 
be associated with SNPs of large effect size. The largest pharmacogenetics study up to 
date was a collaboration between the CATT and the IVAN study, comprising 1347 
patients.19 Using a cut-off to define non-response will unlikely yield any information 
as that will leave the study with only ~130-260 (10-20%) of cases. Adapting the classic 
GWAS that compares cases to controls and utilizing response as a continuous variable 
may help increase the chance of finding associations. 
Defining and better understanding non-response
Besides predictors, it is also important to re-evaluate the outcome of non-response. To 
develop individualized treatment strategies, we first need a better understanding of why 
an individual responds poorly in the first place. In DME we are becoming more aware 
of different pathways influencing response. In chapter 4b we showed that some patients 
do not respond to anti-VEGF, but do respond to intravitreal steroids. This could point 
towards different disease mechanisms at play. Although steroids have no particular role 
in AMD,50 similarly different biological pathways could be involved in non-response 
in AMD-patients. We should start by classifying non-responders according to these 
pathways, such as scar formation or pharmacological resistance, and predictions could 
in turn become more focused on these specific biological pathways instead of clusters 
of pathways all leading to vision loss. This could make response prediction more 
complicated, especially in an ophthalmology clinic where physicians have only 10 
minutes per patient, but it will probably better represent the actual biology of non-
response, leading to more accurate and more relevant predictions.      
Currently, we do not have clear definitions of non-response. Recently, guidelines were 
published by Amoaku et al. based on literature and expert opinion attempting to label 
non-response for use in clinical practice.51 They have chosen a combination of visual 
acuity and CRT as definition. Moreover, they divide response into good, poor, and 
non-response. Good response was defined by resolution of fluid, and/or improved visual 
acuity of more than 5 letters. Poor response was less than 25% reduction from the 
baseline in CRT, persistent or new fluid, or change in visual acuity between 0 to 4 
letters. Non-response was defined as an increase in retinal fluid or hemorrhage and/
or loss of over 5 letters. These guidelines were developed in order to facilitate decision 
making for when to discontinue or switch treatments in clinical practice. It is important 
to adhere to these guidelines so as to make treatment across clinics more comparable. 
This definition is not necessarily the best or closest to the biology of non-response, but 
practically, we need to start somewhere. It would be interesting to see how these specific 
cut-offs are represented in clinical practice, how many patients would be considered 
non-responder and what the effect would be of a secondary treatment in this specific 
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group on visual prognosis. Also, we should evaluate whether quality of life is different 
between these subgroups to determine whether these are truly relevant distinctions. 
Discrepancy between clinical practice and RCTs
We still poorly understand why there are such a large differences between the RCT and 
clinical practice populations. We saw in chapter 2 that patients presented themselves 
with relatively low baseline vision. This could be translated into either more severe 
disease in general or vision loss due to treatment delay. Treatment delay can be dealt 
with, so it would be important to find out what causes this, especially considering 
baseline vision is such an important predictor for further response. Although we learn 
about treatment delay from other research, a lot of these issues may be country- or even 
clinic-specific. For example, obtaining health insurance approval is currently not an 
issue in the Netherlands. Possibly, there is a lack of awareness among patients, or a delay 
in referral from other professionals such as the general physician or the optometrists. A 
structured mapping of Dutch patients’ referral history could help determine what causes 
this delay, and interventions can be directed accordingly. 
Costs assessment
Costs management of anti-VEGF treatment can be improved by including observations 
from clinical practice. Although we are confident that bevacizumab is rightfully the first 
choice in nAMD treatment, our cost estimates could still be improved. We know the 
clinical benefit and differences in efficacy of anti-VEGF drugs through RCTs comparing 
them to placebo treatment,21, 22 followed by comparisons amongst the different anti-
VEGF agents.23, 41, 42 RCTs are the best available evidence for drug effectiveness and 
the randomized controlled design is crucial to avoid any bias that may occur through 
selection bias or confounding bias. Thus RCTs provide the most reliable information in 
terms of potential effectiveness and cost-effectiveness. There is however a downside to the 
use of RCTs in cost-effectiveness analyses. The effectiveness observed in RCTs is often 
not reached in clinical practice, and thus quality of life of AMD-patients is reduced. 
Furthermore, in chapter 2 we see that not only the mean effectiveness appears to be 
lower, but the variability of treatment effect also appears to be larger in the real world, 
and the amount of people ending up in the expensive non-responder category is much 
higher. Because we do not know how this affects cost-effectiveness of bevacizumab and 
aflibercept, it is important to expand cost-effectiveness analyses of anti-VEGF in AMD 
with observational data. Although observational studies have their own limitations and 
biases,52 we should take them into account when estimating a treatment’s overall value. 
For a treatment as vastly used and expensive as anti-VEGF, this could have important 
implications for health care policy. 
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Recommendation beyond treatment optimization
This thesis has mainly covered anti-VEGF treatment of nAMD and we have seen how 
this treatment has realized enormous improvements for millions of nAMD patients 
worldwide. Anti-VEGF treatment, however, is not a cure. Despite treatment, patients 
will usually not achieve perfect vision and recurrences of CNV are common.53 While we 
are trying to optimize anti-VEGF treatment, the damage is already partly done in the 
eyes of these patients. 
At the moment, there are no cures for AMD, nor can we prevent it. We can slow 
progression somewhat by addressing modifiable risk factors such as smoking and 
diet.54-56 The Age-Related Eye Disease Study (AREDS) study is the only study up to 
date that was able to prove a benefit from any intervention on AMD progression.57 It 
showed that we could lower the risk of progression to advanced AMD by 25% by taking 
supplements containing 500 mg vitamin C, 400 IU vitamin E, 15 mg beta-carotene, 
80 mg zinc oxide and 2 mg copper as cupric oxide. Investigating this treatment effect 
required over 4000 patients and 10 years of follow-up. Approximately 50% of patients 
with intermediate AMD advance to CNV or GA within 10 years.58 This means that a 
substantial group of AMD patients actually do not progress to the advanced stages. In 
chapter 7, we delve deeper into the mechanism of progression by assessing the effect 
of zinc on complement levels in AMD patients. Although we did not have end-points 
like development of advanced AMD, it gave us an initial understanding of a potential 
mechanistic approach to reduce progression. Understanding these mechanisms of 
progression to advanced AMD is important in this multifactorial disease and likely 
multiple pathways are involved in disease progression.59 Insight into which pathways 
lead to progression can help us target and personalize preventive measures. Ultimately, 
the most optimal way to prevent vision loss in AMD patients and to simultaneously 
reduce AMD-related costs, is to prevent advanced AMD from developing at all.  
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Summary
Wet age-related macular degeneration (AMD) is the most important cause of severe 
vision loss in the elderly. Due to aging of the population, AMD is becoming an 
increasing health concern. Within 5 years almost 12 million people worldwide will 
require treatment for wet AMD. Therefore, we need to work towards optimization of 
this treatment in the areas of effectiveness, costs and procedure.  
Chapter 1 is the introduction of this thesis and serves to familiarize the reader with 
the treatment of wet AMD with anti-vascular endothelial growth factor (anti-VEGF) 
injections in the eye.  Currently, the three available anti-VEGF drugs are bevacizumab, 
ranibizumab and aflibercept. Large randomized clinical studies have shown good results 
of anti-VEGF therapy, however often these levels of effectiveness are not reached in 
clinical practice. Non-response remains a widespread problem, which raises the question 
whether we can predict non-response in advance and what is the best treatment strategy. 
In Chapter 2 we evaluate the effectiveness of the anti-VEGF drug ranibizumab as 
primary treatment for wet AMD in Dutch clinical practice. Although the effectiveness 
we observed was not of the level as that in randomized controlled trials, ranibizumab 
was able to prevent a large part of AMD related vision loss. 
In Chapter 3 we looked for different predictors of non-response. Genetic factors that 
are involved in the mechanisms behind wet AMD seem to be related to treatment 
response. Especially accumulation of genetic risk factors may have a relevant effect on 
the eventual vision change after treatment. Different genetic and clinical factors together 
in a model, may predict non-response in part. A prediction model that we developed 
based on several of these factors, was able to predict non-response with an accuracy of 
77%. 
After non-response to anti-VEGF treatment has been established for a patient, it is key 
to start the appropriate second line treatment. In the first part of Chapter 4 we evaluate 
second line treatment with the anti-VEGF drug aflibercept in patients with AMD who 
did not respond to bevacizumab. Treatment with aflibercept significantly reduced fluid in 
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the retina and therefore seems an effective alternative for non-responders to bevacizumab. 
In the second part of this chapter we compared two second line treatments for diabetic 
macular edema after primary treatment with bevacizumab. We compared second line 
treatment with ranibizumab to the steroidal anti-inflammatory drug triamcinolone. 
We concluded that triamcinolone seemed to yield better short-term results and could 
therefore be preferred as second line treatment. 
There are large differences in costs between the anti-VEGF drugs bevacizumab, 
ranibizumab and aflibercept. In Chapter 5 we evaluate the cost-effectiveness of these 
three AMD treatments. Bevaicuzmab is a factor 20 cheaper than the other two drugs, 
however all of them are equally effective. Therefore, we believe bevacizumab the 
most appropriate primary treatment of wet AMD. Unfortunately, not everyone in 
the ophthalmological community agrees and a large subset of the world does not use 
bevacizumab as primary treatment. In this chapter we explain why bevacizumab should 
be first choice in AMD and discuss the enormous waste in health care spending that 
accompanies the use of the other drugs. 
In Chapter 6 we review the treatment procedure and conducted a randomized trial 
to determine whether an ultrathin needle could reduce the pain associated with the 
anti-VEGF injection procedure. We saw that pain from the injection was limited and 
that injecting with an ultrathin needle could not reduce this. Moreover, we studied 
the influence of psychosocial factors and found that anxiety, negative expectations, and 
dissatisfaction with the treatment negatively influenced the pain experience.   
In Chapter 7 we try to get a better understanding of the preventive measures in AMD. 
From previous studies we know that vitamin and zinc supplements slow the progression 
of AMD. Since the complement system plays such a prominent role in the development 
of AMD, we hypothesized that supplements with zinc exert their protective action by 
inhibiting complement activation. In a clinical study we instructed patients to take a 
daily zinc supplement for four months. We saw that zinc could indeed lower complement 
activation in patients with high intrinsic complement levels. 
Finally, in Chapter 8 we discuss the findings from this thesis. We discuss the challenges 
related to predicting non-response to anti-VEGF drugs, the large gap in effectiveness 
of anti-VEGF treatment between clinical practice and clinical trials, and how to reduce 
costs of AMD treatment. This section concludes with practical advice for further 
research. 
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Samenvatting
Natte leeftijdsgebonden maculadegeneratie (LMD) is de belangrijkste oorzaak van 
ernstig visusverlies op latere leeftijd. Door vergrijzing is LMD een toenemende zorg 
voor ons gezondheidsstelsel. Over 5 jaar zullen bijna 12 miljoen mensen wereldwijd 
behandeld moeten worden voor natte LMD. Daarom is het van belang dat deze 
behandeling geoptimaliseerd wordt qua effectiviteit, kosten en procedure.  
Hoofdstuk 1 vormt de inleiding op dit proefschrift en dient om de lezer bekend te 
maken met de behandeling van natte LMD met anti-vasculaire endotheliale groeifactor 
(anti-VEGF) injecties in het oog. Grote medicijnstudies laten goede resultaten van deze 
behandeling zien, maar in de klinische praktijk worden deze resultaten vaak niet bereikt. 
In Hoofdstuk 2 wordt de effectiviteit van het anti-VEGF medicijn ranibizumab 
geëvalueerd als primaire behandeling voor natte LMD in de Nederlandse klinische 
praktijk. Hoewel de resultaten zijn niet zo goed als in de klinische medicijnstudies, is 
ranibizumab in staat een groot gedeelte van het visusverlies door LMD te voorkomen. 
In Hoofdstuk 3 hebben we gezocht naar verschillende voorspellers voor behandelrespons. 
Genetische factoren die betrokken zijn bij het mechanisme achter natte LMD blijken 
geassocieerd met de respons op behandeling. Met name een opeenstapeling van 
genetische factoren kan een belangrijk verschil maken in de uiteindelijke verbetering van 
het zicht na behandeling. Verschillende klinische en genetische factoren samen in een 
voorspellingsmodel kunnen tot op zekere hoogte non-respons voorspellen. Wij zagen dat 
dit model met een accuraatheid van 77% non-respons van respons kon onderscheiden. 
Nadat non-respons op anti-VEGF behandeling is vastgesteld bij een patiënt, moet een 
juiste tweedelijns behandeling worden ingezet. In het eerste deel van Hoofdstuk 4 
evalueren we tweedelijnsbehandeling met het anti-VEGF middel aflibercept bij personen 
met LMD die niet goed op bevacizumab hebben gereageerd. Behandeling met aflibercept 
verminderde significant het vocht in het netvlies en lijkt dus een effectieve tweede keus. 
In het tweede deel van dit hoofdstuk bekijken we welke tweedelijnsbehandelstrategie 
het beste is voor diabetisch macula oedeem na primaire behandeling met bevacizumab. 
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We vergelijken tweedelijnsbehandeling met ranibizumab of de ontstekingsremmer 
triamcinolon en concluderen dat triamcinolon betere korte termijn resultaten geeft.    
Vanwege grote kostenverschillen tussen de anti-VEGF medicijnen bevacizumab, 
ranibizumab en aflibercept evalueren we in Hoofdstuk 5 de kosten-effectiviteit van deze 
drie LMD-behandelingen. Bevacizumab is een factor 20 goedkoper dan de andere twee 
medicijnen, maar alle drie zijn ze gelijkwaardig in effectiviteit. Daarom beschouwen 
wij bevacizumab als meest geschikte eerstelijnsbehandeling voor natte LMD. Helaas 
blijkt dat deze mening niet gedeeld wordt door een groot gedeelte van de wereld en is 
dit medicijn nog niet overal de eerste keus behandeling. In dit hoofdstuk betogen wij 
waarom dit wel zou moeten zijn en bespreken hierbij de gigantische kostenverspilling 
die gepaard gaat bij het gebruik van de andere twee middelen. 
In Hoofdstuk 6 nemen we de behandelprocedure onder de loep en hebben we onderzocht 
of het gebruik van een ultradunne naald voor anti-VEGF injecties de pijnbeleving bij 
de injectie doet verminderen. Wij zagen dat de pijn van de injectie beperkt was en dat 
deze niet verminderd kon worden door een ultradunne naald. Daarnaast bekeken we 
of psychosociale factoren invloed hadden op de pijn van de injectie en het bleek dat 
angstgevoelens, negatieve verwachtingen en ontevredenheid met de procedure de pijn 
negatief beïnvloedde. 
In Hoofdstuk 7 proberen we een beter begrip te krijgen van preventieve behandeling 
van LMD. Uit voorgaande studies weten we dat voedingssupplementen met vitaminen 
en zink de progressie van LMD kan verminderen. Omdat het complementsysteem een 
grote rol speelt bij het ontstaan van LMD, bestudeerden wij of zink supplementen de 
activatie van het complementsysteem kan verminderen. Zinksuppletie kan inderdaad 
de complementactivatie verlagen bij LMD patiënten met een intrinsiek verhoogde 
complementactivatie. 
Ten slotte worden in Hoofdstuk 8 de vondsten van dit proefschrift bediscussieerd. We 
bespreken de uitdagingen die we tegenkomen bij het voorspellen van non-response bij 
anti-VEGF middelen, het grote verschil in effect van anti-VEGF tussen de klinische 
praktijk en klinische medicijnstudies, en hoe we de kosten van de behandeling kunnen 
verminderen. 
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Dankwoord
Soms zie je ze wel eens. Van die wetenschappelijke artikelen met maar één auteur 
erboven. Vaak denk je dan: “Zou die persoon dat echt allemaal alleen hebben gedaan?” 
Na een paar jaar in het onderzoek te hebben doorgebracht, sta ik daar sceptisch 
tegenover. Soms voel je je alleen als promovendus, maar in werkelijkheid is onderzoek 
een echte teamsport. Van technische of statistische ondersteuning, tot data verzameling, 
tot simpelweg met elkaar in discussie gaan en ideeën delen, onderzoek doe je in een 
team. Zo ook dit proefschrift. Ik ben trots dat mijn naam op de kaft mag staan, maar 
eerlijk gezegd, heb ik dit niet alleen gedaan en ik had het ook niet alleen gekund. Ik heb 
dit proefschrift onder andere te danken aan de tijd, energie en steun van veel andere 
mensen en daarom is dit hoofdstuk speciaal aan deze personen toegewijd.  
Om te beginnen natuurlijk met mijn promotoren en copromotoren. Niet veel 
promovendi hebben het geluk onder 4 professoren te mogen promoveren. Natuurlijk 
heeft het ook zijn nadelen (wel eens geprobeerd 4 professoren tegelijkertijd in één kamer 
te krijgen?), maar ik heb ik veel geleerd en vaak kunnen profiteren van de expertise van 
al mijn begeleiders en daar ben ik dankbaar voor. 
Beste professor Hoyng, beste Carel, jij bent degene die mij heeft aangenomen op mijn 
project toen ik als groene senior co naar de afdeling kwam. Dat zou op zich al genoeg 
kunnen zijn om je voor te bedanken, maar het gaat gelukkig verder. Je hebt me passie 
geleerd voor onderzoek in het algemeen en oogheelkundig onderzoek in het bijzonder. 
Je enthousiasme is aanstekelijk. Je hebt me de waarde van wetenschap naast de kliniek 
laten zien en ik mag hopen dat ik dat nog lang die twee mag combineren. Wanneer ik 
terugkom in Nijmegen hoop ik weer met je te mogen samenwerken in het researchteam 
van de afdeling oogheelkunde. 
Beste professor van der Wilt, beste Gert-Jan, wanneer ik een overleg met jou had zorgde 
ik altijd dat ik mijn oren en geest open hield. Ik wist namelijk dat jij met een unieke 
invalshoek zou komen en jij wist op een of andere manier altijd dat laatste puntje op 
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de i te zetten wat mijn werk net wat interessanter zou maken. Bedankt dat je een goede 
leermeester bent geweest en voor het verbreden van mijn perspectief.
Beste professor Rovers, beste Maroeska, ik weet niet hoe mijn promotie er uit had gezien 
zonder jou. Je hebt me geleerd te kijken als een onderzoeker en je hebt me bovendien 
geleerd te kijken naar mezelf. Jouw betrokkenheid die je naar al je promovendi 
toont maakt zoveel verschil. Veel van de groei die ik tijdens mijn promotiejaren heb 
doorgemaakt is dankzij jou, daarvan ben ik overtuigd. Bedankt dat je altijd aan mijn 
kant stond en een rolmodel was.  
Beste professor Klevering, beste Jeroen, laten we eerlijk zijn, we zijn allebei niet de 
makkelijkste mensen om mee samen te werken... Dat gezegd hebbende, denk ik dat we 
eigenlijk best een goed team waren en zaten we vaak op één lijn. En ook al verliet ik 
onze gesprekken soms in frustratie, ik kwam telkens weer terug als ik advies nodig had. 
Zoveel waarde hecht ik aan jouw mening. Bedankt dat je me altijd gepusht hebt en me 
hebt laten streven naar meer. 
Ik heb een hoop mensen ontmoet tijdens mijn promotietijd en veel van hen hebben een 
blijvende indruk achtergelaten of een grote rol gespeeld in mijn projecten. Veel van mijn 
collega’s zijn ook vrienden geworden, dat kan ik iedereen toewensen. 
Beste professor den Hollander, beste Anneke, je was niet mijn promotor, maar jouw 
expertise op het gebied van genetica zorgde ervoor dat jij een belangrijke bijdrage hebt 
geleverd aan veel van mijn projecten. Daarnaast was het indrukwekkend te zien hoe je 
je perfect staande wist te houden als geneticus op een klinische afdeling tussen al die 
artsen en je een dikke stempel hebt weten te drukken op het oogheelkundig onderzoek 
in Nijmegen. 
Beste Eiko, ik benijd je positie niet. Je bent de middleman die de verstrooide professoren 
aan de bovenkant en de gestreste promovendi aan de onderkant probeert te managen. 
Bedankt dat zelfs met alle hectiek je toch altijd tijd vrij wist te maken voor een kopje 
koffie en een babbel wanneer ik het nodig had. 
Beste Hans, niemand kan met zoveel enthousiasme een statistisch model bouwen als jij. 
Toen jij me voor het eerst een predictiemodel liet zien was ik verkocht! Bedankt voor het 
lenen van je statistische inzicht bij al mijn projecten.
Beste John, toen we elkaar ontmoetten was het direct duidelijk, wij zijn tegenpolen. Het 
enige dat we gemeen hebben is onze grote mond. Toch bedankt voor alle discussies, ze 
waren stiekem best leuk. 
Beste Dzenita, ik ken weinig vrouwen met zo’n sterk karakter als jij en dat bewonder ik 
enorm. Weet dat we allemaal tegen je op kijken. 
Dear Mahesh, I’m still trying to reproduce that biryani you once made for us. Thank 
you for your company and hospitality. See you around in Maryland!
Dear Shazia, thank you for your kindness. Wishing you lots of success in Amsterdam!
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Beste Ramon, jij bent het zonnetje in huis. Bedankt voor je vrolijkheid, dat hebben 
promovendi soms even nodig. 
Beste Nicole, je bent een harde werker. Van jouw toewijding en ijver kunnen we allemaal 
leren. 
Dear Constantin, you have always been a bit quirky, but it suits you. Thanks for 
reminding us to stay curious and to follow our dreams. 
Beste Michel, je gevoel voor humor is op zijn zachtst gezegd uniek te noemen. Bedankt 
voor het delen van je bijzondere invalshoeken, op letterlijk alles. 
Beste Myrte, jij laat niet over je heen lopen en bent niet bang je mening te geven. Ik 
ook niet en soms botst dat, maar ik waardeer het enorm in je. Daarnaast ben je iemand 
waar mensen op kunnen rekenen. Jij wordt een geweldige oogarts en een fijne collega. 
Beste Nathalie, wij zouden onze stem kunnen kwijtraken en nog even gedetailleerde 
gesprekken kunnen voeren als daarvoor. De blikken zeiden alles. Wij vonden in elkaar 
iemand bij wie we onze theatrale aard vrij konden laten gaan zonder raar gevonden te 
worden. Wat fijn om een gelijkgestemde in ons promovendigroepje te hebben! Als het 
Scapino Ballet ooit nog een stervende zwaan zoekt zal ik jou nomineren. 
Beste Maartje, jij kent het werkelijke belang van de vrimibo (vrijdag middag borrel, 
red.). Het leven van een promovendus is soms frustrerend, maar alles lijkt net wat 
minder erg met een cappuccino of een wijntje erbij. Ik ben blij dat we onze verhalen 
konden delen. Bedankt voor alle uren kletsen en natuurlijk vooral bedankt dat je me aan 
Martijn hebt voorgesteld! 
Dear Laura, we are the pharmacogenetics team! We have travelled far and wide together 
to unravel the mystery of treatment response. Thank you for all those very professional 
trips to Cologne collecting data and enjoying some much deserved leisure (how fortunate 
for us that the cheapest hotel in Cologne just happened to have a luxury spa attached 
to it). 
Beste Freerk, wij zijn samen met Maartje “the Rocky trio”. Ik denk dat dit proefschrift 
niet geschikt is om uit te leggen wat dat betekent. Iets met bierbrouwerijen en keihard 
“love me like you do” van Ellie Goulding meeschreeuwen in de auto. 
Beste Stanley, je bent echt een manusje van alles. Bedankt voor je bereidheid je talenten 
met ons te delen. 
Beste Roos, je staat open voor iedereen en dat is mooi. Bedankt voor alle gezelligheid op 
het werk en daarbuiten. 
Beste Eveline, als iemand weet van doorpakken ben jij het en ik bewonder je 
leiderschapskwaliteiten. Ik hoop dat de afdeling oogheelkunde beseft hoeveel geluk ze 
hebben met jou als beheerder van de AMD-database. Namens mij in ieder geval bedankt 
voor het delen van je betrokkenheid, je luisterende oor en je kracht. Jij komt er wel. 
Beste Vivian, Sanne en Dyon, jullie kwamen als promovendi bij de groep toen ik net op 
het punt stond te vertrekken. Ik hoop dat jullie net als ik leren van onderzoek te houden 
en dat jullie veel fijne mensen ontmoeten! 
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Beste Maarten, Esther, Tim, Machteld, Casper, Inger, Jorte, Mayke, Charlotte, Janneke 
en iedereen van de Evidence Based Surgery groep, bedankt! Vissie vrijdag en LVVDMB 
zijn een begrip geworden. Langzaam gaat iedereen een beetje zijn eigen weg, maar wat 
was EBS een fijne groep om mee op te trekken. Deze club was als een warm bad. Casper 
moet ik speciaal noemen, zoals jij voor mensen klaar staat is bijzonder en ik ben blij dat 
ik dat ook heb mogen ervaren. Bedankt voor alle steun. 
Bedankt aan alle arts-assistenten van de afdeling oogheelkunde voor hun hulp 
bij mijn projecten. In het bijzonder dank ik Samuël Verkerk voor zijn hulp met de 
intravitreale injecties, Milan Phan voor de hulp met het diabetisch maculaoedeem 
onderzoek en Paulien Huis in ’t Veld voor de samenwerking op het gebied van Birdshot 
Chorioretinopathy. 
Het stafsecretariaat is de spil van een afdeling en zo ook op de afdeling oogheelkunde. 
Bedankt Berna, Francis en Laura. Ik denk dat ik mijn promotoren nooit zou hebben 
gezien als jullie er niet waren om alles in het gareel te houden.
Natuurlijk ook bedankt aan iedereen van de administratie en de verpleegpost van de 
afdeling oogheelkunde. Mijn trials zouden in het honderd zijn gelopen zonder jullie 
geduld en hulp. Christa, bedankt dat je de onofficiële coördinator van al mijn onderzoek 
op het injectiespreekuur was.
Eén van de leukste dingen om te doen tijdens een promotie is samenwerken met andere 
afdelingen. Op een gegeven moment begin je te denken dat leeftijdsgebonden macula 
degeneratie de enige aandoening is die er toe doet, maar een samenwerking met een 
andere afdeling is de meest effectieve manier om van die tunnelvisie af te komen. Thanks 
to all my collaborators from the University of Cologne, professor Fauser, Lebriz Altay and 
Manuel Hermann, for your collaboration on treatment response to anti-VEGF. Bedankt 
Joris Elshout en Douwe Bergsma van het Donders Instituut voor de samenwerking 
naar hemianopsie. Bedankt professor Evers en Henriët van Middendorp van de 
afdeling Medische Psychologie voor de hulp met onze psychologische vragenlijsten. 
Bedankt Roger Lomme van de afdeling Chirurgie voor de hulp met het testen van onze 
injectienaalden op varkensogen. 
Tijdens de verdediging mag een promovendus twee paranimfen naast zich hebben staan. 
Mijn paranimfen verdienen een speciale paragraaf in dit hoofdstuk. Met Melanie heb ik 
de reis van jonge geneeskundestudent tot basisarts doorgemaakt en met Yara heb ik mijn 
promotietijd bij de oogheelkunde mogen delen. Allebei hebben ze twee belangrijke fases 
in mijn leven van dichtbij meegemaakt en samen vormen ze dus het perfecte paar om 
mij naar de afronding van mijn promotie te begeleiden.
Beste Melanie, onze vriendschap is onvoorwaardelijk. Soms spreken we elkaar een tijdje 
niet als we het druk hebben, maar het maakt allemaal niets uit. Als ik je nodig heb ben je 
er. Geen vragen, gewoon doen. Je bent een van de meest oprechte mensen die ik ken en 
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die openheid zorgt ervoor dat jij me als geen ander kent. Dit begon tijdens onze studie 
al. We begrepen elkaar gewoon, één blik in jouw richting en ik wist dat jij hetzelfde 
dacht. Helaas hadden we samen vaak pech op een of andere manier, ik weet niet hoe we 
het voor elkaar kregen. Maar als er iemand is die ik alle geluk van de wereld toewens, 
dan ben jij het wel.
Beste Yara, samen waren we het epidemiologie team op oogheelkunde. Ons grootste 
project samen is er uiteindelijk niet meer van gekomen, maar het was absoluut het 
meeste leerzame project dat ik heb gehad. Dat was nou juist omdat ik het met jou kon 
doen. Je liet me kritisch denken en het was zo enthousiasmerend om met jou samen te 
werken. Je bent niet van het eind goed al goed, maar hoe je er komt moet ook kloppen. 
Dat is soms een ondergewaardeerde eigenschap in deze “publish or perish” cultuur, maar 
ik waardeer hem zeer. Als jij het doet, dan weet je dat het goed is. Je bent integer en 
betrouwbaar en daarom ben je een goede oogarts, een goede onderzoeker en een goede 
vriendin. 
Fijne collega’s zijn heel belangrijk voor een prettige promotietijd, maar de mensen 
daarbuiten maken soms nog meer verschil. Mariël, Daisy en Lily, wat waren we toch 
groen toen we nog geneeskundestudentjes waren. Samen met jullie ben ik volwassen 
geworden. We zijn weliswaar allemaal een beetje uitgewaaierd, maar ik ben blij om te zien 
hoe we allemaal ons plekje hebben gevonden. Bedankt voor de fijne vriendinnenavondjes, 
gewoon even lekker keuvelen is soms het beste medicijn tegen de stress van alledag! 
Een belangrijk onderdeel van wie je uiteindelijk wordt heeft te maken met wie je heeft 
opgevoed. Pap, ik geloof dat je wel eens hebt geprobeerd een artikel van me te lezen. 
Het was vast ver van je bed, maar je deed altijd je best te begrijpen waar ik nou eigenlijk 
mee bezig was. Bedankt voor je onvoorwaardelijke steun. Mam, bedankt dat je altijd in 
me geloofde. Zelfs als ik aan mezelf twijfelde deed jij dat nooit. Je bent er niet bij om dit 
mee te maken, maar ik weet dat je trots zou zijn.  
Lieve Martijn, de timing van onze ontmoeting was ronduit slecht te noemen. Maar zelfs 
met het vooruitzicht dat ik binnen een aantal maanden naar Amerika zou vertrekken 
konden we elkaar toch niet loslaten. Ik weet niet hoe we het hebben gedaan, maar we 
zijn ondanks alles zo close geworden en de liefde bleef maar groeien. Toen ik je vroeg 
om bij me te komen in Washington DC twijfelde je niet lang. Het moest zo zijn. Op 9 
januari 2017 zijn we in ons Nijmegen getrouwd. Ik ben zo blij dat je het avontuur met 
me aandurfde. I love you. 
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